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1 Abstract 
Parkinson’s disease (PD) is the second most common neurodegenerative disease following 
Alzheimer’s disease and the most common movement disorder. Clinically, a motor phenotype 
can be observed only after approximately 50% of dopaminergic neurons in the substantia nigra 
(SN) have been lost with rigor, resting tremor, bradykinesia or akinesia, and postural instability 
being the cardinal symptoms. Yet, to date, a definite diagnosis is only possible by analysis of 
post-mortem brain tissue. Here, a degeneration of the SN can be observed, and Lewy bodies and 
Lewy neurites in remaining dopaminergic neurites represent the histopathological hallmark of 
the disease.  
On the molecular level, several routes of evidence suggest that the formation of small, soluble 
αSyn oligomers is causative for the loss of dopaminergic neurons in the SN, yet the toxic αSyn 
species and the exact mechanism of toxicity remain obscure. To date, agents for symptomatic 
therapy of PD are available, but no causative therapeutic approaches have been identified so far.   
In order to achieve an earlier diagnosis and develop disease-modifying therapies, a better 
understanding of underlying molecular pathogenic mechanisms is desirable. Established cell 
lines represent suitable models to identify potential disease-modifying therapeutics and to study 
αSyn-mediated toxic mechanisms. To the best of our knowledge, by the beginning of this project, 
overexpression of αSyn in cell models was either constitutive or relied on transient transfection 
or viral transduction.  
In this study, we aimed to develop a strategy for the creation of stable cell lines which inducibly 
overexpress variants of αSyn by addition of certain chemical agonists. The system should be 
applicable to a variety of established and primary cell lines for the investigation of aggregation, 
modulation, and toxicity of αSyn oligomers with regard to PD and other synucleinopathies. 
We created vectors for the inducible overexpression of αSyn (S), the fluorescence protein Venus 
(V), αSyn coupled to Venus (SV), and αSyn coupled to the N-terminal (V1S) or C-terminal Venus 
fragment (SV2) for a bimolecular fluorescence complementation assay (BiFC). Inducibility was 
achieved by applying the GAL4_EcR-UAS (GE) or the Cre_ERT2-loxP (CET2) system, respectively. 
The expression constructs were stably integrated into the genome of the host cell line by 
lentiviral transduction. 
We here demonstrate the successful application of this strategy for the creation of inducibly 
αSyn overexpressing cell lines in H4 and LUHMES cells. We observed stronger inducibility of 
transgene expression in H4_GE cells compared to H4_CET2 cells. Expression characteristics of 
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inducible H4_GE cells were investigated in detail based on both fluorescence intensity and 
protein amount. All cell lines showed low background expression and a maximum increase in 
transgene expression upon incubation with 1 or 10 µM tebufenozide for 4-6 days.  
Exposure to heavy metals has been described as risk factor for the development of PD in 
epidemiological studies. In particular, ferric iron appears to be increased in the SN of PD patients 
and incubation of recombinant αSyn with DMSO or DMSO and FeCl3 results in the formation of 
distinct oligomer species. Using the H4_GE cell models described in this work we observed a 
strong increase in fluorescence intensity in the BiFC assay upon incubation with DMSO in 
combination with FeCl3 which was not observed for other tri-, di-, or monovalent ions. 
Additionally, an increase in αSyn protein load and higher molecular αSyn species were detected 
in western blot and sucrose gradient centrifugation. Taken together, these data suggest 
increased aggregation of αSyn in the H4_GE cell model upon incubation with DMSO and FeCl3. 
In summary, the system presented in this work holds high potential for the creation of αSyn 
overexpressing cell lines to evaluate risk factors of αSyn aggregation and αSyn-mediated toxicity 
as well as to screen for anti-aggregative compounds for potential disease-modifying therapeutics 
for PD and other synucleinopathies.   
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2 Introduction 
2.1 Parkinson’s Disease 
Neurodegenerative disorders comprise a group of diseases that lead to a progressive loss of 
neurons resulting in disease-specific symptoms1. This loss of neurons is commonly accompanied 
by the deposition of disease-specific protein aggregates. Exemplarily, these aggregates consist of 
prion protein in Creutzfeldt-Jakob disease (cytoplasmic), huntingtin in Huntington’s disease 
(cytoplasmic), tau protein (cytoplasmic) and amyloid-beta peptide (extracellular) in Alzheimer’s 
disease (AD), and alpha-synuclein (αSyn) (cytoplasmic) in Parkinson’s disease (PD) and other 
synculeinopathies including dementia with Lewy bodies (DLB) or multiple system atrophy 
(MSA)2,3.  
PD is the second most common neurodegenerative disease following AD and the most common 
movement disorder and was first described in 1817 in James Parkinson’s An Essay on the 
Shaking Palsy4. On the cellular level, degeneration of synapses and axons in the striatum 
precedes the loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) leading 
to a depletion of dopamine in the nigrostriatal circuitry5. The typical clinical phenotype is 
characterized by the four cardinal symptoms rigor (stiffness of muscles), tremor (resting tremor 
with a frequency of 4-6 Hz), slowness or absence of motion (bradykinesia/akinesia), and 
postural instability6 and can only be observed after 50 to 80% of dopaminergic neurons have 
already been lost (Figure 2-1 A). With further symptoms including sleep disturbances, visual 
halluzinations and illusions, cognitive deterioration and dementia, depression and anxiety, and a 
variety of sensory symptoms7,8, PD places a heavy burden on both patients and relatives.  
The loss of dopaminergic neurons in the substantia nigra (SN) (Figure 2-1 B) and Lewy bodies or 
Lewy neurites in some of the remaining neurons represent the histopathological hallmarks of PD 
(Figure 2-1 C), but degeneration can also be observed in other brain areas that use different 
neurotransmitter systems9. However, since Lewy body pathology is not proportional to the 
extent of cell death or the severity of the clinical phenotype and since also asymptomatic 
individuals show Lewy bodies in an age-dependent manner, it is still under debate if Lewy 
bodies are a sign of presymptomatic PD10 or of normal aging11.  
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Figure 2-1: Background on Parkinson’s disease 
A) Illustration of the typical clinical phenotype of a PD patient by Sir William Richard Gowers12 
(source: https://de.wikipedia.org/wiki/Parkinson-Krankheit).  
B) Midbrain sections of healthy control (top) and PD patient (bottom). Arrows point to SN which 
is degenerated in the PD case (pictures from Prof. Dr. med. Armin Giese, LMU Munich). 
C) Staining of a brainstem neuron with hematoxylin and eosin (H&E) showing a cytoplasmic 
Lewy body (top) (pictures from Dr. med. Tobias Högen, LMU Munich). Staining of Lewy bodies 
and Lewy neurites with an anti-αSyn antibody (αSyn-42) (bottom).  
D) αSyn fibrils observed in electron microscopy (from Michael Schmidt and Dr. med. Johannes 
Levin, LMU Munich). 
  
 
 
In industrialized countries approximately 0.3% of the population suffer from PD13 with probably 
slightly higher prevalence in men than in women (of approximately 1.5 to 1)14. The biggest risk 
factor for the development of PD is increasing age: The disease occurs only seldom in individuals 
below the age of 50 years and a strong increase in prevalence can be observed from 60 years 
on14. Thus, approximately 0.6% of the 65-69-year-olds are affected in Europe, and the 
prevalence increases to approximately 2.6% in the age group of 85-89 years14-16. Thus, with an 
expected prolonged lifespan over the next decades the number of PD patients is likely to further 
increase in the future. In 2010, approximately 630,000 people had been diagnosed with PD in 
the United States. It has been estimated that this number will increase to 819,000 by 2020, 1.06 
million by 2030, 1.24 million by 2040, and 1.34 million by 205017. With increasing number of 
patients, medical costs are likely to increase in the future (in the United States from 
approximately 8 billion $ in 2010 to 18.5 billion $ in 2050)17.  
Clinical diagnosis of PD relies on motor and nonmotor abnormalities, with motor parkinsonism 
(i.e., bradykinesia plus rest tremor or rigidity) being the core feature18. Since the motor 
phenotype occurs only after a substantial amount of dopaminergic neurons has already been 
lost, treatment of PD is currently limited to already advanced disease stages. To date, a definite 
diagnosis of PD is only possible by post-mortem histopathological examination since 
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parkinsonian symptoms can be observed in patients suffering from a variety of neurological 
disorders19. Indeed, a study from 1992 found that clinical diagnosis of PD was correct in only 
76% of cases20. For this, better tools to diagnose PD with higher reliability and earlier in the 
course of disease are urgently required to improve the treatment of PD patients but also to 
improve clinical trials and epidemiological research19.  
Current treatment of PD patients is largely focused on the compensation for the pathological 
depletion of dopamine. Thus, PD patients are typically treated with levodopa, a dopamine 
precursor that can cross the blood-brain barrier (BBB) and is afterwards converted to dopamine 
by neuronal decarboxylases. Treatment with levodopa is often combined with administration of 
carbidopa, an inhibitor of peripheral decarboxylases that prevents decarboxylation of levodopa 
to dopamine and is incapable of crossing the BBB. Unfortunately, the effect of levodopa 
administration decreases over time. Another possibility to overcome symptoms caused by 
depletion of dopamine is the treatment with dopamine receptor agonists. Additionally, 
substances to reduce dopamine metabolism like monoamine oxidase B (MAOB) inhibitors or 
catechol-O-methyl-transferase (COMT) inhibitors can be given to slow down the degradation of 
dopamine to inactive metabolites19,21. A neurosurgical approach is taken by deep brain 
stimulation. Here, a neurostimulator, or “brain pacemaker”, is implanted that stimulates areas 
like the globus pallidus, subthalamic nucleus, or thalamus to substitute missing inhibition from 
the SN and thus decrease inhibition of the motor cortex22.  
To date, there is no cure and no disease-modifying therapy for PD available. Therefore, a better 
understanding of underlying disease mechanisms is inevitable for the development of better 
diagnostic tools – allowing an earlier and more reliable diagnosis of PD – and for the 
development of disease-modifying therapies. 
  
Introduction 
 
 
6 
2.2 Alpha-Synuclein and its Physiological Role 
Synuclein proteins – purified from Torpedo californica – were first characterized by Maroteaux 
et al.23 in 1988. The acronym “synuclein” refers to the initially described localization in synapses 
and in the nucleus23-31. By now, the synuclein family has been subdivided into three groups, 
termed alpha-, beta-, and gamma-synuclein (with gamma-synuclein being equivalent to breast 
cancer specific gene 1 (BCSG-1))30. Meanwhile, alpha-synuclein (αSyn) has been found to localize 
not only to synapses and the nucleus but also to the cytosol, the mitochondria-associated 
membrane of the endoplasmic reticulum (ER), and the inner membrane of mitochondria. 
Hence, αSyn appears to travel actively between different compartments32-34.  
In humans, αSyn is expressed from the SNCA gene located on 4q21, i.e., the long (q) arm of 
chromosome 4 at position 21. It belongs to the family of natively unfolded proteins and accounts 
for approximately 0.5% to 1% of total protein in soluble cytosolic brain fractions19,25,35. The 
highest expression of αSyn is observed in neurons in both the central and peripheral nervous 
system32,35. αSyn exists mainly as a small soluble protein of 140 residues with a molecular 
weight of 14 kDa whose primary structure can be subdivided into three distinct regions19,25: the 
N-terminal lipid-binding region (1-60), the central NAC region (non-amyloid-beta component) 
(61-95), and the hydrophilic C-terminal region (96-140)19,25 (Figure 2-2 A). Two further 
isoforms can be observed as a result of alternative splicing: αSyn-126 (lacking the amino acids 
41 to 54 in exon 3) and αSyn-112 (lacking the amino acids 103-130 in exon 5)35,36. 
The physiological function of αSyn is still subject of ongoing research. It has been shown that 
mice lacking alpha- and/or beta-synuclein show normal survival and no obvious brain 
defects19,37. The only observed phenotype in mice with a depletion of αSyn expression was a 
different modulation in dopamine release and recycling pool homeostasis. However, the lack of 
more obvious phenotypes might be due to an artificial environment without evolutionary 
pressure and compensatory mechanisms or a redundancy of other synucleins32,38-41, since age-
related neurodegeneration and endocytosis abnormalities can be observed in mice lacking 
alpha-, beta-, and gamma-synuclein42,43 and acute knockdown using RNAi expressed from adeno-
associated viruses promotes degeneration in neurons of the SN32,44.  
Although it has been observed in a variety of cell compartments, αSyn has been described to be 
mainly enriched in presynaptic vesicles of vertebrates32,45-47. A lipid-binding property of αSyn 
can already be postulated based on its primary structure since its N-terminal region consists 
almost entirely of imperfect 11-mer repeats with a degenerate KTKEGV consensus motif35,48 
which is related to an alpha-helical lipid-binding motif of apolipoproteins (Figure 2-2 A).  
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Figure 2-2: Background on αSyn 
A) Amino acid sequence of αSyn (140-amino-acid isoform) with three distinct regions: N-terminal 
lipid-binding region (1-60), central NAC region (61-95), and hydrophilic C-terminal region 
(96-140). 11-mer repeats with degenerate KTKEGV consensus motif are underlined. All known 
disease-associated mutations are located within the N-terminal region (affected sequence 
positions are highlighted in color and amino acid substitutions are indicated below) (modified 
after Beyer, 200748).  
B) 3D structure of micelle-bound human αSyn according to Ulmer et al., 200549. Position of 
disease-associated mutations are highlighted in color (figure kindly provided by Dr. Viktoria 
Ruf, LMU, modified). 
 
 
Indeed, it has been shown that the exposure of αSyn to lipid micelles leads to a change in 
secondary structure from unfolded to alpha-helix in the N-terminal region19,49,50 (Figure 2-2 B) 
and that a fraction of αSyn interacts with the presynaptic membrane and membranes of synaptic 
vesicles51-54. It has been hypothesized that this binding of αSyn to vesicles inhibits their fusion 
with other membranes. The association of αSyn to lipid membranes seems to be supported by a 
topologically stressed bilayer–water interface: Accordingly, it appears to be critically dependend 
on surface curvature and lipid composition favored by strong surface curvature and negatively 
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charged lipids or membranes composed of zwitterionic lipids in the gel state but not in the 
liquid-crystalline state48,55,56.  
In line with its lipid-binding properties, the physiological function of αSyn may play a role in the 
regulation of the homeostasis of the presynaptic vesicular pool, of synaptic vesicle cycling and 
endocytosis23,32,35,37,57-59, and the regulation of neurotransmitter release19,60,61, especially for 
dopamine39,62-65. Apart from direct lipid-binding, there may also be an indirect effect of αSyn 
towards the regulation of synaptic transmission. In line with this, it has been described that 
αSyn can bind to and inhibit phospholipase D2 (PLD2) which is involved in vesicular trafficking 
and breakdown of phosphatidylcholine66-69. 
Several members of the family of natively unfolded proteins have been shown to have chaperone 
function19. For αSyn, the C-terminal region has been suggested to show chaperone activity 
(Figure 2-2 A). Thus, αSyn may act as auxiliary chaperone for the cysteine string protein alpha 
(CSPalpha) which acts as co-chaperone for soluble N-ethylmaleimide-sensitive factor 
attachment protein receptor (SNARE) proteins located in synaptic vesicles19,51. By this, αSyn may 
be involved in the facilitation and stabilization of SNARE complexes with overexpression of αSyn 
leading to decreased exocytosis in cultures of embryonic hippocampal neurons32,70,71. It has also 
been suggested that the C-terminal region can prevent the self-assembly of αSyn by interacting 
with its hydrophobic core region32,72,73 which is involved in the aggregation process of 
monomers into aggregates and amyloid fibrils19,74.  
The control of αSyn activity and/or its localization could be mediated by post-translational 
modifications (such as phosphorylation) for which the C-terminal region shows several putative 
sites32,75,76. Thus, αSyn can be phosphorylated at S129 by casein kinase I and G protein-coupled 
receptor kinases, modulating its lipid-binding properties69,77. Moreover, the C-terminal region 
has been shown to target recombinant αSyn into the nucleus, whereas the N-terminal and core 
region were required to target αSyn to the presynapse24,78.  
However, the functions of αSyn described above are by far not complete and a variety of 
additional mechanisms with involvement of αSyn have been suggested. According to this, its 
expression has been shown to be upregulated in early development79. Additionally, αSyn 
conveys protection against oxidative stress by inhibiting the c-Jun N-terminal kinase (JNK) 
stress signaling pathway in neuronal cells80. It has also been shown to bind to histones81 and 
affect histone acetylation24,82 and to influence the function of nuclear proteins32,78,81,82. 
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2.3 Evidence for αSyn as Important Factor in Neurodegeneration 
The first evidence for an involvement of αSyn in neurodegenerative disorders came in 1993, 
when αSyn was identified as non-amyloid-beta component in amyloid preparations from 
patients suffering from AD27,28. Later on, αSyn was also found to be the principal component of 
Lewy bodies24,45,83 where it occurs as highly ordered amyloid-type fibril45,84,85 (Figure 2-1 D) and 
usually appears to be subjected to post-translational modifications like cleavage, S129 
phosphorylation, oxidation, and nitration, which increase the rate of oligomer formation19,32,86-92. 
The aggregation of αSyn can also be observed in solution in vitro where full-length αSyn and 
peptides derived from it form aggregates and amyloid fibrils with a morphology comparable to 
fibrils purified from Lewy bodies19,93,94.  
Critically important for the aggregation process appears to be the NAC-region (comprising 
amino acids 61-95) (Figure 2-2 A) which consists largely of hydrophobic amino acids: The 
aggregation behavior of beta-synuclein (βSyn) – which differs from αSyn by the absence of 
eleven amino acids (73-83) in the NAC-region – has been discussed controversially, but overall a 
reduced aggregation propensity compared to αSyn can be postulated95-99. Moreover, an area of 
12 amino acids inside the NAC region (71-82) was shown to be necessary and sufficient for αSyn 
fibrillization100.  
A causal part of αSyn in disease progression can be assumed due to the presence of aggregated 
αSyn in neuronal populations which correlates to the onset of cell loss32,101-103. This αSyn 
pathology precedes cell loss in a model where mice had been injected with preformed fibrils, 
suggesting that pathological αSyn species are the main driver of neurodegeneration32,103-105. 
Although the vast majority of PD cases is sporadic106, clues for an involvement of αSyn in the 
development of PD also come from gene mutations detected in familial PD cases. Thus, several 
disease-associated mutations leading to single amino acid exchanges have been identified in the 
SNCA gene: A53T107, A30P108, E46K109, H50Q110, G51D111, and A53E112 (Figure 2-2 A, B). The 
pathological mode of action of these mutations is currently largely unsolved, but A30P, E46K, 
and A53T have been shown to increase the aggregation rate of αSyn94,113. Additionally, 
duplication or triplication of the SNCA gene cause parkinsonian symptoms with the age of onset 
and severity of symptoms correlating with the gene copy number19,105,114-116. Recently, a number 
of polymorphisms in the promoter region of αSyn has been described as risk factors for PD117, 
and genome-wide association studies indicate a connection between the SNCA locus and 
PD32,118,119. In line with this are experiments in mice and flies where overexpression of human 
αSyn was accompanied by neuronal dysfunction, loss of neurons and synaptic terminals, and an 
unphysiological motor phenotype19,120,121.  
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Interestingly, several genetic risk factors for PD comprising mutations in other genes than SNCA 
might actually exert their pathological potential via αSyn. Accordingly, mutations in 
gluocerebrosidase which cause Gaucher’s disease also increase the amount of αSyn and the risk 
for PD122,123. In addition, Lewy pathology has been observed for mutations in a variety of 
proteins including DJ-1, PINK1, GBA and likely also LRRK2, Parkin, and ATP13A2124-129.  
Not only genetic risk factors but also several environmental risk factors for the development of 
PD have been shown to influence αSyn aggregation130. According to epidemiological studies, the 
exposure to heavy metals like iron represents one such risk factor131. Indeed, alterations in brain 
iron levels with an increased iron load in the SN have been described in PD 132-134.  Elevated brain 
iron levels in PD patients can be detected using magnetic resonance tomography or transcranial 
sonography (TCS). This might already be possible early in the course of disease, and elevated 
brain iron levels might precede neurodegeneration since several persons rated as healthy 
subjects showed increased echogenicity and were clinically diagnosed with PD several years 
later135,136. In the post-mortem tissue of PD patients, elevated brain iron levels and a shift in the 
ferrous-to-ferric iron ratio towards ferric iron can be observed137,138. In line with this, iron 
chelators show a neuroprotective effect in the SN in PD models139-143. 
In vitro, ferric iron and other metal ions have been shown to increase αSyn aggregation131,144,145, 
and αSyn promotes the production of reactive oxygen species (ROS) in the presence of iron146. 
Interestingly, oxidative stress in turn increases the formation of iron-induced αSyn oligomers144, 
presumably resulting in a vicious circle. According to post-mortem studies in PD brains, several 
molecules appear to be damaged as a result of oxidative stress including lipids, proteins, and 
DNA132,147. 
Additionally, pesticides like paraquat148 or rotenone149,150 have been suggested to increase αSyn 
aggregation and to promote PD-like progression via increased release of αSyn from enteric 
neurons151. The interaction with αSyn and the stabilization of a protofibril stage of aggregation 
by dopamine and related catecholamines152,153 might in parts explain, why dopaminergic 
neurons in the SNpc are particularly vulnerable to αSyn-mediated toxicity in PD. Taken together, 
several lines of evidence point to a central role of αSyn in the development of PD.  
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2.4 The Toxic αSyn Species and the Pathological Mechanism 
To date, the toxic species and the pathological mechanism(s) of αSyn aggregation remain 
obscure24.  
Besides the prototypical amyloid fibrils with a typical width of 12-15 nm that can be found in 
LBs several different molecular species have been described24,32,152,154-156. These include short 
β-sheet-rich fibril-like intermediates, termed protofibrils, that can assemble linearly forming 
chains154 or circularly forming ring structures consisting of 25 to several hundred αSyn 
molecules32,152,156. Since cell death cannot be explained by the presence of fibrillar αSyn 
aggregates, and since overexpression of αSyn can lead to disruption of organelles and cell death 
in the absence of detectable fibrillary deposits, it was suggested that such smaller, oligomeric 
species – which may be on- or off-pathway to amyloid fibrils – might comprise the cytotoxic 
αSyn species157-160. To date, this hypothesis has not been proven but is supported by several 
lines of (indirect) evidence19,161,162.  
Concerning their structural features, αSyn oligomers show similarities to oligomers of other 
disease-associated peptides such as amyloid-beta, polyglutamine, or prion peptide 106-126, 
supporting the hypothesis of a common pathological mechanism in different neurodegenerative 
disorders163. Iron has been shown to promote aggregation of αSyn resulting in toxicity in cell 
culture164-166, and the inhibition of αSyn oligomer formation reduces cytotoxicity, suggesting a 
toxic effect of αSyn oligomers165. Moreover, large iron-induced αSyn oligomers lead to increased 
intracellular calcium dyshomeostasis and excitotoxic neuronal death by enhancing pre- and 
post-synaptic α-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA) receptor-mediated 
synaptic transmission167. Further indirect evidence comes from αSyn-expressing cells which 
show increased but unspecific cation permeability162,168. Moreover, αSyn oligomers were shown 
to increase calcium permeability and cause cell death32,169. In vivo, the overexpression of αSyn 
with mutations that favor oligomer formation (E57K and E35K) in the midbrain of rats results in 
increased loss of dopaminergic neurons, whereas mutations that lead to a quick fibrillization of 
αSyn are less toxic32,169.  
Since αSyn protofibrils can display an annular structure that is reminiscent of bacterial pore-
forming toxins161,170, a common hypothesis for the oligomer-mediated toxicity is the formation of 
pore-like structures in cellular membranes leading to membrane permeabilization170,171. This is 
supported by the finding that the binding affinity of αSyn to membranes depends on its 
aggregation state with intermediates – formed during the conversion from monomeric αSyn to 
fibrils – showing highest affinity19,172. Moreover, the binding of αSyn protofibrils to phospholipid 
vesicles is much stronger than that of monomeric or fibrillar αSyn161,170,173. Interestingly, αSyn 
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oligomers show a modified lipid-binding behavior compared to monomeric αSyn: In contrast to 
monomeric αSyn, iron-induced oligomers can bind to membranes independently of charge, lipid 
composition, or surface curvature with high affinity56. Recently, our group was able to show that 
iron-induced αSyn oligomers lead to the insertion of distinct pore species in lipid bilayers in 
vitro171. Taken together, this might account for a pathological mechanism in which αSyn 
oligomers can bind to the plasma membrane or membranes of cell organelles such as ER or 
mitochondria with high affinity, where the insertion of pores results in impaired organell 
function leading to reduced cell viability.   
Meanwhile, a number of studies suggests a role of oxidative stress and mitochondrial 
dysfunction in αSyn-mediated toxicity19. First hints for an involvement of mitochondria came in 
1976, when Barry Kidston, a 23-year-old chemistry graduate student, developed parkinsonian 
symptoms three days after consumption of the self-synthesized opioid drug MPPP (1-methyl-4-
phenyl-4-propionoxypiperidine or desmethylprodine). When Kidston died 18 months later 
(from a cocaine overdose), brain autopsy revealed destruction of dopaminergic neurons in the 
SN. Some years later, several young adults developed sudden, severe parkinsonism after 
consumption of synthetic heroin. In both cases, contaminations with MPTP (1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridin), a selective inhibitor of mitochondrial complex-I, were detected174-176. 
Treatment of squirrel monkeys with MPTP-induced permanent parkinsonism177, while mice 
lacking αSyn appeared to be resistant against MPTP induced degeneration of dopaminergic 
neurons178,179. Additionally, it has been described that αSyn binds to mitochondria and that 
changes in the amount of αSyn can influence mitochondrial function32,180-183. Furthermore, the 
expression of mutant αSyn leads to mitochondrial defects, promotes cell death and enhances 
susceptibility to oxidative stress19.  
It has also been suggested that αSyn exists mainly as physiological tetramer184 and that the 
interaction of αSyn multimers with membranes is a physiological event. Then, disease-
associated mutations located within a small part of the N-terminal region could lead to 
disruption of physiological αSyn multimers and thus decrease membrane binding affinity of 
αSyn32,184-189. Furthermore, the disruption of tetrameric αSyn to unfolded monomers has been 
discussed as starting point for pathological αSyn aggregation32,190. However, the tetramer 
hypothesis is under strong debate and the scientific relevance remains questionable191.  
Several additional mechanisms have been described for αSyn-mediated toxicity such as ER 
stress and unfolded protein response (UPR) activation, which are likely to be both cause and 
effect in the pathogenesis of PD, or dysfunction of the ubiquitin proteasome system, calcium 
homeostasis dysregulation, and neuroinflammation19,32.   
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All in all, to date it, remains unclear if one specific pathological oligomeric αSyn species or 
several different pathological species can act via one specific or several different pathological 
mechanisms. Yet, the development of small molecule modulators of αSyn oligomerization 
appears to represent a promising strategy towards new treatment options for 
neurodegenerative disorders in general and PD in particular192. Indeed, inhibition of 
polyglutamine oligomerization has shown beneficial effects in models of Huntington’s disease193, 
and anle138b – which inhibits αSyn oligomer formation and prion propagation in vitro – also 
displays beneficial effects on pathology in in vivo models of synucleinopathies and prion 
diseases192. 
 
2.5 Cell Models for the Investigation of Synucleinopathies 
Using models to study disease mechanisms is inevitable, yet every model system will differ from 
the process being modelled. Moreover, since studying disease mechanisms is usually performed 
for diseases where the pathomechanism is not fully understood yet, models will rely on an 
incomplete assembly of well-known characteristics of the disease of interest and, thus, will not 
necessarily represent a complete picture of it194. For this, choosing a combination of different 
suitable models should increase the probability of gaining relevant information concerning the 
process being modelled. 
While in vitro methods hold high potential to study principle mechanisms in short time and a 
simplified environment, no information concerning cytotoxicity can be obtained. Animal studies, 
on the other hand, hold the benefit of investigating mechanisms in a complex environment but 
are usually much more expensive and time-consuming, more restricted concerning the number 
of independent experiments and require some lead time due to governmental regulations. 
Besides, the use of rodent models and rodent cells has been discussed critically since these 
models may have low predictivity for human disease states195,196. 
A promising strategy to improve the poor translation rate from animal models to human 
patients is represented by a more detailed characterization of drug candidates in combinations 
of more and better in vitro and in vivo models. Thus, attempts to provide elaborated disease 
models based on human cells are ongoing197,198. Cell models with a human background provide 
the opportunity to close a fundamental gap between in vitro studies and experiments performed 
in animals since they represent a more complex experimental setup than in vitro experiments 
with the potential to assess complex interactions and cytotoxicity on a much shorter time scale 
than experiments performed in animal models. Concerning αSyn-mediated toxicity, they also 
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enable the investigation of timing of αSyn aggregation relative to downstream events, hereby 
increasing the chance of identifying αSyn-mediated toxic effects162.  
The investigation of αSyn oligomers is hampered by the fact that oligomers represent transient 
intermediates whose formation depends on non-covalent interactions and appears to be highly 
dynamic162. Thus, oligomerization is influenced by external conditions like concentration, 
temperature, and medium composition95,199-201. Since αSyn oligomers are submicroscopic 
particles, their detection requires indirect biochemical methods such as native gel 
electrophoresis, density gradient centrifugation, or size exclusion chromatography. 
Alternatively, microscopic methods can be applied that include additional preparatory steps 
such as atomic force microscopy, or fluorescence labeling like fluorescence intensity distribution 
analysis200,202-205. However, apart from being time-consuming and labor-intensive, none of these 
methods enables the investigation of the formation of αSyn oligomers in a cellular environment 
in real time206. To overcome this problem, a bimolecular protein fragment complementation 
assay (PCA) has been developed to study αSyn aggregation207,208 applying both luminescence 
using Gaussia princeps luciferase and fluorescence using a variety of fluorescence proteins 
including Venus, a variant of the yellow fluorescent protein (YFP)209-216. 
Several cell culture models have been established to study αSyn oligomerization and αSyn-
mediated toxicity. Over the last years, more and more studies using human induced pluripotent 
stem cells (iPSCs) have been published217-219, and these models will certainly gain further 
relevance in the future. However, by now, the usage of iPSCs has two important drawbacks 
compared to established cell lines: It is very money- and time-consuming1. 
Cultures of primary midbrain dopaminergic neurons, usually derived from mice or rats, hold 
high potential to study the effect of αSyn aggregation and cytotoxicity220. These primary neurons 
are suited to dissect mechanisms of neurodegeneration including neurite retraction and 
neuronal death. Moreover, they enable the investigation of pharmacological compounds and 
their underlying mechanism(s)1,221. On the other hand, the preparation of primary cultures from 
midbrain dopaminergic neurons requires some experience and is time-consuming. Moreover, 
primary neurons are usually less susceptible to transient transfection mechanisms1. 
Furthermore, breeding and maintenance of transgenic rodents requires man power and the 
existence of an animal facility. Finally, the use of rodent dopaminergic neurons might be limited 
since humans are the only known species which is affected by the development of PD32,222.  
Several established human cell lines have been used to unravel mechanisms of αSyn-mediated 
neurodegeneration. In contrast to iPSCs or cultures from primary dopaminergic neurons, 
established cell lines tend to acquire some artificial features over time. HEK293 cells or H4 cells, 
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e.g., show multiplication of chromosomes. Thus, their phenotype might be more different from 
human dopaminergic neurons compared to iPSCs or primary dopaminergic neurons, although 
the existence of more than one cell type in primary cultures can often not be excluded. On the 
other hand, established cell lines have several advantages compared to iPSCs and primary 
cultures: Most of them, such as HEK293 cells and H4 cells, are quite easy in handling and 
susceptible to transient transfection. Furthermore, the cell populations are very comparable 
between different experiments. 
The commonly used HEK293 cells were derived from human embryonic kidney1,223 and have 
been used extensively to study pathological mechanisms of PD1,224-228. However, a drawback of 
HEK293 cells is the lack of a neuronal phenotype. 
Another group of established cell lines with neuronal background has been derived from brain 
tumors. SH-SY5Y cells, for example, have been derived from human neuroblastoma cells and are 
commonly used to investigate neurodegenerative mechanisms1 including the overexpression of 
αSyn1,229 and transmembrane seeding of αSyn aggregation230. However, SH-SY5Y cells are hard 
to differentiate into a postmitotic mature dopaminergic state1. NT2 and hNT are human cell lines 
that have been derived from embryonic teratocarcinomas and can be differentiated to a 
postmitotic neuronal phenotype231,232. H4 cells, derived from human neuroglioma represent 
another commonly used cell line for the investigation of αSyn oligomerization and related 
toxicity210,233,234. Based on H4 cells, Outeiro et al. established a cell line which stably 
overexpresses variants of αSyn213. A drawback of all of these tumor-derived cell lines is that they 
show only a moderate neuronal phenotype1.  
Since brain cells physiologically show very low proliferation rates, they are naturally more 
difficult to cultivate than established cell lines. This problem can be overcome by Lund human 
mesencephalic (LUHMES) cells. This cell line was derived from 8-week-old human fetal ventral 
mesencephalic cells and immortalized by tetracycline-regulated expression of v-myc using the 
LINXv-myc retroviral vector235. In the absence of tetracycline, expression of v-myc from a 
minimal human cytomegalovirus (CMV) promoter is enhanced by a tetracycline transactivator 
resulting in continuous proliferation. Upon addition of tetracycline, the tetracycline 
transactivator is inactivated and expression of v-myc is turned off. Additional incubation with 
glial cell line-derived neurotrophic factor (GDNF) and cyclic adenosine monophosphate (cAMP) 
induces differentiation to a neuronal phenotype within five days236. Once differentiated, 
LUHMES cells show features of dopaminergic neurons: They release dopamine and show 
neuronal electric properties237,238. LUHMES cells have been used to study dopamine-related cell 
death mechanisms236,238,239 but also other features of neurodegeneration239,240 and seem to 
become more and more popular in PD research. Moreover, the cultivation of LUHMES cells does 
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not require addition of components obtained from animals (like fetal bovine serum, FBS). Thus, 
using LUHMES cells is in line with the development of alternative systems to reduce the amount 
of sacrificed animals in science. Unfortunately, transient transfection is very inefficient in 
LUHMES cells. Thus, for efficient transfection a lentiviral approach is necessary1. 
So far, formation, modulation, and toxicity of αSyn oligomers have mainly been studied in two 
kinds of cell models: First, cell models in which the overexpression of αSyn is induced by 
transient transfection241 or viral transduction242. Second, cell models in which the gene coding 
for αSyn is stably inserted and constitutively overexpressed243. Both strategies hold several 
drawbacks: (1) When using transient transfection or viral transduction, the fraction of transgene 
expressing cells and the strength of overexpression are subject to great inter-experimental 
variation. Moreover, individual experiments are rather time-consuming and expensive. 
Additionally, the initiation of expression cannot be defined accurately, and for several cells (such 
as primary cells and LUHMES cells) transient transfection is very inefficient. (2) Constitutive 
overexpression of αSyn enables the investigation of αSyn oligomers only in steady state but not 
the investigation of de novo oligomer formation. This hinders the identification of compounds 
which prevent αSyn aggregation but are not capable of degrading preformed αSyn aggregates. 
Moreover, the constitutive overexpression of αSyn and the resulting αSyn-mediated toxicity may 
result in selection for cells that are resistant to αSyn-mediated toxicity. This might interfere with 
the investigation of potential toxic effects. For these reasons, a system for the fast and easy 
creation of stable and inducible αSyn overexpression that is applicable to a variety of cell lines to 
investigate αSyn-mediated effects in different synucleinopathies would be desirable.  
 
2.6 Aim of this Study and Project Strategy 
The aim of this study was to develop a system for the fast and easy creation of cell lines which 
inducibly overexpress variants of αSyn upon incubation with certain chemical agonists that can 
be applied to a variety of established and primary cell lines for the investigation of aggregation, 
modulation, and toxicity of αSyn oligomers with regard to PD and other synucleinopathies.  
We decided to overexpress different kinds of αSyn constructs based on untagged human 
wildtype αSyn-140 which is the most abundant splice-variant of αSyn in humans (Figure 2-3 A). 
Since this variant can only be visualized indirectly, we also used a construct where αSyn-140 is 
coupled to the fluorescence protein Venus for direct visualization (Figure 2-3 B). Venus is a YFP-
variant and holds the advantage over GFP244-248 that it shows improved maturation (especially at 
37°C) and brightness, and is less sensitive towards environmental influences249,250. Since 
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fluorescence tags might interfere with the protein function, results obtained with this kind of 
construct have to be controlled carefully. Moreover, we used a bimolecular fluorescence 
complementation (BiFC) system in order to study the aggregation of αSyn (Figure 2-3 C). BiFC 
assays have widely been used to study protein-protein interactions251 and have been established 
for studying αSyn interaction by Outeiro et al.213. In short, the protein of interest (here: αSyn) is 
coupled to the N-terminal or C-terminal part of a fluorescence protein (here: Venus), 
respectively. Each construct alone does not show any fluorescence signal. Upon interaction of 
two suited αSyn proteins the N-terminal and C-terminal part of Venus are brought into close 
proximity. This results in complementation of these fragments and a fluorescence signal can be 
detected. Thus, the BiFC assay enables the detection of αSyn oligomers without background 
signals from monomeric αSyn. Moreover, if we assume that the complementation of N- and C-
terminal Venus is a statistic event, the fluorescence intensity should be directly proportional to 
the extent of aggregation. This allows a fast and easy readout for high-throughput screening 
assays for anti-aggregative compounds. On the other hand, it has been described that the 
complementation of fluorescence proteins might stabilize pre-existing protein-protein 
interactions213. Moreover, the signal-to-noise ratio is a common problem in BiFC systems which 
is difficult to control for251. Additionally, we planned to establish cell lines that overexpress 
Venus alone as a control. To be able to estimate the fraction of transduced cells we also 
established cell lines which inducibly overexpress untagged αSyn and constitutively overexpress 
mCherry-NLS, a fluorescence protein which is coupled to a nucleotide localization sequence. In 
this case, all cells that took up the αSyn construct will show a fluorescence signal with an 
emission maximum of 610 nm in the nucleus248. 
Inducible expression in cell lines is often achieved using Tet-On or Tet-Off systems252,253. Since 
differentiation of LUHMES cells is mediated by a Tet-Off system, we decided to apply induction 
systems which act independently of tetracycline and followed two different strategies: 
First, we used a modified GAL4-UAS system254, GAL4_EcR-UAS (GE), which has been established 
in zebrafish by Esengil et al.255 and has been optimized for cell culture application by Peer-
Hendrik Kuhn (unpublished) (Figure 2-3 D-E). In this system, the DNA-binding and 
homodimerization regions of GAL4 (a yeast transcription factor) have been coupled to the 
activation domain of the herpes simplex virus regulatory protein VP16 and the ligand binding 
domain of the insect-specific ecdysone receptor from Bombyx mori (GAL4_EcR). There are no 
known vertebrate orthologues of EcR, and EcR agonists have no known effect in vertebrates255-
258. The GAL4_EcR protein is constitutively expressed from a human ubiquitin-C promoter (Ubi), 
while the gene of interest (GOI) is located downstream of an upstream activation sequence 
(UAS) and requires binding of GAL4 to the UAS in order to be transcribed from a minimal E1b 
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promoter. In the absence of an ecdysone agonist, binding of GAL4_EcR to the upstream 
activation sequence (UAS) is prevented by unclear mechanisms255. Thus, transcription of the GOI 
does not take place (Figure 2-3 D). The interaction of an ecdysone agonist, such as tebufenozide, 
with the EcR induces binding of GAL4_EcR to the UAS. As a consequence, transcription of the GOI 
is induced, resulting in its expression and production of the protein of interest (POI) (Figure 
2-3 E). 
Second, we also established viruses for inducible expression using the Cre_ERT2-loxP (CET2) 
system259-261. Here, Cre recombinase is coupled to the modified estrogen receptor ERT2, which 
shows higher affinity for 4-OH-tamoxifen over estrogen compared to wildtype (wt) ER260. The 
Cre_ERT2 protein is constitutively expressed from a human ubiquitin-C promoter. The GOI is 
located downstream of a constitutively active human phosphoglycerol kinase (hPGK) promoter 
and a floxed puromycin resistence gene (i.e., it is flanked by two loxP sites). In the absence of 
tamoxifen, Cre cannot interact with the loxP sites. Thus, translation of the mRNA stops at the 
termination codon in puromycin and the GOI is not expressed (Figure 2-3 F). Upon binding of 
4-OH-tamoxifen to ERT2, Cre will interact with the loxP sites and excise the floxed puromycin 
gene, leading to expression of the GOI (Figure 2-3 G).  
In order to insert the required machineries for inducible expression we used lentiviruses. It has 
been shown that expression rates are more stable when using lentiviruses compared to 
transient transfection and antibiotic selection262. The transduction of cells with lentivirus 
particles leads to the stable insertion of the expression constructs into the host genome. To 
insert all components of the induction system into the host genome the cells have to be 
transduced with two different kinds of viruses: a driver virus carrying the GAL4_EcR system 
(GAL4 driver) or the Cre_ERT2 system (Cre driver) and a corresponding receiver virus carrying 
the UAS-GOI system (UAS-GOI receiver) or the loxP-GOI system (loxP-GOI receiver).  
For the BiFC system, an equimolar expression rate of the two hemi-Venus constructs (V1S and 
SV2) would be desirable. Expressing two GOIs from one promoter via an IRES sequence holds 
the disadvantage that expression of the GOI downstream of the IRES is usually lower than 
expression of the GOI upstream of the IRES sequence263. To overcome this problem, we decided 
to couple the hemi-Venus constructs by a “self-cleaving” P2A sequence derived from porcine 
teschovirus-1. Several 2A sequences have been described of which the P2A sequence showed the 
highest “cleavage” efficiency in a variety of model system264-266. Separation of transgenes coupled 
via 2A sequences occurs on the level of translation due to ribosomal skipping of a peptide 
bond267. In contrast to IRES sequences, 2A sequences are shorter and show stoichiometric 
expression of multiple proteins264.  
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In summary, we here present a valuable system for the fast and easy creation of cell lines with 
inducible αSyn overexpression relying on the CET2 system or the GE system. The system applies a 
strategy based on lentiviral transduction to stably integrate the expression machinery of both 
systems into the host genome. Overexpression of αSyn only occurs upon incubation with a 
certain agonist (4-OH-tamoxifen or tebufenozide).  
The system was first established in H4 cells, a human neuroglioma cell line which has become a 
well-established model in research for neurodegenerative diseases. H4 cells are very robust and 
quite easy and cheap in handling, making them a valuable model to establish the above 
described expression systems and for high-throughput screening assays. Since the H4 cell lines 
relying on the GE system (H4_GE cells) showed higher transgene induction than the H4 cell lines 
relying on the CET2 system (H4_CET2 cells), the H4_GE cells were further characterized and the 
GE system was applied for the creation of additional cell lines. 
We show a detailed analysis of the expression characteristics of the tebufenozide-dependent 
transgene expression in H4_GE cells. Using the H4_GE cell model we found that incubation with 
DMSO and ferric iron led to a stronger increase in fluorescence intensity in a bimolecular 
fluorescence complementation (BiFC) model for αSyn aggregation compared to other tri-, bi-, 
and monovalent metal ions. Additionally, incubation with DMSO and FeCl3 increased αSyn 
protein load in all tested αSyn overexpressing H4_GE cells and led to the detection of higher 
molecular αSyn species after sucrose gradient centrifugation. Taken together, these results 
suggest that incubation with DMSO and FeCl3 increased aggregation of αSyn in the H4_GE cell 
model. Furthermore, the strategy for the creation of stable inducible cell lines was not limited to 
H4 cells but was also succesfully applied to LUHMES cells. 
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Figure 2-3: Overview of αSyn constructs and induction systems 
Cell models were generated for the inducible overexpression of different αSyn constructs:  
A) Unmodified human αSyn. 
B) αSyn coupled to the fluorescent protein Venus. 
C) αSyn coupled to the N-terminal part of Venus (V1; 1-157) or the C-terminal part of Venus (V2; 
158-240) for a BiFC assay. 
Inducible overexpression using the GAL4_EcR-UAS (GE) system:  
D) No expression of the GOI in the absence of tebufenozide since binding of GAL4 to the UAS is 
inhibited. 
E) Expression of the GOI is induced upon interaction of tebufenozide with EcR resulting in 
binding of GAL4 to the UAS. 
Inducible overexpression using the Cre_ERT2-loxP (CET2) system: 
F) No expression of the GOI in the absence of 4-OH-tamoxifen since binding of Cre recombinase 
to the loxP sites is inhibited and translation is terminated at the stop-codon of puro. 
G) Expression of the GOI is induced upon interaction of 4-OH-tamoxifen with ERT2 resulting in 
excision of the floxed puro gene by Cre recombinase.  
Syn: αSyn; V1: N-terminal Venus fragment; V2: C-terminal Venus fragment; Ubi: human ubiquitin-C 
promoter; EcR: ecdysone receptor; UAS: upstream activation sequence; E1b: minimal E1b-promoter; 
GOI: gene of interest; POI: protein of interest; Cre: Cre recombinase; ERT2: estrogen receptor, optimized 
for tamoxifen over estrogen; hPGK: human phosphoglycerol kinase promoter; Puro: puromycin 
resistance gene; red triangle: loxP site 
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3 Materials and Methods 
3.1 Creation and Transformation of XL2-Blue Competent E. coli 
In order to obtain competent cells for transformation, 10 ml of antibiotic-free LB medium (5 g/l 
yeast extract (Carl Roth, 2363.1), 10 g/l tryptone/peptone (Carl Roth, 8952.3), 10 g/l NaCl (Carl 
Roth, 3957.1)) were inoculated with 2 µl of XL2-Blue competent cells (kind gift from Klaus 
Förstemann) and incubated in a shaker at 37°C and 225 rpm overnight. 1 ml of the overnight 
culture was then added to 100 ml LB medium and incubated in a shaker at 37°C and 130 rpm 
until it reached an optical density (OD600) of 0.7-0.8. Optical density was measured using a 
photometer (Eppendorf AG, Hamburg). Afterwards the culture was cooled on ice and transferred 
to two 50-ml Falcons and centrifuged at 4°C and 3220 relative centrifugal force (rcf) for 15 min 
(5810 R, Eppendorf, Hamburg). The supernatant was discarded and the pellet was resuspended 
in 25 ml of freshly diluted precooled and sterile filtered 0.1 M CaCl2 solution and incubated on 
ice for 30 min. Afterwards the cells were centrifuged for 15 min at 3,320 rcf and 4°C. The 
supernatant was discarded and the pellet was resuspended in 2.5 ml of precooled 0.1 M CaCl2 
solution supplemented with 10% glycerol. The competent cells were then frozen in liquid 
nitrogen in 100 µl aliquots and stored at -80°C.  
For transformation cells were thawed on ice before 1 to 100 ng of plasmid (but not more than 
10 µl total volume) was added. Cells were incubated on ice for 30 min and afterwards 
heat-shocked for 1 minute at 42°C without shaking in a thermomixer (Eppendorf, 5355000.011). 
After incubating the cells on ice for 3 min, 900 µl of antibiotic-free LB medium was added and 
the mixture was incubated at 37°C and 225 rpm for 1 h in a shaker (CERTOMAT IS, Braun). 10 to 
200 µl were plated on LB-Amp plates (100 µg/ml ampicillin (Carl Roth, K029.2)), LB-Kan plates 
(100 µg/ml kanamycin (Carl Roth, T832.1)), or LB-Spec plates (100 µg/ml spectinomycin 
(Sigma, S4014), respectively.  
 
3.2 Plasmid Cloning 
Plasmids were expanded in XL2-Blue cells and extracted using the NucleoSpin Plasmid Mini kit 
(Macherey-Nagel, 740588.250). Glycerol stocks of transformed XL2-Blue cells were generated 
by mixing 600 µl of cell suspension with 200 µl glycerol (AppliChem, A1123.1000). 
The plasmids and primers used in this work are summarized in Table 3-1 and Table 3-2, 
respectively. 
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The constructs αSyn (S), VenusN-terminal fragment (V1), V1-αSyn (V1S), αSyn-VenusC-terminal fragment 
(SV2), SV2-P2A-sequence-V1S (SV2-P2A-V1S), SV2-P2A-sequence-V1 (SV2-P2A-V1), 
αSyn-Venusfull-length (SV), and Venus (V) (see Figure 2-3 A, B, C) were amplified from plasmids 
#1-#4 (see also Figure 8-1, kind gift from Pamela McLean) using polymerase chain reaction 
(PCR) and primers that carry a suitable restriction site. Plasmids #1-#4 were sequenced using 
primers MB1 and MB2. The different constructs were amplified according to Table 3-3. 
Following PCR amplification, amplificates were separated via agarose gel electrophoresis and 
purified using the NucleoSpin® Gel and PCR Clean-up kit (Macherey-Nagel, 740609.250). For 
ligation into the desired plasmids, constructs were cut with the corresponding restriction 
enzymes. In order to insert the construct SV2-P2A-V1S, the construct SV2-P2A-V1 was cut with 
the restriction enzymes HindIII and ClaI and the construct P2A-V1S was cut with the restriction 
enzymes ClaI and NotI. Both restricted constructs were ligated simultaneously into the desired 
plasmid. For transient transfection and constitutive expression, constructs were cloned between 
the HindIII and NotI site of the P12-HA-TGFa-FLAG-plasmid (Table 3-1, kind gift from Peer-
Hendrik Kuhn and Stefan Lichtenthaler).  
For the creation of lentiviral expression plasmids, αSyn constructs were first inserted between 
the HindIII and NotI site of the entry vector pCR8/GW/TOPO+pCS2-MCS (Figure 8-2 A, kind gift 
from Peer-Hendrik Kuhn and Stefan Lichtenthaler) and later on transferred to the destination 
vectors using the Gateway® Technology (Table 3-4, see also chapter 3.3). Destination vectors 
F2P-Delta Zeo-LoxP-Ko.Puro-LoxP-STNST-GW(DEST) (db 636, Figure 8-2 B), F2-Delta Zeo-
Kozak-Puro-5XUAS-E1b-(GW)Dest (db 597, Figure 8-2 C), F2-Delta Zeo-Kozak-Hygro-5XUAS-
E1b-(GW)Dest (db #44, Figure 8-2 D), and F2-Delta Zeo-Kozak-Zeo-5XUAS-E1b-(GW)Dest 
(db #45, Figure 8-2 E) were kindly provided by Stefan Lichtenthaler and Peer-Hendrik Kuhn. 
Destination vector F-Delta Zeo-Kozak-mCherry-NLS-5X UAS-E1b-(GW)Dest (db #92, Figure 
8-2 F) was created by amplifying mCherry-NLS from template plasmid #87 (addgene, plasmid 
#39319) using primers 42MB_SalI-mCherry_f and 43MB_NsiI_mCherry_r and subcloning 
between the XhoI and NsiI restriction sites of plasmid #45. 
Point mutations I152L in V1 and L201V in V2 were inserted using Pfu Turbo Cx hotstart DNA 
Polymerase (Agilent Technologies, 600412) in template plasmid #21 with primers 
MB31_V1_I152L_f and MB32_V1_I152L_r and in template plasmid #20 using primers 
MB33_V2_L201V_f and MB34_V2_L201V_r, respectively. After PCR, template plasmids were 
DpnI-digested for 1 h at 37°C followed by inactivation for 10 minutes at 80°C resulting in 
plasmids #63 and #53, respectively. 
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To create plasmid #71, V1SI152L was amplified from template plasmid #63 using primers 
MB24_V1_HindIIIf and MB6_V1S_Not1_r. For plasmid #73, V1I152L+Spacer was amplified from 
template plasmid #63 using primers MB24_V1_HindIIIf and MB39_V1+Sp_Not1_r. For plasmid 
#75, SV2L201V was amplified from template plasmid #53 using primers MB3_SV2_Hind3_f and 
MB25_V2_NotI_r. All constructs were then subcloned between the HindIII and NotI restriction 
sites of plasmid #14. 
The inserts of all newly created plasmids were sequenced (Eurofins Scientific, Luxemburg). For 
sequencing of inserts in plasmids with P12-HA-TGFa-FLAG backbone we used Eurofins standard 
primer T7 (5’-TAATACGACTCACTATAGGG-3’). For sequencing of inserts in plasmids with 
pCR8/GW/TOPO+pCS2-MCS backbone we used primer MB37_pCR8_r or Eurofins standard 
primer M13 uni (-21) (5’-TGTAAAACGACGGCCAGT-3’). For sequencing of inserts in plasmids 
with F2-Delta Zeo-Kozak-Puro-5XUAS-E1b-(GW)Dest (597) backbone we used primers 
MB26_691_fw and MB28_636+691_r. For sequencing of inserts in plasmids with F2P-Delta Zeo-
LoxP-Ko.Puro-LoxP-STNST-GW(DEST) (636) backbone we used primers MB27_636_fw and 
MB28_636+691_r.  
 
3.3 Gateway® Reaction 
In order to transfer the generated constructs into different expression plasmids we used the 
Gateway® Technology268. This technology utilizes the site-specific recombination provided by 
bacteriophage lambda269. Here, the gene of interest (GOI) is cloned between optimized 
attachment (att) sites attL1 and attL2 of the entry clone which serve as binding sites for 
recombination proteins. The destination vector carries a control of cell death B (ccdB) gene 
flanked by an attR1 and attR2 site. In the LR reaction, the recombination of the entry clone and 
the destination vector results in the creation of an expression clone which carries the GOI 
between two attB sites, and a by-product carrying ccdB between attP sites. CcdB is a bacterial 
toxin that targets the GyrA subunit of DNA gyrase270,271 and thus inhibits proliferation of most 
E. coli strains by preventing cleavage of double-stranded DNA. This results in a negative 
selection for bacteria that take up ccdB-containing vectors like unreacted destination vector or 
LR reaction by-product. 
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Table 3-1: List of plasmids 
This table summarizes information on plasmids that have been used in this study. #DB: Database number. 
#DB Insert Backbone 
#1 V1S pCS2 
#2 SV2 pCS2 
#3 SV pCS2 
#4 Venus pCS2 
#11 SV2-P2A-V1S P12-HA-TGFa-FLAG 
#12 SV2-P2A-V1 P12-HA-TGFa-FLAG 
#13 SV P12-HA-TGFa-FLAG 
#14 αSyn P12-HA-TGFa-FLAG 
#15 Venus P12-HA-TGFa-FLAG 
#20 SV2 pCR8/GW/TOPO+pCS2-MCS 
#21 V1S pCR8/GW/TOPO+pCS2-MCS 
#22 V1 pCR8/GW/TOPO+pCS2-MCS 
#23 SV pCR8/GW/TOPO+pCS2-MCS 
#24 αSyn pCR8/GW/TOPO+pCS2-MCS 
#25 Venus pCR8/GW/TOPO+pCS2-MCS 
#32 SV2 F2P-Delta Zeo-LoxP-Ko.Puro-LoxP-STNST-GW(DEST) (636) 
#33 V1S F2P-Delta Zeo-LoxP-Ko.Puro-LoxP-STNST-GW(DEST) (636) 
#34 V1 F2P-Delta Zeo-LoxP-Ko.Puro-LoxP-STNST-GW(DEST) (636) 
#35 SV F2P-Delta Zeo-LoxP-Ko.Puro-LoxP-STNST-GW(DEST) (636) 
#36 αSyn F2P-Delta Zeo-LoxP-Ko.Puro-LoxP-STNST-GW(DEST) (636) 
#37 Venus F2P-Delta Zeo-LoxP-Ko.Puro-LoxP-STNST-GW(DEST) (636) 
#38 SV2 F2-Delta Zeo-Kozak-Puro-5XUAS-E1b-(GW)Dest (597) 
#39 V1S F2-Delta Zeo-Kozak-Puro-5XUAS-E1b-(GW)Dest (597) 
#40 V1 F2-Delta Zeo-Kozak-Puro-5XUAS-E1b-(GW)Dest (597) 
#41 SV F2-Delta Zeo-Kozak-Puro-5XUAS-E1b-(GW)Dest (597) 
#42 αSyn F2-Delta Zeo-Kozak-Puro-5XUAS-E1b-(GW)Dest (597) 
#43 Venus F2-Delta Zeo-Kozak-Puro-5XUAS-E1b-(GW)Dest (597) 
#44 ccdB F2-Delta Zeo-Kozak-Hygro-5XUAS-E1b-(GW)Dest  
#45 ccdB F2-Delta Zeo-Kozak-Zeo-5XUAS-E1b-(GW)Dest  
#46 SV2 in 44 F2-Delta Zeo-Kozak-Hygro-5XUAS-E1b-(GW)Dest  
#47 Venus in 44 F2-Delta Zeo-Kozak-Hygro-5XUAS-E1b-(GW)Dest  
#48 SV2 in 45 F2-Delta Zeo-Kozak-Zeo-5XUAS-E1b-(GW)Dest  
#49 Venus in 45 F2-Delta Zeo-Kozak-Zeo-5XUAS-E1b-(GW)Dest  
#53 L201V in MB20 pCR8/GW/TOPO+pCS2-MCS 
#63 I152L in V1S pCR8/GW/TOPO+pCS2-MCS 
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Table 3-1: List of plasmids (continued) 
#DB Insert Backbone 
#71 V1S P12-HA-TGFa-FLAG 
#73 V1+Spacer P12-HA-TGFa-FLAG 
#75 SV2 P12-HA-TGFa-FLAG 
#87 mCherry-NLS pmCherry-C1 
#88 V1_I152L+Spacer P12-HA-TGFa-FLAG 
#90 SV2_L201V P12-HA-TGFa-FLAG 
#91 V1S_I152L P12-HA-TGFa-FLAG 
#92 ccdB F-Delta Zeo-Kozak-mCherry-NLS-5X UAS-E1b-(GW)Dest 
#97 psPAX2  
#98 VSV-G pcDNA3.1  
#99 Zeo-GAL4-VP16 FUGW 
#100 Zeo-GAL4-VP16-EcR FUGW 
#101 F2U-Delta Zeo-iCre FUGW 
#102 F2U-Delta Zeo-iCre_ERT2 FUGW 
#120 S F-Delta Zeo-Kozak-mCherry-NLS-5X UAS-E1b-(GW)Dest 
597 ccdB F2-Delta Zeo-Kozak-Puro-5XUAS-E1b-(GW)Dest 
636 ccdB F2P-Delta Zeo-LoxP-Ko.Puro-LoxP-STNST-GW(DEST) (636) 
---   Empty pCR8/GW/TOPO+pCS2-MCS 
 
 
For the LR reaction, 75 ng of the entry clone and 0.5 µl of the destination vector (150 ng/µl) were 
incubated in a 1.5-ml microcentrifuge tube. TE buffer, pH 8.0, was added to a total volume of 
4 µl. Afterwards the LR ClonaseTM II enzyme mix (Invitrogen, 11791-020) was thawed on ice, 
briefly vortexed and spun down. 1 µl of LR ClonaseTM II enzyme mix was added to the reaction 
followed by vortexing briefly and short centrifugation. The reaction mixture was incubated at 
25°C for 1 h before 1 µl of Proteinase K solution was added to stop the reaction. Afterwards the 
samples were incubated for 10 min at 37°C. XL2-Blue competent cells were transformed with 2 
µl of the LR reaction mixture, plated on LB plates containing 100 µg/ml ampicillin (Carl Roth, 
K029.2), and incubated at 37°C overnight. A summary of entry clones, destination vectors 
(Figure 8-3 A-D), and resulting plasmids is shown in Table 3-4. 
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Table 3-2: List of primers 
This table summarizes information on primers that have been used for molecular cloning or sequencing 
reactions in this study. 
Primer Name Sequence (5’-3’) 
MB1_BGH_r TAGAAGGCACAGTCGAGG 
MB2_SV40_polyA_r GAAATTTGTGATGCTATTGC 
MB3_SV2_Hind3_f GATCAAGCTTGCCACCATGGATGTATTCATGAAAGG 
MB4_SV2_P2A_r CACGTCTCCAGCCTGCTTCAGCAGGCTGAAGTTAGTAGCTCCGCTTCCCTTGTACAGCTCGTCCATGC 
MB5_V1S_P2A_f GCTGAAGCAGGCTGGAGACGTGGAGGAGAACCCTGGACCTATGGTGAGCAAGGGCGAGGAGC 
MB6_V1S_Not1_r GATCGCGGCCGCTTAGGCTTCAGGTTCGTAG 
MB7_Ven1_Not1_r GATCGCGGCCGCCTACTTGTCGGCGGTGATATAGACG 
MB8_SV_Hind3_f GCGCAAGCTTGCCACCATGGATGTATTCATGAAAGG 
MB9_SV_PspOMI_r  GATCGGGCCCTCTACAAATGTGGTATGGCTG 
MB10_V_Hind3_f GATAAAGCTTGCCACCATGGTGAGCAAGGGCGAGG 
MB11_Syn_Not1_r GATCGCGGCCGCCTAGGCTTCAGGTTCGTAGTCTTG 
MB24_V1_HindIIIf GATCAAGCTTGCCACCATGGTGAGCAAGGGCGAGGAGC 
MB25_V2_NotI_r GATCGCGGCCGCTTACTTGTACAGCTCG 
MB26_691_fw CGACTCTAGAGGGTATATAATGG 
MB27_636_fw AGCCCGGTGCCTGAATGCATTAGATAACTTCG 
MB28_636+691_r GGAGCAACATAGTTAAGAATACC 
MB31_V1_I152L_f CCACAACGTCTATCTCACCGCCG 
MB32_V1_I152L_r CGGCGGTGAGATAGACGTTGTGG 
MB33_V2_L201V_f CGACAACCACTACGTGAGCTACC 
MB34_V2_L201V_r GGTAGCTCACGTAGTGGTTGTCG 
MB37_pCR8_r CAGGAAACAGCTATGACC 
MB39_V1+Sp_Not1_r GATCGCGGCCGCCTACTTAAGGGACCCACCACC 
42MB_SalI_mCherry_f GATCGTCGACGCCACCATGGTGAGC 
43MB_NsiI_mCherry_r GATCATGCATTTATCTAGATCCGGTGGATCC 
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Table 3-3: Overview of the amplification of the different constructs 
This table summarizes information on the PCR amplification for the moleclular cloning of the different 
constructs for inducible overexpression. 
Construct Template Forward Primer Reverse Primer 
αSyn Plasmid #3 MB8_SV_Hind3_f MB11_Syn_Not1_r 
V1 Plasmid #1 MB24_V1_HindIIIf MB7_Ven1_Not1_r 
V1+Spacer Plasmid #1 MB24_V1_HindIIIf MB39_V1+Sp_Not1_r 
V1S Plasmid #1 MB24_V1_HindIIIf MB6_V1S_Not1_r 
SV2 Plasmid #2 MB3_SV2_Hind3_f MB25_V2_NotI_r 
SV2-P2A Plasmid #2 MB3_SV2_Hind3_f MB4_SV2_P2A_r 
P2A-V1S Plasmid #1 MB5_V1S_P2A_f MB6_V1S_Not1_r 
P2A-V1 Plasmid #1 MB5_V1S_P2A_f MB7_Ven1_Not1_r 
SV2-P2A-V1 SV2-P2A P2A-V1 MB3_SV2_Hind3_f MB7_Ven1_Not1_r 
SV Plasmid #3 MB8_SV_Hind3_f MB9_SV_PspOMI_r 
V Plasmid #3 MB10_V_Hind3_f MB9_SV_PspOMI_r 
 
 
3.4 Cell Maintenance 
All cell lines were tested regularly for mycoplasma contamination using PCR Mycoplasma Test 
Kit I/C (PromoKine, PK-CA91-1096) and following the manufacturer’s instructions.  
 
 HEK293T Cells 3.4.1
HEK293T cells (ATCC, CRL-3216, kind gift from Peer-Hendrik Kuhn) were maintained in T75 
flasks (Hartenstein, ZF12) in normal growth medium consisting of DMEM (PAN, P04-03600) 
supplemented with 1% glutamine (PAN, P04-80100) and 10% fetal bovine serum (FBS; Pan, 
P30-3702) and grown at 37°C in a humidified 95% air/5% CO2 atmosphere. Cells were passaged 
twice a week by washing with DPBS (PAN, P04-36500) once and subsequent enzymatic 
dissociation by incubation with 2 ml trypsin-EDTA (Sigma, T3924) for 2 min. Subsequently, 8 ml 
of normal growth medium were added and cells were aspirated and transferred to fresh culture 
vessels using a subcultivation ratio of 1:3 to 1:10.  
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Table 3-4: Overview of plasmids of the Gateway® reaction 
This table summarizes information on plasmids used as entry clone and destination vector and the resulting 
expression clone (viral plasmid). #DB: Database number. 
Entry Clone Destination Vector 
Viral 
Plasmid 
#DB Backbone Construct #DB Backbone #DB 
#20 pCR8/GW/TOPO+pCS2-MCS SV2 636 F2P-Delta Zeo-LoxP-Ko.Puro-LoxP-STNST-GW(DEST) #32 
#21 pCR8/GW/TOPO+pCS2-MCS V1S 636 F2P-Delta Zeo-LoxP-Ko.Puro-LoxP-STNST-GW(DEST) #33 
#23 pCR8/GW/TOPO+pCS2-MCS SV 636 F2P-Delta Zeo-LoxP-Ko.Puro-LoxP-STNST-GW(DEST) #35 
#24 pCR8/GW/TOPO+pCS2-MCS S 636 F2P-Delta Zeo-LoxP-Ko.Puro-LoxP-STNST-GW(DEST) #36 
#25 pCR8/GW/TOPO+pCS2-MCS V 636 F2P-Delta Zeo-LoxP-Ko.Puro-LoxP-STNST-GW(DEST) #37 
#20 pCR8/GW/TOPO+pCS2-MCS SV2 597 F2-Delta Zeo-Kozak-Puro-5XUAS-E1b-(GW)Dest #38 
#21 pCR8/GW/TOPO+pCS2-MCS V1S 597 F2-Delta Zeo-Kozak-Puro-5XUAS-E1b-(GW)Dest #39 
#23 pCR8/GW/TOPO+pCS2-MCS SV 597 F2-Delta Zeo-Kozak-Puro-5XUAS-E1b-(GW)Dest #41 
#24 pCR8/GW/TOPO+pCS2-MCS S 597 F2-Delta Zeo-Kozak-Puro-5XUAS-E1b-(GW)Dest #42 
#25 pCR8/GW/TOPO+pCS2-MCS V 597 F2-Delta Zeo-Kozak-Puro-5XUAS-E1b-(GW)Dest #43 
#20 pCR8/GW/TOPO+pCS2-MCS SV2 #44 F2-Delta Zeo-Kozak-Hygro-5XUAS-E1b-(GW)Dest #46 
#25 pCR8/GW/TOPO+pCS2-MCS V #44 F2-Delta Zeo-Kozak-Hygro-5XUAS-E1b-(GW)Dest #47 
#20 pCR8/GW/TOPO+pCS2-MCS SV2 #45 F2-Delta Zeo-Kozak-Zeo-5XUAS-E1b-(GW)Dest #48 
#25 pCR8/GW/TOPO+pCS2-MCS V #45 F2-Delta Zeo-Kozak-Zeo-5XUAS-E1b-(GW)Dest #49 
#24 pCR8/GW/TOPO+pCS2-MCS S #92 F-Delta Zeo-Kozak-mCherry-NLS-5X UAS-E1b-(GW)Dest #120 
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For long-term storage cells were enzymatically dissociated as described above upon reaching 
80% confluency. After addition of normal growth medium cells were transferred to 15-ml or 
50-ml centrifuge tubes (Hartenstein, ZR97 or ZR82, respectively) and centrifuged at 180 rcf for 
8 min. Medium was discarded and cells were resuspended in cryoprotectant medium consisting 
of 90% normal growth medium and 10% DMSO (Sigma, D2438), transferred to cryogenic vials 
and frozen in a Mr. Frosty Freezing Container (Thermo Scientific, 5100-0001) at -80°C 
overnight. Afterwards, the vials were stored at about -140°C in the gas phase of a liquid nitrogen 
cell tank.  
 
 H4 Cells 3.4.2
H4 human neuroglioma cells (ATCC, HTB-148) were maintained in T75 flasks (Hartenstein, 
ZF12) in normal growth medium consisting of Opti-MEM (Invitrogen, 31985-070) supplemented 
with 10% FBS (Pan, P30-3702) and grown at 37°C in a humidified 95% air/5% CO2 atmosphere. 
Cells were passaged twice to three times a week by washing with DPBS (PAN, P04-36500) once 
and subsequent enzymatic dissociation by incubation with 2 ml trypsin-EDTA (Sigma, T3924) 
for 6 min. Subsequently, 8 ml of normal growth medium were added and cells were aspirated 
and transferred to fresh culture vessels using a subcultivation ratio of 1:3 to 1:10.  
For long-term storage cells were enzymatically dissociated as described above upon reaching 
80% confluency. After addition of normal growth medium cells were transferred to 15-ml or 50-
ml centrifuge tubes (Hartenstein, ZR97 or ZR82, respectively) and centrifuged at 180 rcf for 
8 min. Medium was discarded and cells were resuspended in cryoprotectant medium consisting 
of 95% normal growth medium supplemented with 5% DMSO (Sigma, D2438), transferred to 
cryogenic vials and frozen in a Mr. Frosty Freezing Container (Thermo Scientific, 5100-0001) 
at -80°C overnight. Afterwards the vials were stored at approximately -140°C in the gas phase of 
a liquid nitrogen cell tank.  
 
 LUHMES Cells 3.4.3
The Lund human mesencephalic (LUHMES) cell line is a subclone of the MESC2.10 cell line272. 
This cell line was derived from 8-week-old human fetal ventral mesencephalic cells and 
immortalized by tetracycline-regulated expression of v-myc using the LINXv-myc retroviral 
vector235.  
Materials and Methods 
 
 
 
30 
3.4.3.1 Maintenance 
LUHMES cells (ATCC, CRL-2927) were maintained in precoated T75 flasks (Hartenstein, ZF12) in 
complete growth medium consisting of DMEM-F12 (Invitrogen, 31985-070) supplemented with 
1% 100-fold N2 supplement (Invitrogen, 17502-048) and human basic fibroblast growth factor 
(bFGF; Invitrogen, 13256-029) and grown at 37°C in a humidified 95% air/5% CO2 atmosphere.  
Flasks were precoated with 7 ml of freshly diluted 50 µg/ml poly-L-ornithin (PLO; Sigma, 
P3655) overnight at room temperature. Afterwards PLO was removed and flasks were rinsed 
three times with sterile double distilled water and allowed to air-dry uncapped standing upright 
in a biological cabinet for 10 min. Subsequently, 5 ml of freshly diluted 1 µg/ml human 
fibronectin (Sigma, F0895) was added and flasks were incubated at 37°C. After 3 h, fibronectin 
solution was removed and discarded and flasks were rinsed three times with sterile double 
distilled water and allowed to air-dry uncapped standing upright in a biological cabinet for 
10 min. Flasks were either used immediately afterwards or stored at 4°C for up to 5 days.  
Cells were passaged every two to three days by washing with DPBS (PAN, P04-36500) once and 
subsequent enzymatic dissociation by incubation with 4 ml of 1x trypsin solution (2 ml 
2x trypsin (137mM NaCl (Carl Roth, 3957.1), 5.4 mM KCl (Sigma, P5405), 6.9 mM NaHCO3 
(Sigma, S-5761), 5.6 mM D-Glucose (Carl Roth, HN06.3), 0.68 mM EDTA (Carl Roth, 8043.1), 
0.5 g/l trypsin (Sigma, T7409)) and 2 ml DPBS (PAN, P04-36500)) for 3 min. Subsequently, 6 ml 
of wash medium (DMEM-F12 (Invitrogen, 31985-070) supplemented with 1% 100-fold 
N2 supplement (Invitrogen, 17502-048)) were added and cells were aspirated and transferred 
to 15-ml or 50-ml centrifuge tubes (Hartenstein, ZR97 or ZR82, respectively) and centrifuged at 
180 rcf for 8 min. Medium was discarded and cells were resuspended in complete growth 
medium and transferred to fresh precoated culture vessels using a subcultivation ratio of 1:3 to 
1:10.  
For long-term storage cells were enzymatically dissociated as described above upon reaching 
80% confluency. After centrifugation medium was discarded and cells were resuspended in 
cryoprotectant medium consisting of 70% complete growth medium, 20% FBS (Pan, P30-3702) 
and 10% DMSO (Sigma, D2438), transferred to cryogenic vials and frozen in Mr. Frosty Freezing 
Containers (Thermo Scientific, 5100-0001) at -80°C overnight. Afterwards, the vials were stored 
at approximately -140°C in the gas phase of a liquid nitrogen cell tank.  
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3.4.3.2 Differentiation 
V-myc expression in LUHMES cells occurs from a minimal human cytomegalovirus (CMV) 
promoter under control of a tetracycline transactivator, resulting in continuous proliferation in 
the absence of tetracycline. Differentiation of LUHMES cells is induced by addition of 
tetracycline, glial cell line-derived neurotrophic factor (GDNF) and N6,2’-O-Dibutyryladenosine 
3’,5’-cyclic monophosphate (db-cAMP)272.  
LUHMES cells were differentiated following the two-step protocol described in Scholz et al.237. 
Cells were enzymatically dissociated and centrifuged as described above and diluted to a 
concentration of 437,000 cells/ml in 8 ml of complete growth medium and transferred to a 
precoated T75 flask. 24 h later, complete growth medium was replaced with differentiation 
medium consisting of DMEM-F12 (Invitrogen, 31985-070) supplemented with 1 µg/ml 
tetracycline (Sigma-Aldrich, T7660), 2 ng/ml recombinant human GDNF (R&D Systems, 
212-GD-010) and 1 mM db-cAMP (Sigma-Aldrich, D0627-250MG). 48 h later, cells were 
enzymatically dissociated by incubation with 4 ml of 2x trypsin solution for 4 min. Subsequently, 
6 ml of wash medium were added and cells were aspirated and transferred to 15-ml or 50-ml 
centrifuge tubes and centrifuged at 180 rcf for 8 min. Medium was discarded and cells were 
resuspended in differentiation medium, diluted to a concentration of 350,000 cells/ml and 
transferred to fresh precoated culture vessels. Differentiation medium was replaced every two 
days. 
Alternatively, LUHMES cells were differentiated following a one-step protocol. For this, LUHMES 
cells were immediately diluted in differentiation medium at a concentration of 300,000 cells/ml 
after enzymatic dissociation and centrifugation. Differentiation medium was replaced every two 
days without additional enzymatic dissociation. 
 
3.5 Virus Production and Purification 
To produce infectious but replication-incompetent virus particles two different packaging 
plasmids encoding for viral enzymes (db #97, Figure 8-3 E) and surface proteins (db #98, Figure 
8-3 F), and expression plasmids were transiently transfected into HEK293T cells (see Table 3-5). 
The virus production protocol described here was provided by Peer-Hendrik Kuhn and has been 
slightly adapted.  
To produce virus in one 10-cm dish, HEK293T cells were maintained in normal growth medium 
and expanded to approximately 1.5 T75 flasks. Cells were then washed once with DPBS and then 
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enzymaticly dissociated by incubation with 2 ml trypsin-EDTA (Sigma, T3924) for 2 min. 
Subsequently, 8 ml of normal growth medium were added and the cells were aspirated and 
transferred to 15-ml or 50-ml centrifuge tubes and centrifuged at 180 rcf for 8 min. Medium was 
discarded, cells were resuspended in room temperature Opti-MEM supplemented with 10% FBS, 
counted using a Neubauer counting chamber (VWR, 631-0926), and diluted to a final 
concentration of 600,000 cells/ml in a volume of 1.5 ml.  
For each 10-cm dish a DNA mix and a Lipofectamine® 2000 mix was generated. The DNA mix 
consisted of 5 µg of psPAX2 (#97), 2.7 µg of VSV-G (#98) and 5.5 to 6.5 µg of the expression 
plasmid (Table 3-5) in 750 µl Opti-MEM. For the Lipofectamine® 2000 mix 750 µl Opti-MEM and 
38 µl of Lipofectamine® 2000 (Invitrogen, 11668-019) were mixed and incubated for 5 min at 
room temperature. Afterwards the Lipofectamine® 2000 mix was mixed with the DNA mix and 
incubated for 15 min at room temperature before the cell mix was added.  
Afterwards, 6 ml of Opti-MEM supplemented with 10% FBS were pipetted into a 10-cm dish 
(Hartenstein, GK03). 3 ml of the DNA Lipofectamine® 2000 cell mixture were added and 
incubated at 37°C in a humidified 95% air/5% CO2 atmosphere. After 24 h the transfection mix 
was carefully replaced with 8.5 ml of normal growth medium. 24 h later, the virus-containing 
medium was carefully aspirated, pipetted into a 50-ml centrifuge tube and stored for 24 h at 4°C 
(1st harvest). The cells in the 10-cm dish were again incubated in normal growth medium for 
another 24 h at 37°C in a humidified 95% air/5% CO2 atmosphere before viruses were 
harvested for a second time and pooled with the 1st harvest.  
To get rid of cellular debris, the 50-ml tube was centrifuged at 3000 rcf for 15 min. Afterwards, 
the supernatant was filtered using a 0.45-µm filter (Carl Roth, KH55.1) to remove further 
cellular particles. Centrifuge polymer tubes (Beckman Coulter, 358126) were thoroughly 
washed with 70% ethanol in a biological cabinet. Ethanol was aspirated and tubes were allowed 
to air-dry for 20 min. Afterwards the virus supernatant was loaded into the tubes and 
centrifuged at 22,000 rpm in an SW28 rotor (Beckman Coulter, 342196) for 2 h at 4°C in an 
ultracentrifuge (Sorvall Discovery 90SE). The supernatant was discarded and the pellet was 
incubated in TBS-5 buffer (50 mM Tris-HCl (pH 7.8), 130 mM NaCl, 10 mM KCl, 5 mM MgCl2, 
10% BSA weight per volume (w/V)), sterile filtered through a 0.22-µm filter (Hartenstein, FI02)) 
overnight. The pellet was carefully resuspended without producing air bubbles, transferred to a 
1.5-ml reaction tube (Hartenstein, RSL1), and centrifuged at 800 rcf for 2 min at 4°C. 
Supernatant was frozen in 20-µl aliquots in 0.5-ml reaction tubes (Hartenstein, RSL0) or PCR 
tubes (Eppendorf, 0030 124359) at -80°C.  
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Table 3-5: List of viruses 
This table summarizes the plasmids used for production of infectious but replication-incompetent viruses. Co-
transfection of HEK293T cells with viruses #97 and #98 and an expression plasmid resulted in production of 
viruses shown in the right column. #DB: Database number. 
Plasmid 
#DB 
Kind of 
Plasmid 
Insert Comment 
Virus 
#DB  
#97 Packaging psPAX2 Encodes for viral enzymes gag-pol to generate lentiviruses  
#98 Packaging VSV-G Encodes for the envelope glycoprotein VSV-G from Vesicular Stomatitis Virus (broad tropism)  
#99 Expression Zeo-GAL4-VP16 Constitutive GAL4 driver V99 
#100 Expression Zeo-GAL4-VP16-EcR Inducible GAL4_EcR driver (+tebufenozide) V100 
#101 Expression F2U-Delta Zeo-iCre Constitutive Cre driver V101 
#102 Expression F2U-Delta Zeo-iCre_ERT2 Inducible Cre_ER
T2 driver (+4-OH-tamoxifen) V102 
#32 Expression SV2 Cre-loxP receiver (puromycin resistance) V32 
#33 Expression V1S Cre-loxP receiver (puromycin resistance) V33 
#34 Expression V1 Cre-loxP receiver (puromycin resistance) V34 
#35 Expression SV Cre-loxP receiver (puromycin resistance) V35 
#36 Expression S Cre-loxP receiver (puromycin resistance) V36 
#37 Expression V Cre-loxP receiver (puromycin resistance) V37 
#38 Expression SV2 GAL4-UAS receiver (puromycin resistance) V38 
#39 Expression V1S GAL4-UAS receiver (puromycin resistance) V39 
#40 Expression V1 GAL4-UAS receiver (puromycin resistance) V40 
#41 Expression SV GAL4-UAS receiver (puromycin resistance) V41 
#42 Expression S GAL4-UAS receiver (puromycin resistance) V42 
#43 Expression V GAL4-UAS receiver (puromycin resistance) V43 
#46 Expression SV2 GAL4-UAS receiver (hygromycin resistance) V46 
#47 Expression V GAL4-UAS receiver (hygromycin resistance) V47 
#48 Expression SV2 GAL4-UAS receiver (zeocin resistance) V48 
#49 Expression V GAL4-UAS receiver (zeocin resistance) V49 
#120 Expression S GAL4-UAS receiver (mCherry-NLS) V120 
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3.6 Transient Transfection of H4 Cells 
In order to transiently transfect H4 cells, cells were enzymatically dissociated as described 
above and seeded at a concentration of 100,000 cells/ml and incubated at 37°C, 5% CO2 for 24 h 
before the transfection mix was added. Per 1 ml cell-containing medium the transfection mix 
consisted of 100 µl serum-free Opti-MEM, 0.5 µg plasmid and X-tremeGENETM HP DNA 
Transfection Reagent (3 µl/µgplasmid; Roche Diagnostics, 06366236001). The transfection mix 
was incubated for 15 to 30 min at room temperature before it was pipetted into the wells. The 
medium was mixed by rocking the plate gently. Afterwards, the cells were incubated at 37°C in a 
humidified 95% air/5% CO2 atmosphere. 24 to 72 h after transfection cells were processed 
according to the following analysis.  
 
3.7 Compound Testing Using Transiently Transfected H4 Cells 
In order to test compounds using transiently transfected H4 cells, cells were seeded at a 
concentration of 100,000 cells/ml and incubated with different compounds at different 
concentrations at a final DMSO concentration of 0.1% or 1% DMSO as a control at 37°C in a 
humidified 95% air/5% CO2 atmosphere. After 24 h, the medium was aspirated, cells were 
carefully washed once with DPBS and fresh normal growth medium was added. Afterwards, the 
cells were transiently transfected as described above and incubated at 37°C in a humidified 95% 
air/5% CO2 atmosphere for 2 h. Then, medium was aspirated, cells were carefully washed once 
with DPBS and fresh normal growth medium containing the corresponding compound or DMSO 
as a control was added. 48 h after transfection, cells were processed according to the following 
analysis. 
 
3.8 Creation of Stable Cell Lines 
 H4 Cells 3.8.1
3.8.1.1 Optimization of the H4 Transduction Protocol 
In order to obtain as many transduced cells as possible we tested the transduction efficiency of 
viruses V99 and V41 (see Table 3-5) using different protocols. For all protocols H4 cells were 
handled as described in chapter 3.4.2.  
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Protocol AH4: 
Virus was diluted 1:200 in cell-containing medium. H4 cells were diluted to a concentration of 
50,000 cells/ml. 2 ml of cell suspension was pipetted into one well of a 6-well plate and 10 µl of 
both V99 and V41 were added. The composition was mixed by rocking the plate gently.  
 
Protocol BH4: 
Virus was diluted 1:50 in cell-containing medium. H4 cells were diluted to a concentration of 
50,000 cells/ml. 2 ml of cell suspension were pipetted into one well of a 6-well plate and 40 µl of 
both V99 and V41 were added. The composition was mixed by rocking the plate gently.  
 
Protocol CH4:  
Virus was diluted 1:12 in cell-containing medium. H4 cells were diluted to a concentration of 
100,000 cells/ml. 200 µl of the cell suspension were mixed with 20 µl V99 and 20 µl V41 in a 
0.5-ml reaction tube and incubated for 5 min at room temperature. Afterwards, the mixture was 
seeded into a 24-well plate.  
 
Protocol DH4: 
Virus was diluted 1:3.5 in cell-containing medium. H4 cells were diluted to a concentration of 
50,000 cells/ml. 50 µl of the cell suspension were mixed with 20 µl V41 in a 0.5-ml reaction tube 
and incubated for 5 min at room temperature. Afterwards the mixture was seeded into a 96-well 
plate. 72 h after transduction virus-containing medium was aspirated and replaced with normal 
growth medium. Cells were expanded to 6-well plates and then expanded to T75 flasks when 
they reached 80% confluency and maintained as described above. After two weeks, the obtained 
H4_41 cells were diluted to a concentration of 50,000 cells/ml. 50 µl of the cell suspension were 
mixed with 20 µl V99 in a 0.5-ml reaction tube and incubated for 5 min at room temperature. 
Afterwards the mixture was seeded into a 96-well plate and the cells were expanded as 
described in chapter 3.4.2. 
For all protocols, cell nuclei were stained with 10 µg/ml DAPI (Carl Roth, 6335.2) or 0.5 µg/ml 
Hoechst33342 (Invitrogen, H1399) 72 h after transduction and pictures were taken using a 
fluorescence microscope (Hundt, Wetzlar or Olympus, Hamburg). The fraction of fluorescing 
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cells was determined manually using the ImageJ software. Alternatively, virus-containing 
medium was aspirated and replaced with normal growth medium. Cells were expanded to T25 
flasks and then expanded to T75 flasks when they reached 80% confluency and maintained as 
described in chapter 3.4.2.  
 
3.8.1.2 Creation of Stable Inducible H4 Cell Lines 
H4 cells were diluted to a concentration of 50,000 cells/ml. In order to achieve inducible 
expression based on the GAL4_EcR-UAS (GE) system, 50 µl of the cell suspension were mixed 
with 20 µl of V39, V41, V42, V43, or V120 in a 0.5-ml reaction tube, respectively. In order to 
achieve inducible expression based on the Cre_ERT2-loxP system, 50 µl of the cell suspension 
were mixed with 20 µl of V32, V35, V36, or V37 in a 0.5-ml reaction tube, respectively. The 
mixture was incubated for 5 min at room temperature. Afterwards, the mixture was seeded into 
a 96-well plate. 72 h after transduction, virus-containing medium was aspirated and replaced 
with normal growth medium. The created cell lines H4_39, H4_41, H4_42, H4_43, H4_120, H4_32, 
H4_35, H4_36, and H4_37 were expanded and maintained as described in chapter 3.4.2.  
All following viral transductions were performed according to the transduction protocol 
described above. The created cell lines H4_39 and H4_32 were transduced with V46 or V33, 
respectively, resulting in cell lines H4_39-46 and H4_32-33. The cell lines H4_41, H4_42, H4_43, 
H4_120 and H4_39-46 were transduced with V100, resulting in cell lines H4_100-41, H4_100-42, 
H4_100-43, H4_100-120 and H4_100-39-46. The cell lines H4_32-33, H4_35, H4_36, and H4_37 
were transduced with V102, resulting in cell lines H4_102-32-33, H4_102-35, H4_102-36, and 
H4_102-37. H4_100-42 was transduced with V42 a second time generating cell line H4_100-422. 
H4_100-39-46 was transduced with V46, generating cell line H4_100-39-462, which was then 
transduced with V39, generating cell line H4_100-392-462. The later on commonly used cell lines 
were renamed according to Table 3-6. 
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Table 3-6: List of H4 cell lines 
This table summarizes the inducible H4 cell lines created in this study. 
Old Name New Name 
H4_100-41 H4_GE-SV 
H4_100-422 H4_GE-S 
H4_100-43 H4_GE-V 
H4_100-120 H4_mC_GE-S 
H4_100-392-462 H4_GE-V1S+SV2 
H4_102-35 H4_CET2-SV 
H4_102-36 H4_ CET2-S 
H4_102-37 H4_ CET2-V 
H4_100-32-33 H4_ CET2-V1S+SV2 
 
 
 LUHMES Cells 3.8.2
3.8.2.1 Optimization of the LUHMES Transduction Protocol 
In order to obtain as many positively transduced LUHMES cells as possible we tested the 
transduction efficiency of viruses V99 and V43 (see Table 3-5) using different protocols. For all 
protocols LUHMES cells were handled as described in chapter 3.4.3.  
 
Protocol ALUHMES: 
LUHMES cells were diluted to a concentration of 50,000 cells/ml. 2 ml of the cell suspension 
were transferred to one well of a 6-well plate. 20 µl of V43 were added. The composition was 
mixed by rocking the plate gently and incubated at 37°C in a humidified 95% air/5% CO2 
atmosphere. 24 h after transduction, medium was aspirated and replaced by 2 ml complete 
growth medium supplemented with 20 µl of V99. 24 h later, virus medium was discarded and 
the LUHMES cells were passaged into a T75 flask. 72 h later, cells were seeded into 6-well plates 
at a concentration of 50,000 cells/ml.  
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Protocol BLUHMES:  
LUHMES cells were diluted to a concentration of 500,000 cells/ml. 200 µl of the cell suspension 
were mixed with 20 µl V43 in a 0.5-ml reaction tube and incubated for 2 min at room 
temperature. The mixture was transferred to one well of a 6-well plate. 1.8 ml of complete 
growth medium were added and mixed with the cell-virus suspension by rocking the plate 
gently and incubated at 37°C, 5% CO2. 48 h later, virus medium was discarded and the LUHMES 
cells were passaged into a T75 flask. Upon reaching a confluency of 80% the cells were 
transduced with V99 as described above.  
 
Protocol CLUHMES: 
LUHMES cells were diluted to a concentration of 1,000,000 cells/ml. 100 µl of the cell 
suspension were mixed with 20 µl V43 in a 0.5-ml reaction tube and incubated for 5 min at room 
temperature. The mixture was transferred to one well of a 6-well plate. 1.9 ml of complete 
growth medium were added and mixed with the cell-virus suspension by rocking the plate 
gently and incubated at 37°C, 5% CO2. 72 h later, virus medium was discarded and the LUHMES 
cells were passaged into a fresh 6-well plate. Upon reaching a confluency of 80% the cells were 
passaged into a T75 flask. Upon reaching a confluency of 80% the cells were transduced with 
V99 as described above. 72 h later, virus medium was discarded and the LUHMES cells were 
passaged into a T75 flask. Upon reaching a confluency of 80% the cells were seeded into 6 well 
plates at a concentration of 50,000 cells/ml.  
For all protocols, cell nuclei were stained with Hoechst33342 (0.5 µg/ml; Invitrogen, H1399) 
72 h later, and pictures were taken using a fluorescence microscope (Olympus, Hamburg). The 
fraction of fluorescing cells was determined manually using the ImageJ software. 
 
3.8.2.2 Creation of Stable Inducible LUHMES Cell Lines 
LUHMES cells were diluted to a concentration of 1,000,000 cells/ml. 100 µl of the cell 
suspension were mixed with 20 µl of V100 in a 0.5-ml reaction tube and incubated for 5 min at 
room temperature. The mixture was pipetted into one well of a 6-well plate. 1.9 ml of complete 
growth medium were added and mixed with the cell-virus suspension by rocking the  
plate gently and incubated at 37°C in a humidified 95% air/5% CO2 atmosphere for 2 h. 
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Table 3-7: List of LUHMES cell lines 
This table summarizes the inducible LUHMES cell lines created in this study. 
Old Name New Name 
LUHMES_1004-414 LUHMES_GE-SV 
LUHMES_1004-424 LUHMES_GE-S 
LUHMES_1004-434 LUHMES_GE-V 
LUHMES_1004-1204 LUHMES_mC_GE-S 
LUHMES_1004-394-464 LUHMES_GE-V1S+SV2 
 
 
72 h later, virus medium was discarded and the generated LUHMES_100 cells were passaged 
into a T75 flask. Cells were maintained until they reached a confluency of 80%. Transduction 
was repeated for three times.  
Afterwards the generated LUHMES_1004 cells were transduced four times as described above 
with V39, V41, V42, V43, or V120, respectively. LUHMES_1004-394 cells were then transduced 
four times as described above with V46, generating cell line LUHMES_1004-394-464. The 
generated cell lines were renamed according to Table 3-7. 
 
3.9 Induction of Transgene Expression 
Tebufenozide (Santa Cruz, sc-280110) was diluted in DMSO to a final concentration of 100 mM. 
Based on this solution, 1,000-fold stock solutions were made with concentrations ranging from 
100 nM to 100 mM. To induce transgene expression, cells were incubated with 100 pM to 
100 µM tebufenozide and a final DMSO concentration of 0.1%. 
(z)-4-OH-tamoxifen (Abcam, ab141943) was diluted in DMSO to a final concentration of 
100 mM. Based on this solution, 1,000-fold stock solutions were created with concentrations 
ranging from 100 nM to 100 mM. To induce transgene expression, cells were incubated with 
100 pM to 100 µM 4-OH-tamoxifen and a final DMSO concentration of 0.1%. 
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3.10 BCA Assay 
To determine the protein concentrations of the cell lysates for western blot, sucrose gradient, or 
fluorescence correlation spectroscopy we used a BCA assay. In this assay, the protein solution 
was incubated with a mixture of bicinchoninic acid and copper(II) sulfate (CuSO2). In the 
presence of protein, Cu2+ is reduced to Cu+ which is subsequently chelated by two molecules of 
bicinchoninic acid. This results in a green to purple color change which is proportional to the 
amount of protein over a broad range of protein concentrations and can be quantified by 
measuring absorbance at ~560 nm273. 
In order to perform this assay, the cell lysates were diluted to an expected concentration of 0.2 
to 1 mg/ml in 25 µl and transferred into the wells of a 96-well plate in quadruplicates. 
Bicinchoninic acid solution (BCA; Sigma, B9643) and CuSO2 (Sigma, C2284) were mixed 50:1 
and 200 µl of the BCA/CuSO2 solution were pipetted to each well. 
For the calibration curve, bovine serum albumin (BSA, 1 mg/ml) was diluted in lysis buffer to 
concentrations of 0.8 mg/ml, 0.6 mg/ml, 0.4 mg/ml, 0.2 mg/ml, and 0 mg/ml in duplicates in a 
96-well plate with a final volume of 25 µl each.  
The plate was then incubated at 37°C for 30 min. Subsequently, absorbance at 560 nm was 
analyzed using a FLUOStar OPTIMA Microplate Reader (BMG Labtech). Protein concentration 
was determined in reference to the fitted standard curve using the provided software (BMG 
Labtech). 
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3.11 Western Blot 
 Cell Lysis for Western Blot 3.11.1
Cells were maintained, enzymatically dissociated and centrifuged as described in chapter 3.4. 
Afterwards the cells were resuspended in 1 ml of precooled DPBS (4°C) and transferred to a 
1.5-ml reaction tube. Cells were centrifuged at 4°C and 16,100 rcf for 10 min (Eppendorf 
centrifuge 5415 R). The supernatant was discarded and cell pellets were resuspended in 40-
80 µl precooled (4°C) lysis buffer (25 mM Tris, 50 mM NaCl, 0.5% Na-deoxycholate, 0.5% Triton 
X-100, pH=8.0; prior to use, protease inhibitor (Roche Applied Science, 04693124001) was 
added) per 1,000,000 cells. Cells were incubated at 4°C and 1,000 rpm on a Thermomixer 
Comfort (Eppendorf, Hamburg) for 30 min and afterwards centrifuged at 4°C and 16,100 rcf for 
10 min. Supernatant was transferred to a precooled 1.5-ml Protein LoBind reaction tube (VWR, 
525-0133) and protein concentration was determined by BCA assay.  
 
 Preparation of the Polyacrylamide Gels 3.11.2
15% polyacrylamide separating gels were prepared by mixing 1.875 ml Lower Tris 4x 
(181.7 mg/ml Tris Base (Carl Roth, 4855.2), 0.4% sodium dodecyl sulfate (SDS, Carl Roth, 
CN30.3), pH 8.8), 1.8 ml H2O, and 3.75 ml Rotiphorese® Gel 30 (Carl Roth, 3029.1). 6.25 µl 
tetramethylethylenediamine (TEMED) (Carl Roth, 2367.3) and 62.5 µl 10% ammonium 
persulfate (APS) (Carl Roth, 9592.2) were added and all components were mixed by inverting 
the 50-ml tube gently. The mixture was cast between clean glass plates for SDS-PAGE. To get rid 
of air bubbles, 400 µl of isopropanol were pipetted on top of the separating gel mixture. 
Subsequently, the gel was incubated for 15 min at room temperature to polymerize. Afterwards, 
isopropanol was discarded and the stacking gel was prepared by mixing 0.85 ml Upper Tris 4x 
(60.6 mg/ml Tris Base, 0.4% SDS, pH 6.6), 2.45 ml H2O, and 462.5 µl Rotiphorese® Gel 30 in a 50-
ml centrifugation tube. 3.75 µl TEMED and 37.5 µl 10% APS were added and all components 
were mixed by inverting the 50-ml tube gently. The mixture was cast on top of the separating gel 
and a gel comb was inserted carefully into the stacking gel without producing air bubbles to 
create 15 pockets. The gel was incubated at 4°C overnight to polymerize.  
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 Sample Preparation 3.11.3
For western blot analysis cell lysates were diluted to a concentration of 2.08 mg/ml. 24 µl of the 
samples were mixed with 6 µl 5x Lämmli sample buffer (10% SDS (w/V), 250 mM Tris (pH 6.8), 
1 mg/ml bromophenol blue, 0.5 M DTT, 50% glycerol (V/V)) and incubated at 95°C for 5-7 min. 
This results in a reduction of preformed disulfide bonds to thiols by DTT and the breakup of 
non-covalent interactions by SDS, thus destroying the proteins’ secondary structure and 
enabling a separation according to molecular weight in the following electrophoresis. 30 µl of 
each sample and Lämmli buffer mixture were pipetted into separate pockets of the 
polyacrylamide gel, so that 50 µg of protein per mixture were used for PAGE. To determine the 
size of occurring western blot bands, 5 µl of PageRulerTM Prestained Protein Ladder (Thermo 
Fisher Scientific, 26616) were pipetted into one pocket of the polyacrylamide gel.  
 
 Electrophoresis 3.11.4
For electrophoresis the gel comb was removed and the gels including glass plates were inserted 
into a PAGE running chamber filled with 1x running buffer (3 mg/ml Tris Base, 14.4 mg/ml 
glycine (Carl Roth, 3790.3), 1 mg/ml SDS). After samples and ladder had been loaded to the gel, a 
voltage of 80 V was applied until samples reached the bottom of the stacking gel (approximately 
30 min). Afterwards a voltage of 120 V was applied until the green marker (10 kDa) of the 
protein ladder reached the bottom of the separating gel (approximately 60 min).  
Afterwards, running buffer was discarded and the gels were removed from the running 
chamber. The glass plates were removed, separating and stacking gel were separated and 
stacking gel was discarded. Until further processing, the separating gel was incubated in blotting 
buffer (3.032 mg/ml Tris Base, 14.4 mg/ml glycine, 20% methanol). 
 
 Blotting 3.11.5
In order to transfer the proteins from the polyacrylamide gel to a polyvinylidene fluoride (PVDF) 
blotting membrane (Millipore, IPVH00010), four pieces of Whatman blotting paper (9 cm x 
7 cm; Hartenstein, GB40) were incubated in blotting buffer until they were fully soaked. For 
activation, the PVDF membrane (9 cm x 7 cm) was incubated in methanol (Hartenstein, CM20) 
for 5 min at RT. Two Whatman blotting papers were put into a blotting chamber on top of each 
other and the PVDF membrane was carefully put on top without inclusion of air bubbles. The 
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separating gel was carefully put on top of the membrane without inclusion of any air bubbles. 
Two Whatman papers were put on top, and the whole “sandwich” was carefully compressed to 
ensure close contact between all parts of it. To transfer proteins from the polyacrylamide gel to 
the PVDF membrane, a current of 50 mA per gel was applied for 2 h. Afterwards, the membrane 
was subjected to labeling with Ponceau S solution or antibody detection.  
 
 Ponceau S Staining 3.11.6
For Ponceau S staining the membrane was incubated in Ponceau S solution (Carl Roth, 5938.1) 
for 2-3 min. Afterwards Ponceau S solution was removed and the membrane was washed with 
desalted water until protein bands appeared with a good signal-to-noise ratio.  
 
 Antibody Labeling 3.11.7
After blotting, the membranes were blocked in 5% milk (AppliChem, A0830) in TBS-T (0.01 M 
Tris-HCl (VWR, 1.08219.1000), 0.15 M NaCl, 0.2% Tween® 20 (AppliChem, A1389)) for 1 h. 
Afterwards, the membranes were incubated overnight with primary antibodies (anti-αSyn 
(15G7274, 4B12 (monoclonal; Hiss, SIG-39730-200)), anti-phospho-αSyn(pSyn; Abcam, 
ab59264), anti-GFP (Abcam, Ab290), anti-GAPDH (Abcam, ab9485), anti-tubulin (Sigma, T4026), 
anti-actin (Sigma, A2066)) diluted in 5% milk in TBS-T supplemented with 0.02% NaN3 
according to Table 3-8.  
After washing the membranes four times with TBS-T for 5 min, they were incubated with a 
secondary antibody (rabbit-anti-rat IgG (H&L) (alkaline phosphatase (AP)-conjugated) (Biomol 
GmbH, 712-405-002), goat-anti-rabbit IgG (AP-conjugated) (JacksonImmoResearch, 111-055-
003), goat-anti-mouse IgG (AP-conjugated) (Cell Signaling Technology, 7056)), goat-anti-rabbit 
(horseradish peroxidase (HRP)-conjugated) (Cell Signaling Technology, 7074), horse-anti-
mouse (HRP-conjugated) (Cell Signaling Technology, 7076)) diluted in 5% milk in TBS-T 
according to Table 3-8 for 1 h. After washing the membranes four times with TBS-T for 5 min 
membranes were prepared for signal detection. 
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Table 3-8: List of antibodies 
This table summarizes the primary and corresponding secondary antibodies used for western blot analyses.  
Primary Antibody Corresponding Secondary Antibody 
Type Dilution Type Dilution 
15G7 (anti-αSyn) 1:2000-1:2500 rabbit-anti-rat (AP-conjugated) 1:2000 
4B12 (anti-αSyn) 1:1000-1:5000 
goat-anti-mouse (AP-conjugated) 
horse-anti-mouse (HRP-conjugated) 
1:5000 
1:5000 
pSyn (anti-phospho-αSyn) 1:1000 
goat-anti-rabbit (AP-conjugated) 
goat-anti-rabbit (HRP-conjugated) 
1:5000 
1:5000 
anti-GFP 1:10000 
goat-anti-rabbit (AP-conjugated) 
goat-anti-rabbit (HRP-conjugated) 
1:5000 
1:5000 
anti-GAPDH 1:3000 
goat-anti-rabbit (AP-conjugated) 
goat-anti-rabbit (HRP-conjugated) 
1:5000 
1:5000 
anti-β-tubulin 1:500 
goat-anti-mouse (AP-conjugated) 
horse-anti-mouse (HRP-conjugated) 
1:5000 
1:5000 
anti-actin 1:200 
goat-anti-rabbit (AP-conjugated) 
goat-anti-rabbit (HRP-conjugated) 
1:5000 
1:5000 
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 Detection 3.11.8
All secondary antibodies used in this study were either conjugated with alkaline phosphatase 
(AP) and signal was detected using CDP-Star (Roche Applied Science, 12041677001), or with 
horseradish peroxidase (HRP) and signal was detected using the ClarityTM Western ECL 
Substrate (BioRad, 1705060). The CDP-Star solution contains dioxetane which is 
dephosphorylated by AP to metastable dioxetane phenolate anion which emits light at a 
wavelength of 466 nm upon its decomposition (see CDP-Star manual for more detailed 
information). The HRP catalyses the oxidation of luminol 3-aminophtalate dianion which is 
accompanied by light emission. The ECL substrate includes an enhancer which increases 
longevity and intensity of the luminescence reaction (see ClarityTM Western ECL Substrate 
Instruction Manual for more detailed information). The chemiluminescence can be detected with 
suitable camera systems. 
For detection of AP-conjugated antibodies, the membranes were washed with AP buffer 
(0.1 M Tris, 0.1 M NaCl, pH 9.5) for 5 min at room temperature. Afterwards the membranes were 
dried with paper towels and the chemiluminescence reaction was started by incubating the 
membranes with 5 drops of CDP-Star (Roche Applied Science, 12041677001) in a plastic cover 
for 2 min. 
For detection of HRP-conjugated antibodies, the membranes were dried using paper towels. Per 
membrane, 500 µl of ClarityTM Western ECL Substrate (Bio-Rad, #1705060) were pipetted onto 
the membrane and incubated in a plastic cover for 2 min before signal detection. 
Chemiluminescence signals were detected with the ChemiLux camera system and the ChemoStar 
software (Intas, Göttingen) 
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3.12 Sucrose Gradient Centrifugation 
 Cell Lysis for Sucrose Gradient Centrifugation 3.12.1
Cells were maintained, enzymatically dissociated and centrifuged as described above. 
Afterwards the cells were resuspended in 1 ml of precooled DPBS (4°C) and transferred to a 
1.5-ml reaction tube. Cells were centrifuged at 4°C and 16,100 rcf for 10 min (Eppendorf 
centrifuge 5415 R). Supernatant was discarded and cell pellets were resuspended in 40 µl SC 
lysis buffer (50 mM Tris (pH 7.4), 175 mM NaCl, 0.1% NP-40, 1x protease inhibitor (Roche 
Applied Science, 04693124001)). The cell suspension was repeatedly pipetted up and down and 
incubated on ice for 15 min. Afterwards, cell suspension was pipetted up and down again and 
incubated on ice for additional 15 min. Next, the suspension was centrifuged at 17,000 rcf and 
4°C for 1 minute. The supernatant was transferred to a precooled 1.5-ml Protein LoBind reaction 
tube (VWR, 525-0133) and protein concentration was determined by BCA assay.  
 
 Sample Preparation and Centrifugation 3.12.2
50-200 µg of total protein were adjusted to a volume of 200 µl in 50 mM Tris (pH 7.4), 175 mM 
NaCl, and 0.1 % NP-40 and used for sucrose gradient centrifugation. Centrifuge tubes were filled 
with buffer A (50 mM Tris-HCl (pH 7.5), 0.1 % NP-40, 0-60 % Sucrose) in layers in the given 
order: 200 µl 60 % sucrose, 400 µl 50 % sucrose, 400 µl 40 % sucrose, 400 µl 30 % sucrose, 
400 µl 20 % sucrose, 400 µl 10 % sucrose, 200 µl sample without sucrose (Figure 3-1). The 
samples were ultracentrifuged at 4°C and 40,000 rpm in an SW60 rotor (Beckmann Coulter) for 
70 min (Sorvall WX Ultra 90, Thermo Scientific). After centrifugation, 12 fractions of 200 µl each 
were collected from top to bottom. 
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Figure 3-1: Schematic representation of sucrose gradient centrifugation 
The sample is loaded on top of layers with increasing sucrose concentration. During ultracentrifugation 
αSyn species migrate according to their density and are finally detected by western blot analysis (figure 
modified from Dr. rer. biol. hum. Felix Schmidt, LMU Munich). 
 
 
 TCA Precipitation 3.12.3
200 µl of the fractions were added to 800 µl of 12.5% trichloroacetic acid (TCA). Afterwards 
samples were inverted and incubated at 20°C overnight. After centrifugation at 20,000 rcf and 
4°C for 15 min, supernatant was discarded and pellets were washed by adding 1 ml acetone 
(-20°C). The samples were inverted repeatedly and centrifuged at 4°C and 20,000 rcf for 15 min. 
Supernatant was discarded and pellet was allowed to dry at room temperature for 5 min. 30 µl 
of 5x Lämmli sample buffer were added and samples were shaken for 10 min at 30°C and 
1,400 rpm. Afterwards, they were incubated at 96°C for 5 min, vortexed briefly and spun down. 
 
 SDS-PAGE and Western Blot 3.12.4
After TCA precipitation samples were subjected to SDS-PAGE and western blot analysis. 12.5% 
polyacrylamide gels were prepared according to chapter 3.11.1. Samples were loaded onto the 
gel with the topmost fraction to the left and the fraction from the bottom to the right (Figure 
3-1). 
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3.13 Confocal Single Particle Spectroscopy 
Single particle spectroscopy represents a powerful tool to characterize αSyn aggregation on 
single particle level using fluorescently labeled αSyn both for in vitro studies and for the 
investigation of cell lysates.  
 
 Measurement Setup 3.13.1
Single particle spectroscopy was performed using an InsightTM Reader (Evotec-Technologies, 
Hamburg). The measurement setup resembles a confocal microscope (Figure 3-2). Laser light is 
emitted by an argon-ion laser at a wavelength of 488 nm and by a helium-neon laser at a 
wavelength of 633 nm. Light of both wavelengths is reflected at the first dichroic mirror and 
focused into the sample volume approximately 150 µm above the glass bottom of a 384-well 
plate (Evotec-Technologies/Perkin Elmer, Hamburg) via a 40x water immersion objective 
(Olympus, Hamburg) with high numerical aperture (1.2). Due to Brownian movement, 
fluorescently labeled particles in the sample solution will pass the laser focus (comprising a 
volume of approximately 1 fl) and emit photons upon excitation by the laser light. Since this 
fluorescence light is emitted in all directions, a part of it passes the objective and follows the way 
of the exciting laser light retrogradely until it passes the first dichroic mirror and is reflected by 
the second dichroic mirror. In order to reduce background signals, the light has to pass a pinhole 
with a diameter of 70 µm. The pinhole is inserted at a position corresponding to the 
intermediate image of a conventional optical microscope. Afterwards, light is separated 
according to its wavelength by the third dichroic mirror. Thus, light of two different wavelengths 
is detected separately by two single-photon avalanche detectors enabling the separate detection 
and analysis of a fluorescence signal in two channels in parallel. As readout, fluctuation of 
fluorescence intensity over time can be observed. Using mathematical evaluation tools, 
information on certain particle characteristics such as concentration, diffusion time and particle 
brightness can be extracted. This allows the conclusion of particle size and thus enables the 
distinction between monomeric and oligomeric protein assemblies. 
Measurements can be performed using a stationary focus or the beam scanner unit in which 
oscillating mirrors move the laser focus horizontally through the sample solution. Scanning the 
sample increases the probability for the detection of rare particles. Thus, while the optimal 
particle concentration for a stationary focus lies in the low nanomolar range (0.1-50 nM), the 
detection limit is decreased to attomolar particle concentrations using the beam scanner275.  
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Figure 3-2: Measurement setup of the InsightTM Reader 
Schematic representation of the InsightTM Reader. Laser light from two lasers (488 nm and 633 nm) is 
focused into the sample volume via dichroic mirrors and a beam scanning unit. Emitted photons pass 
the objective retrogradely and are guided via dichroic mirrors and a pinhole to be detected separately in 
two single-photon avalanche diodes205,275. SPD: single photon detector. 
 
 
 Adjustment 3.13.2
Lasers were turned on 30 min before the experiments to ensure constant laser power during the 
measurement. Afterwards, laser power was adjusted to 200 µW for the argon-ion laser 
(488 nm).  
In order to adjust the device for the measurement, the correct positioning of the focus was 
manually controlled by detection of reflections in the glass bottom using a camera. The focus 
volume and shape were monitored by fluorescence intensity and diffusion time of a defined 
calibration solution containing freely diffusing fluorescence dyes (Alexa 488 and Alexa 647) with 
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known properties. Critical parameters for the adjustment of the optimal focus conditions were 
counts per particle (CPP) and diffusion time (Tdiff) of individual fluorescence molecules. CPP 
represents a measure for the brightness of individual fluorescence molecules independent of 
their concentration. Tdiff is a measure for the focus spot size. Positioning of laser focus, pinhole, 
and sample carrier was controlled via the included FCS+Plus_Control software (Evotech, 
Hamburg). 
Each single measurement was performed for 10-15 seconds at room temperature. In scanned 
measurements samples were scanned in a length of 100 µm with a frequency of 50 Hz of the 
mobile focus (beam scanner) and a displacement of 2,000 µm of the sample carrier. 
 
 Data Analysis 3.13.3
The setup described above allows to determine fluctuations of fluorescence intensity over time. 
Using mathematical evaluation tools like fluorescence correlation spectroscopy276-278 (FCS) or 
fluorescence intensity distribution analysis279,280 (FIDA) further information concerning particle 
number, concentration, brightness, and diffusion time can be obtained. Scanning for intensely 
fluorescent targets202,203 (SIFT) represents an approach to maximize sensitivity for slowly 
diffusing bright particle species like aggregates of fluorescently labeled proteins275. 
 
3.13.3.1 Correlation Analysis 
Autocorrelation analysis (Figure 3-3, A) relies on the characterization of the fluctuation of a 
fluorescence signal over time. Thus, this analysis method can only be applied to measurements 
with stationary focus. For autocorrelation the FCSPP Evaluation 2.0 Software (Evotec 
Technologies) was used. For this type of data evaluation, time is subdivided into so called bins of 
usually 50 ns and the fluorescence signal is converted into a binary signal (0 = no fluorescence 
signal detected; 1 = fluorescence signal detected) resulting in a row of numbers 0 and 1. Using 
the autocorrelation function the values for all bins which are separated by defined time gaps of 
multiples of 50 ns (correlation times; 50 ns, 100 ns, 150 ns, …) are multiplied with each other. 
The products for each correlation time are then summed up and normalized against the overall 
signal.  
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Figure 3-3: FCS and FIDA analysis 
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Figure 3-3: FCS and FIDA analysis 
This figure shows the basic principle of fluorescence correlation spectroscopy (FCS) and fluorescence 
intensity distribution analysis (FIDA) in a simplified manner.  
A) For FCS, time is subdivided into bins of typically 50 ns and signals are evaluated in a binary 
manner. The number of events occurring for distinct correlation times can be visualized using 
a correlation histogram. When a fluorescently labeled particle passes the laser focus, this 
results in a burst lasting for several bins (lower panel, left). This leads to higher values of the 
autocorrelation function (visualized by an increased number of events in the correlation 
histogram (lower panel, right)) for shorter correlation times. As a result, the diffusion time of 
the average particle can be deduced from the shape of the autocorrelation function. 
B) For FIDA, time is subdivided into bins of typically 40 µs. The number of photons per bin is 
recorded (middle column) and can be plotted as intensity distribution histogram (right 
column). For monomeric protein solutions (upper row) the number of photons per bin is quite 
constant, resulting in a sharp peak in the intensity distribution histogram. For solutions with 
protein aggregates of variable size the number of photons per bin will be more variable, 
resulting in a broader peak in the intensity distribution histogram. Thus, the shape of the 
intensity distribution histogram provides insight into the aggregate composition of the 
protein solution.  
 
 
Whenever a fluorescent particle passes the focus it creates a fluorescence burst lasting for 
several bins according to its time in focus. This results in highest autocorrelation values for 
neighboring bins (i.e., time gaps which are shorter than the particle’s duration of stay in the 
focus). The autocorrelation function is mathematically fitted in an iterative process from the 
correlation distribution and the fit quality is estimated using Chi-square. The mean diffusion 
time (Tdiff) and thus the particle size of the average particle can finally be deduced from the 
autocorrelation function.  
Different further parameters like mean particle brightness (CPP) and mean number of particles 
in the laser focus (N) can be inferred: The mean number of photons over measurement time 
(given in kHz) is directly deduced from the measurement and accounts for the total fluorescence 
intensity (Itot). CPP is calculated by dividing total fluorescence intensity by the number of 
particles (Itot/N). Using the FCSPP Evaluation Software different species of molecules can also be 
detected using a multi component fit. Here, a relative amount of particles (in %) and a 
corresponding Tdiff are assigned to each component.  
The cross-correlation represents an analysis for measurements with fluorescence signals in 
more than one channel. This enables the quantitative analysis of intermolecular aggregation 
processes. To this end, the detected signal intensity in one channel is correlated to the signal 
intensity in the second channel for all correlation times. Hence, particle species showing 
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coinciding signals in both channels can easily be distinguished from particles showing a 
fluorescence signal in only one channel.  
Given that Itot remains stable over the measurement, parameters such as concentration, diffusion 
time (Tdiff), and specific brightness of the particle species showing fluorescence signals in both 
channels can be determined. A typical experiment for this application is the investigation of 
receptor-ligand binding using different fluorescently labeled binding partners276-278.  
 
3.13.3.2 Fluorescence Intensity Distribution Analysis (FIDA) 
For fluorescence intensity distribution analysis (FIDA, Figure 3-3 B) the number of photons in 
consecutive time intervals of defined length (so called bins, typically 40 µs) is detected and 
statistically analyzed using the Evaluation 2.0 Software (Evotec Technologies). The number of 
detected photons per bin is illustrated in an intensity distribution histogram and can be 
statistically analyzed via a FIDA multi component fit. Here, a model-based fitting procedure is 
applied to infer the brightness (qn [kHz]) and the concentration (cn) of one to four particle types 
from the total fluorescence intensity of the sample (Itot) depending on the expected amount of 
different kinds of particles275.  
Since fluorescence intensity is the primary measure for FIDA, this kind of analysis is 
independent of diffusion time and can thus be applied both for scanned and unscanned 
measurements. Moreover, the measurement of fluorescence intensity renders FIDA more 
sensitive towards small aggregates than FCS (since fluorescence intensity increases 
approximately linearly with the number of fluorescently labeled particles within one aggregate, 
whereas diffusion time only increases with the third root of particle diameter). However, it 
provides no information on diffusion time.  
 
3.13.3.3 Scanning for Intensely Fluorescent Targets (SIFT) 
Using a stationary focus has limitations when it comes to the detection of rare and large (and 
thus slowly diffusing) particles at low concentrations. Since FIDA is independent of measuring 
diffusion time, the measurement efficiency for such solutions can be increased by scanning for 
intensely fluorescent targets (SIFT)202,203 where the focus scans through the solution (Figure 
3-4 A) using the InsightTM Reader’s scanning unit (Figure 3-2)279,280.  
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Thus, aggregation and co-aggregation processes can easily be analyzed qualitatively in color-
coded intensity distribution histograms that can be evaluated further using SIFT analysis via the 
2D-SIFT Software (Evotec Technologies)202 (Figure 3-4 B). For quantification the histogram can 
be subdivided into several segments and a threshold – evaluated in samples without 
aggregates – can be determined to exclude the signal from low intensity bins202,203,205,281. Since 
the signal of equally intensely fluorescing particles is approximately uniformly distributed over 
the same number of bins, the number of “highly intense bins” correlates with the number and 
concentration of intensely fluorescent target molecules.  
All in all, FIDA is highly sensitive for rare, large particles but provides no information on the 
diffusion time since the mean time a particle is located in the focus is no longer determined by 
its properties but by the scanning velocity. 
 
 Cell Lysis for Fluorescence Correlation Spectroscopy 3.13.4
Cells were maintained, enzymatically dissociated and centrifuged as described above. 
Afterwards the cells were resuspended in 1 ml of precooled DPBS (4°C) and transferred to a 
1.5-ml reaction tube. Cells were centrifuged at 4°C and 16,100 rcf for 10 min (Eppendorf 
centrifuge 5415 R) and supernatant was discarded. Afterwards, cell lysis was performed as 
described previously282. Briefly, cell pellets were resuspended in 200 µl of RIPA buffer (50 mM 
Tris-HCl, pH 7.6, 1% NP-40, 150 mM NaCl, 1 mM EDTA) and incubated on ice for 10 min. 
Afterwards, samples were homogenized by pipetting ten times through a yellow needle and 
subsequently centrifuged for 10 min at 16,100 rcf and 4°C. The supernatant was transferred to 
new precooled 1.5-ml reaction tubes and frozen at -80°C.  
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Figure 3-4: SIFT analysis 
The figure shows the main principles of SIFT in a simplified manner. 
A) Using a stationary focus the detection of large particles is limited by their slow Brownian 
movement (left) and can be improved by moving the laser focus through the sample volume 
using the InsightTM Reader’s beam scanning unit (right). 
B) A qualitative analysis of aggregation and co-aggregation can be obtained by using two-
dimensional color-coded histograms. As example, histograms for monomeric proteins (left 
column), monomeric “red” proteins and aggregated “green” proteins (2nd left column), 
aggregated “red” proteins and aggregated “green” proteins (2nd right column), and mixed 
aggregates of “red” and “green” proteins (right column) are shown. 
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3.14 High Content Screening (Opera®) 
 Cell Maintenance for High Content Screening 3.14.1
Cells were maintained as described above. Prior to measurement, nuclei were stained by 
incubating the cells for 15 min at 37°C in a humidified 95% air/5% CO2 atmosphere with Draq5 
(Thermo Fisher Scientific, 62252) diluted 1:1,000 in medium to a final concentration of 5 µM. 
 
 Measurement Setup of the Opera® System 3.14.2
High content screening was performed using the Opera® high-throughput confocal imaging 
platform (PerkinElmer Cellular Technologies GmbH, Hamburg, Germany). In this setup (Figure 
3-5 A), laser light can be emitted at four different wavelengths: 442 nm, 488 nm, 561 nm, and 
640 nm. The light passes the Nipkow unit with the primary dichroic mirror depending on the 
filters and can be focused on the sample carrier using four different objectives: one 20-fold air 
objective (20x_Air_LUCPLFLN_NA=0.45), and three different water immersion objectives: 
20xW_UAPO20xW3/340_NA=0.7, 40xW_PlanAPO_40xWLSM_NA=0.9, and 60xW_UPLAPO_60x_ 
NA=1.2. Fluorescent dyes or proteins in the sample carrier will emit photons upon excitation by 
laser light with corresponding wavelengths. Since this fluorescence light is emitted in all 
directions, a part of it passes the objective and follows the way of the exciting laser light 
retrogradely until it is reflected by the primary dichroic mirror. Depending on its wavelength, 
fluorescence can finally be detected by three different cameras. Camera 3 can detect 
fluorescence excited with 640 nm. Fluorescence excited with all other lasers is mirrored at the 
detection dichroic mirror 2 (“Detection dichro 2”) and subdivided according to its wavelength at 
the detection dichroic mirror (“Detection dichro”). Depending on the filter settings applied, light 
of given wavelengths is finally detected using Camera 1 or Camera 2. 
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Figure 3-5: Measurement setup of the Opera® 
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Figure 3-5: Measurement setup of the Opera® 
Schematic representation of the Opera® high-throughput confocal imaging platform and the Nipkow 
unit.  
A) Laser light from four lasers (442 nm, 488 nm, 561 nm, and 640 nm) can be focused on the 
sample carrier via dichroic mirrors. Emitted photons pass the objective retrogradely and are 
guided via dichroic mirrors and a Nipkow unit to be detected separately using three different 
cameras.  
B) The Nipkow disk inside the Nipkow unit consists of small holes arranged in an arched manner. 
Inside the Nipkow unit laser light is focused by microlenses in a disk with similar arrangement 
through the Nipkow disk and the objective on the sample. Emitted fluorescence is guided 
retrogradely through the Nipkow disk where the single holes decrease background 
fluorescence by excluding signals from above or below the focus plane. Due to the rotation of 
the Nipkow disk an arched image is recorded for each hole. The images of the different holes 
will finally add up to a complete image.  
 
 
In order to reduce background signals, the light in a conventional confocal fluorescence 
microscope would normally pass a pinhole which is inserted at a position corresponding to the 
intermediate image of a conventional optical microscope and would thus exclude signal from 
fluorescent particles below or above the focus plane. In the Opera® high-throughput confocal 
imaging platform the confocal pinholes are replaced by a Nipkow unit (Figure 3-5 B). In this 
setup, the exciting laser light is focused by a microlense array before it passes the primary 
dichroic mirror, the pinhole disk, and the objective to finally excite fluorescent dyes or proteins 
in the sample. The fraction of fluorescence light that is guided retrogradely passes the pinhole 
disk, a spinning disk with holes arranged in an arched profile. The microlenses on the 
microlense array and the pinholes on the pinhole disk are arranged in a similar manner. Due to 
the rotation of the microlense array and the pinhole disk (with a speed of 25 revolutions per 
second) not a single point is detected but an arched area of the image. Due to the arrangement of 
the microlenses and the pinholes and the spinning of those disks, the single arched areas will 
add up to a complete image of the focal area.  
The autofocus function enables a fully automated acquisition of fluorescence images. Here, 
characteristic reflections of the autofocus laser are detected when passing the bottom of the 
multiwell plate. Afterwards, laser light is focused on a defined height above the bottom of the 
multiwell plate depending on the desired image plane.  
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 Adjustment 3.14.3
Prior to each experiment a reference image and a skew analysis have to be applied in order to 
compensate for systemic errors of the optics and the CCD cameras. 
Uneven brightness distribution within an image was compensated for by using the “reference 
image” function. Using the Opera® adjustment plate, an image of free floating fluorescence dye 
was acquired. This should theoretically lead to evenly distributed fluorescence intensity within 
the image field. Practically, we observed higher intensity in the center of the image and 
decreasing intensity towards the edges. This effect is counteracted by the flat-field correction 
algorithm which (simplified) works by multiplying the recorded image with the inverted 
reference image. 
The mechanical alignment of the CCD cameras alone is subject to variations (for example due to 
changes in temperature) and not sufficient to provide an adequate overlay of high resolution 
images obtained from more than one camera. To counteract this phenomenon the “skew 
analysis” function was applied. The Opera® adjustment plate provides wells with beads with 
different diameters for the different objectives: 10 µm for 10x, 5 µm for 20x, and 2.5 µm for 40x 
and 60x. Images of these beads are recorded for all excitation wavelengths and all detection 
cameras. Afterwards, a theoretical optimal overlay of the obtained images is calculated. This 
optimization is later on applied to all images of one measurement. 
In order to set up an automated experiment, the kind of multiwell plate and the required 
objective were defined. Wavelengths and intensities of laser light as well as corresponding filters 
were defined depending on experimental conditions. A “plate layout” (defining the wells of a 
multiwell plate) and a “sublayout” (defining the area insight the wells) where images should be 
acquired were defined.  
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 Data Acquisition 3.14.4
All data from automated fluorescence imaging shown in this work have been acquired using the 
20x air objective. 
 
3.14.4.1 Initial Characterization of Inducible H4 Cells 
For the initial characterization of inducible H4 cells (see chapter 4.2.2) the following 
experimental setup was applied:  
In “Exposure 1” focus height was set to -9.0 µm for the detection of Venus fluorescence in the 
cytoplasm. Venus fluorescence was excited using the 488-nm laser with a laser power of 
7,110 µW. Fluorescence was detected using Camera 1 with an exposure time of 200 ms and 
twofold binning using a 520/35 filter. 
In “Exposure 2” focus height was set to -13.0 µm for the detection of mCherry fluorescence in the 
nucleus. Fluorescence of mCherry was excited using the 561-nm laser with a laser power of 
3,240 µW. Fluorescence was detected using Camera 2 with an exposure time of 7,000 ms and 
twofold binning using a 600/40 filter. 
In “Exposure 3” focus height was set to -13.0 µm for the detection of Draq5 fluorescence in the 
nucleus. Fluorescence of Draq5 was excited using the 640-nm laser with a laser power of 
3,830 µW. Fluorescence was detected using Camera 3 with an exposure time of 400 ms and 
twofold binning using a 690/50 filter. 
For all three exposures, the filter of the primary dichroic mirror was 488/561/640 and the filter 
of the detection dichroic mirror was 568. Imaging was performed sequentially for all wells. 
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3.14.4.2 Fluorescence Kinetics of H4_GE Cells 
For the characterization of fluorescence kinetics and fluorescence depending on tebufenozide 
concentration in H4_GE cells (see chapter 4.2.2.3) the following experimental setup was applied: 
In “Exposure 1” focus height was set to -8.0 µm for the detection of Venus fluorescence in the 
cytoplasm. Venus fluorescence was excited using the 488-nm laser with a laser power of 
7,110 µW. Fluorescence was detected using Camera 1 with an exposure time of 200 ms and 
twofold binning using a 520/35 filter. 
In “Exposure 2” focus height was set to -12.0 µm for the detection of Draq5 fluorescence in the 
nucleus. Fluorescence of Draq5 was excited using the 640-nm laser with a laser power of 
3,830 µW. Fluorescence was detected using Camera 3 with an exposure time of 120 ms and 
twofold binning using a 690/50 filter. 
For both exposures, the filter of the primary dichroic mirror was 488/640 and the detection 
dichroic mirror was set to empty1. Imaging was performed sequentially for all wells. 
 
3.14.4.3 Evaluation of the Effect of Ferric Iron and DMSO on H4_GE-
V1S+SV2 and H4_GE-V Cells 
In order to evaluate the effect of ferric iron and DMSO on H4_GE-V1S+SV2 and H4_GE-V cells 
(see chapter 4.3) the following experimental setup was applied: 
In “Exposure 1” focus height was set to -8.0 µm for the detection of Venus fluorescence in the 
cytoplasm. Venus fluorescence was excited using the 488-nm laser with a laser power of 
7,110 µW. Fluorescence was detected using Camera 1 with an exposure time of 320 ms and 
twofold binning using a 520/35 filter. 
In “Exposure 2” focus height was set to -12.0 µm for the detection of Draq5 fluorescence in the 
nucleus. Fluorescence of Draq5 was excited using the 640-nm laser with a laser power of 
1,500 µW. Fluorescence was detected using Camera 3 with an exposure time of 40 ms and 
twofold binning using a 600/40 filter. 
For both exposures, the filter of the primary dichroic mirror was 488/640 and the detection 
dichroic mirror was set to empty1. Imaging was performed sequentially for all wells. 
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3.14.4.4 Initial Characterization of LUHMES_GE Cells 
For the initial characterization of LUHMES_GE cells (see chapter 4.4.2.1) the following 
experimental setup was applied: 
In “Exposure 1” focus height was set to -8.0 µm for the detection of Venus fluorescence in the 
cytoplasm. Venus fluorescence was excited using the 488-nm laser with a laser power of 
7,110 µW. Fluorescence was detected using Camera 1 with an exposure time of 360 ms and 
twofold binning using a 520/35 filter. 
In “Exposure 2” focus height was set to -11.0 µm for the detection of Draq5 fluorescence in the 
nucleus. Fluorescence of Draq5 was excited using the 640-nm laser with a laser power of 
3,830 µW. Fluorescence was detected using Camera 3 with an exposure time of 120 ms and 
twofold binning using a 690/50 filter. 
For both exposures, the filter of the primary dichroic mirror was 488/640 and the detection 
dichroic mirror was set to empty1. Imaging was performed sequentially for all wells. 
 
 Data Analysis 3.14.5
An automated image analysis tool was developed  in order to quantify cellular Venus 
fluorescence using the Acapella® software (PerkinElmer Cellular Technologies GmbH).  
Here, nuclei (Figure 3-6 A) and cell boundaries (Figure 3-6 B) were automatically detected based 
on Draq5 signal. Based on this detection, an area for the quantification of mean cellular Venus 
fluorescence intensity was determined (Figure 3-6 C). By setting an arbitrary threshold for the 
mean cellular Venus fluorescence intensity, cells were considered Venus-positive (Figure 3-6 D) 
or Venus-negative (Figure 3-6 E). As a final result, a table with high content data concerning 
different properties was obtained (Figure 3-6 F). 
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Figure 3-6: Opera® data analysis 
Overview of the automated image analysis using the Acapella® software. 
A) Detection of nuclei based on Draq5 fluorescence. 
B) Determination of cell boundaries based on Draq5 fluorescence. 
C) Definition of the area to quantify mean cellular Venus fluorescence. 
D) Cells considered Venus-positive based on an arbitrarily set threshold for mean cellular Venus 
fluorescence. 
E) Cells considered Venus-negative based on an arbitrarily set threshold for mean cellular Venus 
fluorescence. 
F) Final output table showing different sample properties. 
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4 Results 
4.1 Testing the Project Strategy 
 Susceptibility of H4 and LUHMES Cells to Lentiviral 4.1.1
Transduction 
To test if H4 and LUHMES cells are susceptible to viral transduction, we produced a Cre driver 
virus, a GAL4 driver virus, a UAS-Venus receiver virus and a loxP-Venus receiver virus. H4 and 
LUHMES cells were expanded in 6-well plates for 48 h before incubating them in virus 
supernatant of Cre driver and loxP-Venus receiver or GAL4 driver and UAS-Venus receiver, 
respectively, for 5.5 h. Cells were imaged 24 h after addition of virus supernatant. In H4 cells, 
fluorescent cells for both the Cre-loxP system (Figure 4-1 A) and the GAL4-UAS system (Figure 
4-1 B) were observed. For the LUHMES cells we could not detect any fluorescent cell neither for 
the Cre-loxP system (Figure 4-1 C) nor for the GAL4-UAS system (Figure 4-1 D). In contrast, no 
living LUHMES cells were observed at all. We speculated that the reason for this could be the 
presence of fetal bovine serum (FBS) in the virus supernatant. For this reason, we repeated the 
experiment and incubated LUHMES cells with purified GAL4 driver virus and UAS-GFP receiver 
virus (kind gift from P.H. Kuhn) without FBS at a ratio of 1:267. 48 h later, green fluorescent 
LUHMES cells were detectable (Figure 4-1 E). Thus, we concluded that both H4 and LUHMES 
cells were susceptible to lentiviral transduction, although the transduction of LUHMES cells 
required the usage of purified virus. 
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Figure 4-1: Susceptibility of H4 and LUHMES cells to lentiviral transduction 
H4 and LUHMES cells were incubated with virus supernatant (A-D) or purified virus (E) of Cre driver and 
loxP-Venus receiver virus or GAL4 driver and UAS-Venus receiver virus, respectively. For all cells, 
brightfield (upper row) and fluorescence images (lower row) were taken. 
A)  H4 cells showed green fluorescence 24 h after transduction using the Cre-loxP system. 
Scale bar in A is 100 µm and is valid for all panels. 
B)  H4 cells showed green fluorescence 24 h after transduction using the GAL4-UAS system. 
C, D) No viable LUHMES cells after incubation with virus supernatant.  
E) LUHMES cells tolerated incubation with purified virus and displayed green fluorescence 
after 24 h incubation with purified GAL4 driver and UAS-GFP receiver virus.  
 
 
 Incomplete Separation of Hemi-Venus Constructs Using a P2A 4.1.2
Sequence 
In order to ensure equimolar expression in the BiFC system, we decided to couple the hemi-
Venus constructs via a P2A sequence. To test this system, the αSyn-hemi-Venus constructs were 
connected via a P2A sequence (SV2-P2A-V1S). As negative control, SV2 was connected with V1 
(i.e., the N-terminal Venus fragment lacking αSyn) via a P2A sequence (SV2-P2A-V1) (Figure 
4-2 A). HEK293T cells were transiently transfected with both constructs and subjected to 
fluorescence microscopy 48 h after transfection. Surprisingly, we observed green fluorescence in 
both SV2-P2A-V1S-transfected cells and the negative control (Figure 4-2 A). Since no 
background has been described for the αSyn-hemi-GFP system when co-transfecting H4 cells 
with GFPN-terminus-αSyn and GFPC-terminus213, we speculated that this background signal is due to an 
incomplete separation mediated by the P2A sequence.  
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Figure 4-2: Incomplete separation of hemi-Venus fusion proteins connected by a P2A sequence 
HEK293T cells were transiently transfected with SV2-P2A-V1S or a negative control lacking αSyn linked 
to V1 (SV2-P2A-V1) and subjected to fluorescence microscopy and western blot analysis.  
A) Both cells transfected with SV2-P2A-V1S (positive control) and cells transfected with the 
negative control SV2-P2A-V1 showed green fluorescence. Scale bar: 100 µm. 
B) Western blot of cells transfected with SV2-P2A-V1S shows incomplete separation of the two 
hemi-Venus constructs for two individual transfections (lane 1, 2). Lane 3: control with cells 
transfected with SV2. FL: full-length SV2-P2A-V1S construct.  
 
 
To test this hypothesis, we transfected HEK293T cells with the SV2-P2A-V1S constructs in 
duplicates and harvested the cells 48 h after transfection for western blot analysis. For both 
transfections we observed incomplete separation of the full-length construct (Figure 4-2 B, FL). 
Therefore, we discarded the P2A system and decided to use separate viruses for the 
transduction with the V1S and the SV2 construct, respectively. 
 
 Background Fluorescence upon Transduction of Cells with V1 4.1.3
and SV2  
We wondered if the incomplete P2A sequence mediated separation of the hemi-Venus 
constructs was the only explanation for the background signal in the cells that had been 
transfected with the negative control construct (lacking αSyn linked to V1; Figure 4-2 B). For the 
αSyn-hemi-GFP system no background signal has been described for a negative control where 
H4 cells had been co-transfected with GFPN-terminus-αSyn and GFPC-terminus213. Still, background 
fluorescence and an improvable signal-to-noise ratio are commonly observed in BiFC systems 
(including systems where a split-Venus strategy is applied)251.  
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Figure 4-3: Background fluorescence due to self-complementation of hemi-Venus fragments  
H4 cells were transduced with constitutively active GAL4 driver virus and UAS-GOI receiver viruses 
carrying V1, V1S, and SV2 as annotated.  
A) Fluorescence images of transduced cells, nuclei were stained with DAPI. Co-transduction with 
both the positive control (V1S and SV2) and the negative control (V1 + SV2) led to green 
fluorescence. No green fluorescent cells were observed upon transduction with SV2, V1, or 
V1S alone.  
B) The fraction of positive cells was approximately 10% for transduction with V1S + SV2, 
approximately 7% for transduction with V1 + SV2, and exactly 0% for transduction with SV2, 
V1, or V1S alone. 
C) Western blot showing expression of the corresponding constructs on protein level; no 
massive increase in signal intensity of V1 (lane 3) compared to V1S (lane 2) was observed.  
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To our surprise, we did not find any literature concerning the signal-to-noise ratio of the αSyn-
split-Venus system to the beginning of this thesis. Since this system is commonly used, we 
considered that the signal-to-noise ratio for the αSyn-split-Venus system would be an important 
issue to investigate.  
To do so, we transduced H4 cells with purified viruses of constitutive GAL4 driver and UAS-V1 
receiver, with UAS-V1S receiver, with UAS-SV2 receiver, with a combination of UAS-V1S receiver 
and UAS-SV2 receiver (positive control), or a combination of UAS-V1 receiver and UAS-SV2 
receiver (negative control), respectively. 48 h after transduction cells were subjected to 
fluorescence microscopy or harvested for western blot analysis.  
In the positive control (V1S + SV2) about 10% of cells showed green fluorescence (Figure 
4-3 A, B, left column). To our surprise, we also observed green fluorescence in the negative 
control (V1 + SV2, Figure 4-3 A, B, second column) with a fraction of about 7% of positive cells. 
As expected, no fluorescent cells were observed when cells were transduced with any of the 
constructs V1, V1S, or SV2 alone (Figure 4-3 A, B, right three columns).  
The observed background signal in the negative control might be explained by a massive 
overexpression of V1 compared to V1S. To exclude this possibility, we performed western blot 
analysis and did not observe a visible increase in signal intensity for V1 compared to V1S (Figure 
4-3 C).  
Thus, we found noteworthy self-complementation of Venus fragments without αSyn 
oligomerization as driving force resulting in background fluorescence in cells transfected with a 
combination of V1 and SV2.  
 
 No Increase in the Signal-to-Noise Ratio upon Insertion of Point 4.1.4
Mutations into V1 and V2 
Background fluorescence and an unfavorable signal-to-noise ratio are common problems in BiFC 
assays251. It has been described that one possibility of increasing the signal-to-noise ratio is the 
insertion of point mutations at the interface of Venus fragment interaction251 since the 
complementation of the two Venus fragments appears to be at least partly driven by 
hydrophobic interactions of the side chains283. Thus, in order to decrease self-association 
tendencies, hydrophobic amino acids could be replaced by neutral amino acids283,284. For Venus, 
several of these point mutations have been described283,285,286. We inserted two such promising 
single amino acid exchanges – I152L283 and L201V285 – in V1 and V2, respectively287.  
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Figure 4-4: No effect of point mutations in V1 and V2 on signal-to-noise ratio 
H4 cells were transiently transfected with V1S + SV2 as positive control or V1 + SV2 as negative control 
with or without the point mutations I152L (in V1) and L201V (in V2) to test their effect on the signal-to-
noise ratio.  
A)  Fluorescence images showing decreased fluorescence intensity for both the I152L and the 
L201V mutation and both the positive and the negative control. Scale bar: 100 µm. 
B)  Quantification of total fluorescence intensity per protein amount using the InsightTM Reader. 
Fluorescence intensity decreased for both I152L and L201V mutation for both the positive and 
the negative control. 
C)  Signal-to-noise ratio was determined from signal intensities shown in B) and not considerably 
affected by insertion of both point mutations.  
Bars in B) and C) show mean of 1-2 independent experiments.  
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H4 cells were transiently transfected with V1S + SV2 as positive control or V1 + SV2 as negative 
control carrying different combinations of V1wt, V1I152L, V2wt, and V2L201V. 48 h after transfection 
cells were subjected to fluorescence microscopy and cell lysates were analyzed using single 
particle spectroscopy. For both the positive and negative control highest total fluorescence 
intensity was observed for wildtype, i.e., the combination V1wt + V2wt (Figure 4-4 A, B, left 
column). Compared to wildtype, total fluorescence intensity was decreased for I152L, i.e., the 
combination V1I152L + V2wt (Figure 4-4 A, B, second column). The fluorescence intensity 
decreased even more for L201V, i.e., the combination V1wt + V2L201V (Figure 4-4 A, B, third 
column), and was lowest for the combination of both mutations, V1I152L + V2L201V (Figure 4-4 A, 
B, right column). Unfortunately, we did not observe a noteworthy increase in signal-to-noise 
ratio due to either of the point mutations or a combination of both of them (Figure 4-4 C).  
Thus, since the mutations did not critically increase the signal-to-noise ratio and since we 
obtained the highest total fluorescence intensity when using the combination V1wt + V2wt, we 
decided to do our further studies using these constructs. 
 
 
 Decreased Fluorescence Intensity in Cells Transfected with V1S 4.1.5
and SV2 upon Incubation with Known Modulators of αSyn 
Aggregation  
The main advantage of the BiFC system is that it allows the real-time observation of αSyn 
oligomerization in living cells. Thus, it might be a useful tool for high-throughput screenings for 
αSyn anti-aggregative compounds. In order to test if the BiFC system – despite the self-
complementation of the Venus fragments in the absence of αSyn – is suitable for such 
experiments, H4 cells were transiently transfected with αSyn BiFC plasmids and treated with 
anle138b, anle138c, baicalein, or DMSO as control. Anle138b, anle138c, and baicalein have been 
shown to inhibit αSyn aggregation in vitro56,145,192,288-290 and anle138b has also shown beneficial 
effects in various animal models of PD192,291,292. 48 h after transfection, cells were subjected to 
fluorescence microscopy, and fluorescence intensity of cell lysates was determined using single 
particle spectroscopy.  
Fluorescence intensity was decreased following treatment with anle138b, anle138c, or baicalein 
compared to DMSO control, suggesting inhibited aggregation of αSyn (Figure 4-5). Moreover, 
fluorescence intensity was increased upon treatment with DMSO compared to the untreated 
control (Figure 4-5). This is well in line with in vitro findings where incubation of recombinant 
αSyn with DMSO increased aggregation145. 
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Figure 4-5: Reduced fluorescence intensity in the BiFC system as result of aggregation inhibitors 
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Figure 4-5: Reduced fluorescence intensity in the BiFC system as result of aggregation inhibitors 
H4 cells were transiently transfected with the BiFC plasmids and left untreated or were incubated with 
DMSO (control), anle138b, anle138c, or baicalein.  
A) Fluorescence images showed a decrease in fluorescence intensity upon treatment with 
anle138b, anle138c, and baicalein compared to treatment with DMSO. Nuclei were stained 
with Hoechst33342. Scale bar in top left panel is 500 µm and valid for images in the first row. 
Scale bar in the left panel of the second row is 100 µm and valid for images in the second and 
third row. 
B) Cell lysates were analyzed using single particle spectroscopy. Total fluorescence intensity was 
increased in DMSO-treated cells compared to untreated cells and decreased upon treatment 
with anle138b, anle138c, or baicalein compared to DMSO-treated cells.  
 
 
Thus, the BiFC system is suitable to detect anti-aggregative compounds (like anle138b, anle138c, 
and baicalein) as well as substances that increase αSyn aggregation (like DMSO) and therefore 
might represent a valuable tool for high-throughput screening assays. Obviously, additional 
experiments will be needed to carefully evaluate hits from primary screens since false positive 
results cannot be excluded. 
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4.2 Establishment and Characterization of Inducibly αSyn 
Overexpressing H4 Cell Lines  
 Transgene Expression in 98% of H4 Cells for at Least 18 Days 4.2.1
after Lentiviral Transduction 
In the next step, we produced and purified the required lentiviruses to prepare stable cell lines. 
In order to obtain as many lentivirally transduced H4 cells as possible, an optimized 
transduction protocol was established. To this end, cells were incubated with viruses that carry 
a constitutive GAL4 driver (V99, see Table 3-5) and the UAS-SV receiver (V41, see Table 3-5) 
following 4 different protocols. 72 h after transduction cells were imaged and Venus-positive 
cells were counted using ImageJ. For protocol A we obtained approximately 20% of Venus-
positive cells (Figure 4-6 A), protocol B led to approximately 39% of Venus-positive cells (Figure 
4-6 A). Using protocol C we counted ~80% of Venus-positive cells (Figure 4-6 A) and using 
protocol D we obtained 98% of Venus-positive cells (Figure 4-6 A, B, C). Following protocol D, 
the fraction of positive cells remained quite stable for at least 18 days after transduction. 23 days 
after transduction we observed a decrease in the fraction of positive cells (95%) which was not 
significant (p=0.36).  
As a consequence, stable cell lines were created following protocol D. This resulted in the 
following cell lines with inducible expression based on the GE system: 
- H4_GE-S: inducible overexpression of αSyn (transduction with V100 and V42) 
- H4_mC_GE-S: constitutive expression of mCherry coupled to a nuclear localization 
sequence (NLS) resulting in red fluorescence in the nucleus of positively transduced cells 
and inducible overexpression of αSyn (transduction with V100 and V120) 
- H4_GE-V: inducible overexpression of Venus (transduction with V100 and V43) 
- H4_GE-SV: inducible overexpression of αSyn coupled to Venus (transduction with V100 
and V41) 
- H4_GE-V1S+SV2: inducible overexpression of the N-terminal part of Venus coupled to 
αSyn (V1S) and of αSyn coupled to the C-terminal part of Venus (SV2) (transduction with 
V100, V39, and V46) 
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Figure 4-6: Stable and highly efficient transduction of H4 cells following protocol D 
H4 cells were transduced with the constitutive GAL4 driver virus (V99) and the UAS-SV receiver virus 
(V41) according to protocols A-D (see chapter 3.8.1.1). 
A) Quantification of the fraction of Venus-positive cells.  
B) Representative images obtained for protocol D. Nuclei were stained with Hoechst33342. Scale 
bar is 100 µm and valid for both panels. 
C) The fraction of positive cells was not significantly changed for 23 h after transduction (Fisher’s 
exact test, n.s.: not significant (i.e. p>0.05)).  
Data points represent mean of 3 to 4 wells; error bars show SEM; at least 300 cells were counted.  
 
 
The following cell lines with inducible expression based on the CET2 system were created: 
- H4_CET2-S: inducible overexpression of αSyn (transduction with V102 and V36) 
- H4_CET2-V: inducible overexpression of Venus (transduction with V102 and V37) 
- H4_CET2-SV: inducible overexpression of αSyn coupled to Venus (transduction with V102 
and V35) 
- H4_CET2-V1S+SV2: inducible overexpression of the N-terminal part of Venus coupled to 
αSyn (V1S) and of αSyn coupled to the C-terminal part of Venus (SV2) (transduction with 
V102, V32, and V33) 
 
Afterwards, cells were expanded and frozen in liquid nitrogen in “STOCK vials”. Afterwards, one 
“STOCK vial” was unfrozen, cells were expanded to five T75 flasks and frozen in ten “WORK 
vials”. For each experiment one “WORK vial” was unfrozen and cells were discarded after the 
experiment in order to obtain reproducible cell populations and to avoid effects of gene 
silencing. 
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 Characterization of the Inducibly αSyn Overexpressing H4 Cell 4.2.2
Lines  
4.2.2.1 Expression of Fluorescence Proteins in H4_mC_GE-S, H4_GE-V, 
H4_GE-SV, and H4_GE-V1S+SV2  
In order to test the generated cell lines, we incubated them with 10 µM tebufenozide or 0.1% 
DMSO as control for 48 h and analyzed the cells using the Opera® reader. To determine the 
factorial increase in transgene expression upon incubation with tebufenozide, the background 
signal from H4 cells was subtracted from the signal of the corresponding inducible H4_GE cells 
after treatment with tebufenozide or DMSO.  
As expected, we observed no green fluorescence in H4 cells, H4_GE-S cells, or H4_mC_GE-S cells 
treated with DMSO (Figure 4-7 A, C) or tebufenozide (Figure 4-7 B, C). The fraction of Venus-
positive cells was automatically determined using the Acapella® software and was below 1% for 
these cell lines independent of DMSO or tebufenozide treatment. We found approximately 99% 
mCherry-positive cells in the H4_mC_GE-S cell line independent of tebufenozide or DMSO 
treatment, while the fraction of mCherry-positive cells was approximately 0% in all other cell 
lines as expected. Thus, 99% of H4_mC_GE-S cells were transduced successfully with the 
mCherry-NLS-UAS-αSyn receiver virus (V120) (Figure 4-7 D).  
For H4_GE-V cells we observed increased background fluorescence upon treatment with DMSO 
compared to untreated H4 cells (Figure 4-7, C). Following incubation with tebufenozide, 
fluorescence intensity increased dramatically from approximately 33 to 616 counts, suggesting 
an 18.6-fold increase in transgene expression following tebufenozide treatment (Figure 4-7 B, C). 
The fraction of Venus-positive cells increased from 87% to 99% upon treatment with 
tebufenozide (Figure 4-7 D).  
For H4_GE-SV cells, background fluorescence intensity following treatment with DMSO was 
slightly lower than in H4_GE-V cells but still higher than in untreated H4 cells (Figure 4-7 A, C). 
Following induction of expression by tebufenozide, the fluorescence intensity increased by the 
factor 6.8 from approximately 29 to 198 counts (Figure 4-7 B, C). The fraction of Venus-positive 
cells increased from 77% to 94% upon treatment with tebufenozide (Figure 4-7 D).  
For DMSO-treated H4_GE-V1S+SV2 cells, background fluorescence was in the range of 
unmodified H4 cells (Figure 4-7 A, C). Upon incubation with tebufenozide, fluorescence intensity 
increased slightly from approximately 2.6 to 15.1 counts, suggesting an 5.8-fold increase in 
transgene expression upon tebufenozide treatment (Figure 4-7 B, C). The fraction of Venus-
positive cells increased from 0% to 37% upon treatment with tebufenozide (Figure 4-7 D). 
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Figure 4-7: Induction of transgene expression in H4_GE cells  
The generated H4_GE cell lines were incubated with 0.1% DMSO or 10 µM tebufenozide for 48 h. 
A) Representative fluorescence images of cells incubated with 0.1% DMSO. Nuclei were stained 
with Draq5. Scale bar is 100 µm and valid for all panels in A and B. 
B) Representative fluorescence images of cells incubated with 10 µM tebufenozide. 
C) Quantification of the mean cellular Venus fluorescence intensity of H4 cells upon incubation 
with DMSO or tebufenozide using the Acapella® software.  
D) Quantification of the fraction of Venus or mCherry-positive H4 cells upon incubation with 
DMSO or tebufenozide using the Acapella® software. Quantification was performed by setting 
an arbitrary threshold for Venus fluorescence intensity.  
Columns in C and D show mean of 3 independent experiments; error bars show SEM; Tebu: 
tebufenozide. 
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4.2.2.2 Expression of Fluorescent Proteins in H4_CET2-SV, H4_CET2-S, 
H4_CET2-V, and H4_CET2-V1S+SV2 
4.2.2.2.1 Determination of the Optimal Concentration of 4-OH-Tamoxifen for 
Transgene Induction 
Since we had no experience concerning the induction of transgene expression using 
4-OH-tamoxifen in cell culture, we incubated H4_CET2-V cells with different concentrations of 
4-OH-tamoxifen ranging from 100 pM to 100 µM or DMSO as control for 72 h in order to 
determine its optimal concentration. Subsequently, fluorescence intensity and the number of 
cells were determined using the Opera® high-throughput imaging setup. We found the highest 
fluorescence intensity (Figure 4-8 A, B) without obvious adverse effects on cell shape and cell 
survival (Figure 4-8 A, C) to be obtained upon incubation with 10 µM 4-OH-tamoxifen.  
 
 
4.2.2.2.2 Less Efficient Induction of Transgene Expression in H4_CET2 Cells 
Compared to H4_GE Cells 
As for H4_GE cell lines, the H4_CET2 cell lines were incubated with 10 µM 4-OH-tamoxifen or 
DMSO as control for 48 h and analyzed using the Opera® reader. As described in chapter 4.4.2.1, 
the background signal from H4 cells was subtracted from the signal of the corresponding 
inducible H4_CET2 cell lines after treatment with 4-OH-tamoxifen or DMSO for the determination 
of the factorial increase in transgene expression upon incubation with 4-OH-tamoxifen.  
As expected, we observed no fluorescence in H4 cells and H4_CET2-S cells with a fraction of 
Venus-positive cells below 1% independent of treatment with 4-OH-tamoxifen or DMSO (Figure 
4-9 A-D).  
For H4_CET2-V cells we observed increased background fluorescence upon treatment with DMSO 
compared to untreated H4 cells (Figure 4-9 C). Following incubation with 4-OH-tamoxifen, 
fluorescence intensity increased by a factor of 2.9 (Figure 4-9 B, C). The fraction of Venus-
positive cells increased from 12.1% to 35.6% upon treatment with 4-OH-tamoxifen (Figure 
4-9 D). 
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Figure 4-8: Maximum transgene induction in H4_CET2 cells achieved by 10 µM 4-OH-tamoxifen  
H4_CET2-V cells were incubated with different concentrations of 4-OH-tamoxifen ranging from 100 pM 
to 100 µM or DMSO as control for 72 h to determine the optimal concentration.  
A) Fluorescence images showed increasing fluorescence with increasing concentration of 
4-OH-tamoxifen up to a concentration of 10 µM. Nuclei were stained with Draq5. Scale bar is 
100 µm and valid for all panels.  
B) Quantification of fluorescence intensity using the Opera® system. A maximum in fluorescence 
intensity was observed upon incubation with 10 µM 4-OH-tamoxifen.  
C) Quantification of cell number using the Opera® system. Incubation with 100 µM 4-OH-
tamoxifen led to decreased cell number whereas all other concentrations showed no adverse 
effect on cell number. 
 
 
For H4_CET2-SV cells, background fluorescence intensity following treatment with DMSO was 
slightly lower than in H4_ CET2-V cells but still elevated compared to H4 cells (Figure 4-9 A, C). 
Following induction of expression by 4-OH-tamoxifen, fluorescence intensity increased by a 
factor of 2.4 (Figure 4-9 B, C). The fraction of Venus-positive cells increased from 10.2% to 
27.9% upon treatment with 4-OH-tamoxifen (Figure 4-9 D).  
For H4_CET2-V1S+SV2 cells fluorescence intensity was in the range of untreated H4 cells and the 
fraction of Venus-positive cells was below 1% independent of treatment with 4-OH-tamoxifen 
(Figure 4-9 A-D).  
Since we obtained a stronger increase in transgene expression upon treatment with 
tebufenozide in the H4_GE cells compared to 4-OH-tamoxifen treatment in the H4_CET2 cells, we 
continued with the GE-based system for the characterization of expression kinetics.  
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Figure 4-9: Induction of transgene expression in H4_CET2 cells  
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Figure 4-9: Induction of transgene expression in H4_CET2 cells  
The generated H4_CET2 cell lines were incubated with 0.1% DMSO or 10 µM 4-OH-tamoxifen for 48 h. 
A) Representative fluorescence images of cells incubated with 0.1% DMSO. Nuclei were stained 
with Draq5. Scale bar is 100 µm and valid for all panels in A and B. 
B) Representative fluorescence images of cells incubated with 10 µM 4-OH-tamoxifen. 
C) Quantification of the mean cellular Venus fluorescence intensity of H4 cells upon incubation 
with DMSO or 4-OH-tamoxifen using the Acapella® software. Bars show mean of 3 
independent experiments; error bars show SEM; Tam: 4-OH-tamoxifen. 
D) Quantification of the fraction of Venus-positive H4 cells upon incubation with DMSO or 4-OH-
tamoxifen using the Acapella® software. Quantification was performed by setting an arbitrary 
threshold for Venus fluorescence intensity. Bars show mean of 3 independent experiments; 
error bars show SEM; Tam: 4-OH-tamoxifen. 
 
 
4.2.2.3 Expression Characteristics of H4_GE Cells – Cellular Fluorescence 
In order to characterize the created cell lines regarding their transgene expression over time 
and as a function of tebufenozide concentration, all cell lines were incubated for up to 8 days 
post induction (DPI) with different tebufenozide concentrations ranging from 100 pM to 100 µM 
or DMSO as control, respectively.  
No increase in mean cellular Venus fluorescence was observed in H4, H4_GE-S, or H4_mC_GE-S 
cells (Figure 4-10 A). In line with this, the fraction of positive cells remained 0% for all time 
points and tebufenozide concentrations evaluated in H4, H4_GE-S, or H4_mC_GE-S cells (Figure 
4-10 B). Accordingly, no influence of tebufenozide concentration on fluorescence intensity could 
be observed in these cell lines (Figure 4-10 A, B, and visualized for day 5 in C).  
On the contrary, the fluorescence signal increased in a tebufenozide concentration-dependent 
manner from day 0 on in H4_GE-V, H4_GE-SV, and H4_GE-V1S+SV2 cells (Figure 4-10 A).  
In H4_GE-V cells, maximum fluorescence was obtained upon incubation with 1 µM tebufenozide 
on DPI 5 (Figure 4-10 A, C) with an increase from approximately 37.9 counts (for DMSO-treated 
cells on DPI 0) to 3,439.0 counts (all values are indicated after subtraction of background signal), 
equivalent to a 90.8-fold increase in fluorescence intensity following tebufenozide treatment. 
The fraction of positive cells increased from approximately 63% on DPI 0 (due to background 
fluorescence) to 100% 3-7 DPI for cells treated with 1 µM or 10 µM tebufenozide, while a 
maximum of about 89% of DMSO-treated cells were considered Venus-positive on DPI 5. 
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For H4_GE-SV cells, maximum fluorescence was obtained upon incubation with 10 µM 
tebufenozide on DPI 6 (Figure 4-10 A) with an increase from approximately 34.6 counts (for 
DMSO-treated cells at day 0) to 3,350.6 counts, equivalent to a 96.9-fold increase in fluorescence 
intensity following tebufenozide treatment. The fraction of positive cells increased from 
approximately 55% on DPI 0 (due to background fluorescence) to 100% 4-7 DPI for cells treated 
with 10 µM tebufenozide, while a maximum of approximately 88% of DMSO-treated cells was 
Venus-positive on DPI 5 (Figure 4-10 B).  
In H4_GE-V1S+SV2 cells fluorescence intensity increased more slowly than in H4_GE-V and 
H4_GE-SV cells and reached its maximum on DPI 6 upon incubation with 10 µM tebufenozide 
(Figure 4-10 A) with an increase from approximately 0.4 counts (for DMSO-treated cells at 
DPI 0) to 520.5 counts, equivalent to an 1,240.7-fold increase in fluorescence intensity following 
tebufenozide treatment. The fraction of positive cells increased from approximately 1% on DPI 0 
to 99% on DPI 5 and 6 for cells treated with 10 µM tebufenozide, while a maximum of 
approximately 15% of DMSO-treated cells was Venus-positive on DPI 5 (Figure 4-10 B). 
For H4_GE-V, H4_GE-SV, and H4_GE-V1S+SV2 cells, fluorescence intensity increased with 
increasing tebufenozide concentrations in the range of 100 pM to 10 µM and decreased when 
cells were incubated with 100 µM tebufenozide (Figure 4-10 C). 
For all cell lines the number of cells increased until DPI 4 or 5. No obvious effect on cell number 
was observed for all tebufenozide concentrations except for treatment with 100 µM 
tebufenozide where the number of cells was decreased in all cell lines.  
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Figure 4-10: Expression characteristics of H4_GE cells – cellular fluorescence 
H4 cell lines were incubated for up to 8 days with DMSO or with different tebufenozide concentrations 
ranging from 100 pM to 100 µM and imaged using the Opera® system. Quantification was performed 
using the Acapella® software. 
A) Quantification of the mean cellular Venus fluorescence intensity of H4 cells upon incubation 
with DMSO or different concentrations of tebufenozide (color-coded).  
B) Quantification of the fraction of Venus-positive H4 cells.  
C) Quantification of the mean cellular Venus fluorescence intensity of H4 cells in dependence of 
the tebufenozide concentration using the dataset from A) at DPI 5.  
D) Quantification of the number of cells per image field.  
Data points show mean of 3-6 independent experiments; error bars show SEM. 
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4.2.2.4 Expression Characteristics of H4_GE Cells – Protein Amount 
Depending on Tebufenozide Concentration 
In order to further characterize the cell lines regarding their transgene expression properties in 
dependence of the tebufenozide concentration, the cells were incubated for 4 days with different 
tebufenozide concentrations ranging from 10 nM to 10 µM or with DMSO as control, 
respectively. After 4 days cells were harvested, lysed and subjected to western blot analyses.  
As expected, we observed no transgene expression in H4 cells (Figure 4-11 A).  
For all transgene-expressing cell lines we observed very little background expression upon 
incubation with DMSO. In all cases, protein amounts increased with increasing tebufenozide 
concentration up to 1 or 10 µM (Figure 4-11 B, C).   
Cell lines H4_GE-S, H4_mC_GE-S, and H4_GE-V showed the highest transgene expression after 
incubation with 10 µM tebufenozide, whereas maximum transgene expression in H4_GE-SV and 
H4_GE-V1S+SV2 was observed upon incubation with 1 µM tebufenozide. According to the 
quantification of western blot signal intensity we obtained a maximum increase in transgene 
expression compared to DMSO by a factor of 19.7 in H4_GE-S, 45.9 in H4_mC_GE-S, 5.1 in 
H4_GE-V, 7.0 in H4_GE-SV, and 10.0 in H4_GE-V1S+SV2 for SV2 expression. Concerning the 
expression of V1S in H4_GE-V1S+SV2 the factorial increase in transgene expression could not be 
evaluated since no background signal for treatment with DMSO was detected. 
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Figure 4-11: Expression characteristics of H4_GE cells – protein amount depending on tebufenozide 
concentration 
H4 cell lines were incubated for 4 days with DMSO or different tebufenozide concentrations ranging 
from 10 nM to 10 µM. For all samples, expression of housekeeper β-tubulin was used as reference. 
A) Control western blots of H4 cells were treated like the western blots of the corresponding 
samples and showed no expression of αSyn, Venus, SV, V1S, or SV2.  
B) In all transgene expressing cell lines signal intensity increased with increasing tebufenozide 
concentration up to 1 µM or 10 µM for inducible transgenes.  
C) Quantification of western blot signal intensity was performed using ImageJ. Signal intensity 
of transgenes was normalized to housekeeper signal (β-tubulin).  
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4.2.2.5 Expression Characteristics of H4_GE Cells – Kinetics of Protein 
Amount 
In order to further characterize the cell lines regarding their expression kinetics according to 
protein levels, the cells were incubated for up to 5 days with 10 µM tebufenozide since 10 µM 
reached the highest transgene expression in most cell lines (see Figure 4-10 and Figure 4-11). 
Cells were harvested, lysed and subjected to western blot analyses on DPI 0, 1, 2, 3, 4, and 5.  
As expected, no transgene expression was observed in H4 cells (Figure 4-12 A).  
For all transgene expressing cell lines we observed very little background expression in the 
absence of tebufenozide (DPI 0). For all transgene expressing cells lines we observed an increase 
in protein amounts over time (Figure 4-12 B, C).  
According to the quantification of western blot signal intensity we obtained a maximum increase 
in protein amount by a factor of 27.8 in H4_GE-S, 16.7 in H4_mC_GE-S, and 90.3 in H4_GE-V. For 
H4_GE-SV and H4_GE-V1S+SV2 the factorial increase in protein amounts could not be evaluated 
since no background signal was observed on DPI 0. 
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Figure 4-12: Expression characteristics of H4_GE cells – kinetics of protein amount  
H4 cell lines were incubated with 10 µM tebufenozide for 0 to 5 days. For all samples, expression of 
housekeeper β-tubulin was used as reference. 
A) Control western blots of H4 cells were treated like the western blots of the corresponding 
samples and showed no expression of αSyn, Venus, SV, V1S, or SV2.  
B) In all transgene expressing cell lines signal intensity increased over time for inducible 
transgenes.  
C) Quantification of western blot signal intensity was performed using ImageJ. Signal intensity 
of transgenes was normalized to housekeeper signal (β-tubulin).  
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4.3 Increased αSyn Aggregation upon Incubation with DMSO and 
Ferric Iron  
DMSO and FeCl3 have been shown to increase αSyn aggregation in vitro144,145. In order to 
investigate the effect of DMSO and ferric iron on αSyn aggregation in the H4_GE cell model, 
H4_GE-V1S+SV2 and H4_GE-V cells were incubated with different combinations of DMSO 
(ranging from 0.1% to 1.0%) and FeCl3 concentrations (ranging from 0 µM to 1 mM) for 3 days. 
Transgene expression was induced with 10 µM tebufenozide in H4_GE-V1S+SV2 cells and with 
10 nM tebufenozide in H4_GE-V cells for three days in order to reach comparable fluorescence 
intensities. After 3 days, cellular fluorescence intensity was determined using the Opera® setup. 
We found an increase in fluorescence intensity with increasing DMSO and FeCl3 concentrations 
in H4_GE-V1S+SV2 cells (Figure 4-13, A left) but not in H4_GE-V cells (Figure 4-13, A right). The 
increase in fluorescence intensity was most prominent for incubation with FeCl3 compared to 
other tri-, di-, or monovalent metal ions (Figure 4-13, B). 
To test if the observed increase in fluorescence intensity in the BiFC assay is due to αSyn 
aggregation, we also analyzed the effect of DMSO and ferric iron on protein amount of cells 
overexpressing variants of αSyn (H4_GE-S, H4_GE-SV, and H4_GE-V1S+SV2) compared to 
H4_GE-V cells overexpressing Venus. Since we observed many dead and rounded cells among 
both H4_GE-V1S+SV2 and H4_GE-V cells upon incubation with 1% DMSO and iron precipitation 
upon incubation with 1 mM FeCl3, we chose the conditions 0.75% DMSO and 100 µM FeCl3 
versus 0.1% DMSO and 0 µM FeCl3. Allcell lines were incubated for 3 days, then harvested and 
lysed. We observed an increase in protein amount in H4_GE-S, H4_GE-SV, and H4_GE-V1S+SV2 
upon treatment with 0.75% DMSO and 100 µM FeCl3 compared to incubation with 0.1% DMSO, 
while there was no striking effect on Venus protein amount in H4_GE-V cells (Figure 4-14 A). 
Additionally, H4_GE-V1S+SV2 cells and H4_GE-V cells were analyzed using sucrose gradient 
centrifugation. For H4_GE-V1S+SV2 cells we observed higher molecular αSyn species (occurring 
in fractions with higher sucrose concentrations) when cells were treated with 0.75% DMSO and 
100 µM FeCl3 (Figure 4-14 B, left top) compared to cells treated with 0.1% DMSO (Figure 4-14 B, 
left bottom). In contrast, we found no difference between both treatments in H4_GE-V cells 
(Figure 4-14 B, right).  
Taken together, this suggests that incubation with high concentrations of DMSO and FeCl3 
increases aggregation of αSyn in inducibly αSyn-overexpressing H4_GE cells. 
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Figure 4-13: Increased fluorescence intensity in H4_GE-V1S+SV2 cells upon incubation with DMSO and FeCl3 
H4_GE-V1S+SV2 and H4_GE-V cells were incubated with 10 µM or 10 nM tebufenozide, respectively, 
and different concentrations of DMSO and tri-, di-, or monovalent ions for 3 days.   
A) Mean cellular Venus fluorescence intensity was increased upon incubation with higher DMSO 
and FeCl3 concentrations in H4_GE-V1S+SV2 cells (left), but not in H4_GE-V cells (right). Bars 
show mean of three independent experiments. 
B) Fluorescence intensity increased upon incubation with FeCl3 compared to other trivalent 
(AlCl3, GdCl3), divalent (CuCl2, ZnCl2, MnCl2), or monovalent (NaCl) ions. All cells were co-
incubated with 1% DMSO. Data points show mean of 8 to 9 independent experiments; error 
bars show SEM. *: p’<0.05; **: p’<0.01; ***: p’<0.001 (Student’s t-test, Bonferroni corrected 
for multi-testing). 
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Figure 4-14: Increased protein amount and aggregation in αSyn-overexpressing H4_GE cells upon incubation 
with DMSO and FeCl3 
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Figure 4-14: Increased protein amount and aggregation in αSyn-overexpressing H4_GE cells upon incubation 
with DMSO and FeCl3 
H4_GE-V1S+SV2 and H4_GE-V cells were incubated with 10 µM or 10 nM tebufenozide, respectively, 
and different concentrations of DMSO and FeCl3 for 3 days.  
A) Protein amounts increased in cell lines overexpressing variants of αSyn but not in cells 
overexpressing Venus alone upon incubation with 0.75% DMSO and 100 µM FeCl3. For 
quantification signals were normalized to housekeeper. Signals from samples treated with 
0.1% DMSO were set to 100%. Bars show mean of 3 to 4 independent experiments and error 
bars show SEM. 
B) Western blots from cell lysates after sucrose gradient centrifugation of H4_GE-V1S+SV2 (left) 
and H4_GE-V cells (right) incubated with 0.75% DMSO and 100 µM FeCl3 (top) or 0.1% DMSO 
and 0 µM FeCl3 (bottom).  
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4.4 Establishment and Characterization of Inducibly αSyn 
Overexpressing LUHMES Cells  
 Transgene Expression in 75% of LUHMES Cells After Lentiviral 4.4.1
Transduction  
In order to obtain as many transgene expressing LUHMES cells as possible we first tried to apply 
the same protocol that was used for the establishment of the stable H4 cell lines (Figure 4-6 A, 
protocol D). Since all LUHMES cells were dead 24 h after transduction, we next tested three 
different transduction protocols to create stable LUHMES cell lines (see chapter 3.8.2.1). For this, 
LUHMES cells were transduced with the constitutive GAL4 driver virus (V99) and the UAS-Venus 
receiver virus (V43). After imaging the fraction of Venus-positive cells was determined manually 
using ImageJ (Figure 4-15). Using protocol A a fraction of 36% of Venus-positive cells was 
obtained (Figure 4-15 A). Protocol B led to a fraction of 63% (Figure 4-15 A, B) and protocol C to 
a fraction of 75% of Venus-positive cells (Figure 4-15 A).  
 
As for the inducible H4 cells, we next created the following inducible LUHMES cell lines 
following protocol C: 
- LUHMES_GE-S: showing inducible overexpression of αSyn (transduction with V100 and 
V42) 
- LUHMES_mC_GE-S: showing constitutive expression of mCherry coupled to a nuclear 
localization sequence (NLS), resulting in red fluorescence in the nucleus of positively 
transduced cells, and inducible overexpression of αSyn (transduction with V100 and 
V120) 
- LUHMES_GE-V: showing inducible overexpression of Venus (transduction with V100 and 
V43) 
- LUHMES_GE-SV: showing inducible overexpression of αSyn coupled to Venus 
(transduction with V100 and V41) 
- LUHMES_GE-V1S+SV2: showing inducible expression of the N-terminal part of Venus 
coupled to αSyn (V1S) and of αSyn coupled to the C-terminal part of Venus (SV2) 
(transduction with V100, V39, and V46) 
 
Each LUHMES cell line was transduced four times with each virus. 
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Figure 4-15: Highly efficient transduction of LUHMES cells following protocol C 
LUHMES cells were transduced with the constitutive GAL4 driver virus (V99) and the UAS-Venus receiver 
virus (V43) according to protocols A-C (see chapter 3.8.2.1). Nuclei were stained with Hoechst33342. 
A) Quantification of the fraction of Venus-positive cells. Columns show mean of 4 to 5 wells. 
Error bars show SEM. At least 380 cells were counted for each protocol. 
B) Representative images obtained for protocol B. Scale bar is 100 µm and valid for both panels. 
  
 
 Characterization of the Inducibly αSyn-Overexpressing LUHMES 4.4.2
Cells  
4.4.2.1 Increased Transgene Expression upon Incubation with 
Tebufenozide in all LUHMES_GE Cell Lines 
LUHMES cell lines were incubated with differentiation medium for 48 h. Afterwards, cells were 
incubated with differentiation medium supplemented with DMSO or 10 µM tebufenozide for 4 
days.  
As expected, no effect of tebufenozide neither on fluorescence (Figure 4-16 A-C) nor on protein 
expression (Figure 4-16 D) was observed in LUHMES cells.  
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Figure 4-16: Induction of transgene expression in LUHMES_GE cells 
LUHMES cell lines were incubated with differentiation medium for 48 h. Afterwards cells were incubated 
with differentiation medium supplemented with DMSO or 10 µM tebufenozide for 4 days.  
A) Fluorescence images of cells incubated with 0.1% DMSO. Nuclei were stained with Draq5. 
Scale bar is 100 µm and valid for all panels in A and B.  
B) Fluorescence images of cells incubated with 10 µM tebufenozide. 
C) Quantification of the mean cellular Venus fluorescence intensity of LUHMES cells upon 
incubation with DMSO or tebufenozide using the Acapella® software. Tebu: tebufenozide. 
D) Western blot analysis of protein levels in LUHMES cells upon incubation with tebufenozide or 
DMSO. All LUHMES_GE cell lines showed an increase in protein levels upon incubation with 
tebufenozide. 
Data were obtained from one single experiment. 
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For LUHMES_GE-S and LUHMES_mC_GE-S cells, tebufenozide showed no effect on fluorescence 
intensity (Figure 4-16 A-C). While LUHMES_GE-S cells showed a faint αSyn band in the western 
blot in the absence of tebufenozide (Figure 4-16 D), no background expression could be detected 
in LUHMES_mC_GE-S cells (Figure 4-16 D). In both cell lines expression of αSyn increased upon 
incubation with tebufenozide.  
Both in LUHMES_GE-V and LUHMES_GE-SV cells we observed neither background fluorescence 
(Figure 4-16 A) nor protein expression (Figure 4-16 D) upon treatment with DMSO, but 
fluorescence quantification revealed a faint increase in mean cellular Venus fluorescence (Figure 
4-16 C). Transgene expression increased dramatically upon incubation with tebufenozide 
(Figure 4-16 B-D). 
For LUHMES_GE-V1S+SV2 cells we detected no background expression of V1S or SV2 (Figure 
4-16 A, C, D). Upon incubation with tebufenozide, fluorescence increased only slightly (Figure 
4-16 B, C), whereas protein expression was markedly increased (Figure 4-16 D). 
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5 Discussion 
5.1 Development of Stable Inducible Cell Lines – Original Strategy, 
Problems and Troubleshooting 
 Development of Viruses for the Overexpression of Various αSyn 5.1.1
Constructs Using the GE System or the CET2 System 
This thesis presents the development of H4 and LUHMES cells that stably and inducibly 
overexpress different constructs, namely: wt αSyn (S), the YFP variant Venus (V), αSyn coupled 
to Venus (SV), the N-terminal part of Venus coupled to αSyn (V1S), and αSyn coupled to the 
C-terminal part of Venus (SV2), where the co-expression of V1S and SV2 can be used for a 
bimolecular fluorescence complementation assay (BiFC). BiFC systems have been widely used to 
study protein-protein interactions in general207,293 and oligomerization of αSyn in 
particular213,294.  
In order to stably insert the expression machinery into host cells, we produced lentiviruses to 
deliver both the expression driver (GAL4_EcR and Cre_ERT2, respectively) and the receiver 
(UAS-GOI and loxP-GOI, respectively) for the inducible system. We decided to use the GAL4_EcR-
UAS (GE) system and the Cre_ERT2-loxP (CET2) system for inducible expression in our cell lines 
since differentiation of LUHMES cells relies on a Tet-OFF system. For this reason, we had to 
concentrate on inducible systems that do not use tetracycline as agonist or antagonist in order to 
be able to induce expression independent of differentiation. Both the GE and the CET2 system 
were kindly provided by the Lichtenthaler group.  
The GAL4-UAS system has been used extensively for tissue-specific transgene expression in 
Drosophila melanogaster and zebrafish254,295,296. In these model systems, GAL4 is typically 
expressed under control of a tissue-specific promoter in order to achieve tissue-specific 
transgene expression. The GOI is expressed under the control of a minimal promoter which is 
controlled by a UAS. Thus, expression of the GOI depends on binding of GAL4 to the UAS. The 
existence of various driver lines expressing GAL4 in specific tissues and various receiver lines 
expressing different GOIs enables the creation of transgenic animals by breeding of distinct 
driver and receiver lines. This results in the expression of the GOI in a distinct tissue due to 
mendelian recombination.  
In 2007, Esengil et al.255 developed an inducible expression system based on the GAL4-UAS 
system. For this system, the DNA-binding and homodimerization domains of GAL4 (a yeast 
transcription factor) was coupled to a modified subset of the activation domain of the herpes 
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simplex virus regulatory protein VP16 and the ligand binding domain of the ecdysone receptor 
(EcR) of Bombyx mori. Ecdysone is an insect steroid hormone without known effects on 
vertebrate cells256-258. In this system, incubation with an ecdysone agonist, called tebufenozide, 
leads to translocation of GAL4-EcR from the cytoplasm into the nucleus255. Consequently, 
expression of a transgene located downstream of a UAS is induced. 
The Cre-loxP system259,297,298 from bacteriophage P1 is widely used for tissue-specific gene 
knockdown or gene expression and especially popular for studies in mice, where a great variety 
of Cre driver lines is available. It consists of the enzyme Cre recombinase which catalyzes 
recombination of DNA between specific recognition sequences called loxP sites. Similar to the 
GAL4-UAS system, the Cre recombinase can be expressed under the control of a tissue-specific 
promoter for tissue-specific gene expression or knockout. For gene knockout the GOI is 
surrounded by two loxP sites, i.e., it is floxed, and located downstream of a constitutively active 
promoter. In cells that express Cre recombinase the GOI and one of the loxP sites will be excised 
resulting in knockdown of the expression of the GOI. 
For expression of a specific GOI it is located downstream of a constitutively active promoter and 
a floxed spacer gene carrying a termination codon. In the absence of Cre recombinase the GOI 
will not be expressed due to the termination codon. In Cre recombinase-expressing cells the 
spacer gene will be excised resulting in expression of the GOI299.  
For tissue and time-specific transgene expression, Cre recombinase was coupled to a mutated 
ligand-binding domain of the estrogen receptor (ERT2) which showed highest binding affinity 
not for estrogen but for tamoxifen260. Upon binding of tamoxifen to ERT2, Cre_ERT2 is 
translocated to the nucleus where Cre recombinase interacts with the loxP sites300. For time-
specific expression mice can be injected intraperitoneally (i.p.) with tamoxifen. Interestingly, 
this is also possible for embryonic gene expression when pregnant animals are treated with 
tamoxifen301. Time-specific gene knockout or expression is of special interest for the 
investigation of developmental processes or proteins with lethal phenotypes at early 
developmental stages. 
In vivo, tamoxifen is metabolized to several products with 4-OH-tamoxifen displaying greater 
affinity for the estradiol receptor than tamoxifen and showing the most potent antiestrogenic 
effect302-304. Thus, for cell culture experiments, the addition of 4-OH-tamoxifen is preferable, yet 
hampered by its low stability. Recently, endoxifen has been proposed as a potential alternative 
compound305. 
After cloning of the desired constructs, we created lentiviruses for both the GE system and the 
CET2 system. Next, we established a protocol for an effective transduction of H4 cells resulting in 
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long-term stable gene expression (Figure 4-6). Inducible H4 cell lines relying on both induction 
systems (H4_GE cells and H4_CET2 cells) were created. After testing both systems we 
concentrated on the GE system since we obtained higher transgene inducibility in pilot 
experiments (18.6-fold vs. 2.9-fold for Venus, and 6.8-fold vs. 2.4-fold for Syn-Venus) (Figure 
4-7, Figure 4-9). Moreover, this system holds the benefit that transgene expression can be 
turned on and off again, whereas the CET2 system cannot be turned off once the floxed gene has 
been excised. However, lentiviruses for both expression systems were developed and will 
immediately be available for further studies, allowing the production of inducible αSyn 
overexpression models in short time. Possible applications include the production of diverse cell 
lines to study different synucleinopathies. Exemplarily, αSyn deposition was observed in 
astroglial cells in patients suffering from dementia with Lewy bodies (DLB). Moreover, 
oligodendroglial cells could represent an interesting model for multiple system atrophy (MSA), 
where glial cytoplasmic inclusions (GCIs or Papp-Lantos bodies) represent the histopathological 
hallmark306. We have recently started a collaboration to test different strategies against αSyn-
mediated toxicity individually and in combination in several cell culture and animal models. For 
this, we created an inducible oligodendroglial cell line based on MO3.13 cells using the GE 
system. 
Moreover, the system for the development of stable cell lines that inducibly overexpress a 
certain protein of interst upon incubation with a chemical agonist could easily be adjusted for 
the investigation of other disease-associated proteins or peptides like tau307 or amyloid-beta308 
and other cell lines. 
Apart from cell culture applications, especially the loxP-GOI receiver virus might be interesting 
for the inoculation of animals expressing Cre or Cre_ERT2 in dopaminergic neurons or for 
primary neuron cultures from such animals. To a lesser extent, this might also be true for the 
UAS-GOI receiver in GAL4 expressing animal models.  
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 Individual Insertion of V1S and SV2 by Separate Lentiviruses 5.1.2
Ideally, equimolar expression of the V1S and SV2 construct for the BiFC assay would be 
desirable. Therefore, we decided to couple the V1S and SV2 constructs in a first attempt via a 2A 
sequence since 2A sequences have been shown to display quite stoichiometric expression of the 
upstream and downstream transgene, whereas IRES sequences typically show a decreased 
expression of the downstream transgene264. When two genes are linked via a 2A sequence both 
genes and the embedded 2A sequence are transcribed as one mRNA. During translation in the 
ribosome the 2A sequence causes a tilt in the nascent polypeptide chain which leads to 
ribosomal skipping of a peptide bond267. This should result in the occurrence of two separate 
proteins from one mRNA both of which carry a short peptide tag resulting from the 2A 
sequence265.  
Several 2A sequences from different organisms have been established. Here, we decided to use a 
P2A sequence from teschovirus-1 since it showed the best separation properties in different 
model systems including HEK293T, HT1080, and HeLa cells compared to other 2A sequences. 
Importantly, Kim et al.265 observed very low amounts of “uncleaved” protein in HEK293T cells 
when using a P2A sequence. Unfortunately, in our hands and in an experimental setup where we 
transiently transfected HEK293T cells with SV2-P2A-V1S we observed incomplete separation of 
V1S and SV2 in the western blot (Figure 4-2) with great inter experimental variation in 
separation efficiency. This controversial observation might be due to different amounts of 
expressed protein or an influence of the flanking proteins on P2A-mediated cleavage efficiency 
itself. Consequently, we discarded the P2A sequence and transduced the cells with lentiviruses 
carrying V1S or SV2 individually. 
 
 No Improvement of Signal-to-Noise Ratio by the Insertion of 5.1.3
Point Mutations into V1 and V2 
Self-assembly of Venus fragments and resulting background fluorescence is commonly observed 
in BiFC assays. At the beginning of this thesis, no study had evaluated the signal-to-noise ratio of 
an αSyn-hemi-Venus-based BIFC (to the best of our knowledge). However, while the present 
work was in progress, Eckermann et al.99 postulated a signal-to-noise ratio in an αSyn-hemi-
Venus BiFC of approximately 2-10, whereas we observed a signal-to-noise ratio in the range of 
1.5 (Figure 4-4). However, the signal-to-noise ratio might depend greatly on the strength of 
transgene expression and on the cell culture model used, with H4 cells displaying a particularly 
low signal-to-noise ratio99.   
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In order to improve the signal-to-noise ratio in Venus-based BiFCs several point mutations have 
been described mainly located at the interface of the Venus fragments251. The rational is a 
replacement of hydrophobic amino acids with neutral amino acids in order to reduce self-
complementation tendencies due to hydrophobic interactions.  
For the C-terminal Venus fragment, Nakagawa et al. observed a maximum increase in the signal-
to-noise ratio of 4.2-fold for the mutation L201V upon transfection into mouse C3H10T1/2 cells 
whereas the mutation L207V yielded a 3.0-fold increase285. For the N-terminal Venus fragment, 
Kodama et al.283 described an increase in the signal-to-noise ratio of approximately 4-fold for the 
mutations V150L and I152L upon transfection of COS-1 cells. Here, the N-terminal Venus 
fragment was coupled to the bZIP domain of c-Jun (bJun) and the C-terminal Venus fragment 
was coupled to the bZIP domain of c-Fos (bFos). For the negative control, the C-terminal Venus 
fragment was coupled to a mutant version of bFos (ΔbFon). For both mutations an increase in 
signal-to-noise ratio has also been described by Lin et al.286, and an 8.6-fold increase has been 
described for V150A285. Since the overall fluorescence intensity was markedly reduced when 
inserting the mutation of V150L compared to I152L283 we decided to test the mutation I152L in 
our BiFC system. 
We inserted the point mutations I152L into V1283 and L201V into V2285 and transiently 
transfected H4 cells with different combinations of V1wt(S), SV2wt, V1I152L(S), and SV2L201V. 48 h 
after transfection, cells were imaged or harvested and cell lysates were analyzed using the 
InsightTM Reader. While we observed a decrease in total fluorescence intensity when using 
mutated Venus fragments compared to wt Venus, signal-to-noise ratio was not dramatically 
affected (Figure 4-4).  
Thus, in our hand in this experimental setup, the insertion of point mutations I152L and L201V 
into the Venus fragments showed no noteworthy effect on signal-to-noise ratio which is in 
contrast to the observations by Nakagawa et al.285, Kodama et al283., and Lin et al.286. This might 
be due to different amounts of expressed protein or to the usage of different cell lines since it has 
been described that the signal-to-noise ratio of BiFC assays is affected by the applied cell line99. 
Moreover, expression levels and the subcellular localization of the protein connected to the 
Venus fragments might affect the amount of their self-complementation tendencies. 
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5.2 Characterization of H4 Cells 
 Highly Efficient and Stable Lentiviral Transduction in H4 Cells 5.2.1
In order to obtain a high fraction of transgene expressing H4 cells, we tested different 
transduction protocols using a constitutive GAL4 driver virus and the UAS-SV receiver virus. In 
the best case – for protocol D – we obtained approximately 98% transgene expressing cells 72 h 
after transduction. We monitored the cells until 23 days after transduction and observed no 
significant change in the fraction of Venus-positive cells. However, we observed a trend towards 
a decrease in transgene expressing cells at day 23 which might be due to epigenetic events 
resulting in gene silencing309. This effect might depend on the promoter employed: Following 
lentiviral transduction, Oberbek et al. observed a decrease of GFP-positive Chinese hamster 
ovary (CHO) cells using a human cytomegalovirus (CMV) major immediate early 
promoter/enhance after 2 to 3 weeks, whereas the fraction of positive cells was stable when 
applying a human elongation factor-1α (EF-1α) promoter262.  
In order to minimize interexperimental variations of cellular characteristics we applied a 
strategy where we obtained 300 batches of cells with theoretically identical properties for all 
cell lines. Since a new batch is used for every single experiment, a stable transgene expression 
over a time-course of 23 days appears to be sufficient. Indeed, for the experiments presented in 
this work, cells were in culture for less than 13 days.  
After production of stable H4_GE cell lines following protocol D, we obtained almost 100% of 
transgene expressing cells for all cell lines that express fluorescence proteins (H4_mC_GE-S 
(Figure 4-7 D), H4_GE-V, H4_GE-SV, and H4_GE-V1S+SV2 (Figure 4-10 B)). Thus, it is likely that 
we also obtained a very high fraction of αSyn-expressing cells in the H4_GE-S cell line, although 
this has not been shown yet. Immunohistochemical stainings using αSyn-specific antibodies will 
have to be performed in order to determine the fraction of αSyn-overexpressing cells in the 
H4_GE-S cell line. 
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 Induction of Transgene Expression in a Time- and Tebufenozide 5.2.2
Concentration-Dependent Manner 
In order to characterize the cell lines concerning their transgene expression, we used the Opera® 
system and western blot analyses. The Opera® system is a fully automated confocal fluorescence 
microscope. In order to quantify fluorescence intensities we developed a script for the Acapella® 
evaluation software. This software enables – among other readouts – the determination of the 
mean cellular fluorescence intensity, the fraction of positive cells (by using an arbitrary 
threshold for fluorescence intensity), and the number of cells.  
We incubated the different cell lines with different tebufenozide concentrations ranging from 
100 pM to 100 µM for 8 days and imaged the cells every 24 h (Figure 4-10). We found that mean 
cellular fluorescence intensity showed a maximum at day 5 or 6. This corresponds to the data 
obtained from the western blot evaluation of expression kinetics (Figure 4-12). Interestingly, the 
fluorescence intensity and the fraction of positive cells increased more slowly in the H4_GE-
V1S+SV2 cells compared to H4_GE-V or H4_GE-SV cells, while protein amounts increased in a 
comparable fashion. This might be due to the fact that a detectable fluorescence signal in the 
BiFC system requires not only expression of a fluorescence protein but also nucleation of αSyn 
aggregation. This is further supported by investigation of the expression kinetics of H4_GE-
V1S+SV2 cells. While they showed a rather exponential increase in fluorescence intensity over 
time (Figure 4-10 A) protein amounts of V1S and SV2 increased rather linearly 
(Figure 4-12 B, C). 
Furthermore, we found that fluorescence intensity was dependent on tebufenozide 
concentration. These data are in line with our investigation of protein amounts increasing with 
tebufenozide concentration using western blot analysis (Figure 4-11). Our results correspond to 
the expression kinetics in zebrafish embryos published by Esengil et al.255 where transgene 
expression increased in a tebufenozide-dependent manner upon incubation with 1 nM to 10 µM 
tebufenozide. The decreased fluorescence intensity observed when incubating cells with 100 µM 
tebufenozide can most likely be explained by precipitation of tebufenozide. 
For H4_GE-S, H4_mC_GE-S, H4_GE-V, and H4_GE-SV cell lines we found low background 
expression in the absence of tebufenozide by fluorescence microscopy (Figure 4-7 A, B), 
quantification of fluorescence intensity (Figure 4-7 C and Figure 4-10 A) and western blot 
analysis (Figure 4-11 and Figure 4-12). For H4_GE-V1S+SV2 almost no background expression 
could be observed compared to untreated H4 cells. 
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The dynamic range and the increase in transgene expression are important aspects for inducible 
cell lines. The results we obtained for induction of transgene expression showed great variation 
and are summarized in Table 5-1.  
For all cell lines the number of cells increased until day 4 or 5 after induction (Figure 4-10). The 
following decrease in cell number is probably due to the experimental setup where we seeded 
the cells at a concentration of 50,000/ml on day 0 and incubated them without splitting them or 
changing the medium until the end of the experiment. Thus, it is likely that cell growth was 
hampered by a depletion of nutrients and an increasing pH.  
After our cell lines had been established, Moussaud et al. published a paper in which they 
described the development of a comparable model for inducible expression of αSyn in H4 
cells206. For their model, they stably inserted the different αSyn constructs using the Flp-FRT 
recombinase in combination with a tetracycline-driven bidirectional expression system, thus 
enabling the inducible transgene expression via a Tet-Off system. In this system, presence of 
tetracycline inhibits the expression of the transgene, whereas removal of tetracycline induces 
transgene expression. 
In their study, two kinds of protein fragment complementation assays are used to investigate 
αSyn aggregation: Like in the thesis presented here, their first model uses a fluorescence readout 
and relies on complementation of hemi-Venus constructs (V1S and SV2). The second model 
requires a bioluminescence readout. Here, αSyn is coupled to the C-terminal or N-terminal part 
of Gaussia princeps luciferase (SL1 and SL2). Upon aggregation of αSyn the luciferase parts 
complement. In the presence of luciferin and ATP, luciferase catalysis a multistep reaction 
resulting in the emission of light. The luminescence intensity should be approximately 
proportional to αSyn aggregation. For both systems they used Leucine zipper-linked protein 
complementation (V1Lz and LzV2, or LzL1 and LzL2, respectively) as positive control. 
Additionally, they produced H4 cells which inducibly overexpressed wt αSyn. 
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Table 5-1: Relative increase in transgene expression 
This table summarizes the relative increase in transgene expression according to change in fluorescence 
intensity or protein amount. WB: western blot 
 Fold increase 
in fluorescence 
 (Figure 4-10) 
Fold increase 
 in WB signal  
(Figure 4-11) 
Fold increase 
 in WB signal  
(Figure 4-12) 
H4_GE-S  - 19.7 27.8 
H4_mC_GE-S  - 45.9 16.7 
H4_GE-V  90.8 5.1 90.3 
H4_GE-SV  96.9 7.0 no background 
H4_GE-V1S+SV2 V1S 1,240.7 no background no background SV2 no background 10.0 
 
 
A reliable comparison of the characteristics of the cell lines produced by Moussaud et al. and 
ours would require the investigation of both kinds of cell lines in parallel under equal conditions 
and is difficult from published data alone. However, the strategy applied by Moussaud et al. 
holds two fundamental disadvantages compared to our strategy: First, the stable insertion of the 
induction system relies on transient plasmid transfection, but a variety of established cell lines 
(including LUHMES cells) and primary cell lines are rather insusceptible to transient 
transfection with plasmids1. Second, the induction of transgene expression relies on presence or 
absence of tetracycline in a Tet-Off system. Thus, independent transgene induction cannot be 
achieved in model systems where a Tet-On or Tet-Off system is used for inducible expression of 
other proteins. This is for example the case in LUHMES cells where addition of tetracycline turns 
off the expression of v-myc and by this induces their differentiation to dopaminergic 
neurons235,236. 
Moussaud et al. observed low background transgene expression in the presence of tetracycline. 
Transgene expression was detectable from 16 h after removal of tetracycline on using western 
blot analysis. Transgene expression increased over time and reached a maximum 4 days after 
removal of tetracycline. Expression was not monitored from that time on206. In our cells, we did 
not investigate transgene expression before 24 h after induction. Like Moussaud et al. we 
observed low background expression and an increase in transgene expression over time, 
reaching a maximum 4 to 6 days after induction (Figure 4-10, Figure 4-12).  
Interestingly, Moussaud et al. observed αSyn immunoreactivity in H4 V1S&SV2 cells which did 
not display Venus fluorescence suggesting the presence of monomeric αSyn206. This is in line 
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with our findings that expression of V1S and SV2 increased faster than fluorescence intensity in 
H4_GE-V1S+SV2 cells (Figure 4-10, Figure 4-12). One explanation is that the probability of 
nucleation increases with increasing amounts of αSyn and that a certain threshold of αSyn 
monomers might be required in order to induce a sufficient amount of oligomeric αSyn species 
to be detectable via BiFC. 
Additionally, Moussaud et al. found that protein tags for the protein complementation assay 
(PCA) do neither interfere with the normal cellular distribution of αSyn nor with the 
polymerization of αSyn. Yet, αSyn half-life and oligomer stability appeared to be increased in the 
H4 V1S&SV2 cells which might be due to an irreversibility of Venus fragment 
complementation206,209,214,310. Moreover, using the H4 V1S&SV2 cells they performed a 
preliminary screening for anti-aggregative compounds using an EnVision multilabel HTS plate 
reader (PerkinElmer) and concluded that the fluorescent αSyn PCA can be used as high-
throughput primary assay to screen large libraries206. This is in line with our experiments to 
screen for anti-aggregative compounds (Figure 4-5) and aggregation enhancers (Figure 4-13). 
All in all, the paper by Moussaud et al. further supports the relevance of BiFC-based inducible 
αSyn cell models as valuable tools in drug discovery for PD. 
 
5.3 Increased αSyn Aggregation upon Incubation with DMSO and 
FeCl3 
Iron has been discussed extensively and controversially as possible risk factor for the 
development of PD133,311. Elevated levels of iron (and other metal ions) have been described in 
the SN of PD patients when compared to control tissue135,137,138,312 at least in severly affected 
individuals313. High iron levels were also observed in Lewy bodies of the SN of PD patients314 and 
several epidemiological studies describe a correlation between the exposure towards iron (and 
other heavy metals) and an increased risk for PD311,315,316.  
In order to investigate the effect of DMSO and ferric iron on αSyn aggregation in cell culture, we 
induced transgene expression in H4_GE-V1S+SV2 and H4_GE-V cells and incubated them with 
different concentrations of DMSO (ranging from 0.1% to 1.0%) and FeCl3 (ranging from 0 µM to 
1 mM) (Figure 4-13). DMSO concentration cannot be decreased to 0% since tebufenozide, the 
inducer of transgene expression, is dissolved in DMSO. In H4_GE-V1S+SV2 cells, fluorescence 
intensity increased considerably upon incubation with 1.0% DMSO even in the absence of FeCl3, 
whereas incubation with different concentrations of FeCl3 without additional DMSO did not 
markedly influence fluorescence intensity. The strongest increase in fluorescence intensity was 
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observed for the combination of DMSO and FeCl3, reaching a maximum upon incubation with 1% 
DMSO and 1 mM FeCl3.  
In contrast, fluorescence intensity was not affected by incubation with DMSO or FeCl3 in 
H4_GE-V cells, suggesting that the effect on fluorescence intensity observed in H4_GE-V1S+SV2 
cells was not due to an effect on Venus fluorescence itself but due to an increase in 
complementation of the Venus fragments V1 and V2 (Figure 4-13 A). This effect appeared to be 
rather specific for incubation with FeCl3 and was more pronounced than for incubation with 
other tri-, di-, or monovalent ions where only incubation with 100 µM ZnCl2 resulted in slightly 
increased fluorescence intensity in H4_GE-V1S+SV2 cells (Figure 4-13 B). 
To further validate the effect of DMSO and FeCl3 on aggregation of αSyn in cell culture we 
analyzed the protein amount and observed an increase in αSyn protein load in H4_GE-S, 
H4_GE-SV, and H4_GE-V1S+SV2 cells upon treatment with 1% DMSO and 100 µM FeCl3, but no 
change in the Venus protein load in H4_GE-V cells (Figure 4-14 A). An increase in αSyn protein 
load upon its aggregation has been reported before317 and might be due to reduced degradation 
of aggregated αSyn.  
We also performed sucrose gradient analyses from cell lysates obtained from both H4_GE-
V1S+SV2 and H4_GE-V cells incubated with 0.75% DMSO and 100 µM FeCl3, or 0.1% DMSO and 
0 µM FeCl3. We chose the parameters 0.75% DMSO and 100 µM FeCl3 as high control since we 
observed many dead cells upon incubation with 1% DMSO and precipitation of iron upon 
incubation with 1 mM FeCl3. We observed a shift in the αSyn signal to fractions of higher sucrose 
density in H4_GE-V1S+SV2 cells upon incubation with 0.75% DMSO and 100 µM FeCl3 compared 
to incubation with 0.1% DMSO and 0 µM FeCl3, suggesting increased αSyn oligomerization. This 
effect was not observed for Venus in H4_GE-V cells (Figure 4-14 B). However, since αSyn 
oligomers appear to be very sensitive to the cell lysis methods applied, especially concerning 
detergents, we are currently further optimizing the cell lysis conditions for sucrose gradient 
analysis. Thus, these results should be carefully regarded as preliminary. 
Taken together, our data suggest an increase in αSyn aggregation in H4_GE cells upon incubation 
with DMSO and FeCl3. Iron is present in the body in two oxidative states: ferrous iron (Fe2+) and 
ferric iron (Fe3+) and our results are well in line with several findings that point towards ferric 
iron as an important player in the course of pathology. Accordingly, a shift in the Fe2+/Fe3+ ratio 
in favor of Fe3+ has been observed in the SN of PD patients. In line with this, a decreased amount 
of glutathione (GSH) – which can dimerize to glutathione disulfide (GSSG) upon oxidization and 
protect cellular molecules from oxidative stress by acting as electron donor for reactive oxygen 
species – and an increased amount of the ferric iron binding protein ferritin has been 
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described312,313. After injection of FeCl3 into the SN, rats show almost erased dopamine levels in 
the striatum and develop a parkinsonian phenotype318. In line with this, an epidemiological 
study found an increased risk for PD among individuals with high nonheme iron and low vitamin 
C intake319. 
In vitro, incubation of recombinant αSyn with DMSO and with or without FeCl3 leads to the 
formation of distinct oligomer species145. In this study, incubation with DMSO leads to formation 
of intermediate I oligomers in vitro. The additional incubation with FeCl3 induces the formation 
of intermediate II oligomers145 which are capable of inserting pores into lipid bilayers145,171. 
Moreover, ferric iron has been shown to accelerate αSyn fibrillization131. Interestingly, 
oligomerization of αSyn appears to result from direct interaction with ferric iron whereas 
oxidizing agents show no direct effect on αSyn oligomerization. Thus, an effect of oxidative 
stress on aggregation of αSyn might be mediated by oxidation of ferrous iron to ferric iron144.  
 
5.4 Reduced Fluorescence Intensity in the BiFC Assay upon 
Incubation with Known Modulators of αSyn Oligomerization  
Interestingly, we also observed a slight increase in fluorescence intensity in the BiFC assay upon 
transient transfection of H4 cells with V1S and SV2 and incubation with DMSO. In the same 
experimental setup, incubation with three known inhibitors of αSyn aggregation – baicalein, 
anle138c, and anle138b – led to a decrease in fluorescence intensity compared to incubation 
with DMSO (Figure 4-5). These three substances have been shown to have antiaggregative 
properties in vitro, and anle138b has also been shown to have a beneficial effect on disease 
progression in a variety of models for PD and other neurodegenerative disorders56,145,192,288-292. 
We conclude that the αSyn BiFC system might represent a valuable tool for high-throughput 
screening assays for aggregation inhibitors of αSyn despite its poor signal-to-noise ratio. It has 
to be mentioned that this assay system is not specific for compounds that act directly on αSyn 
aggregation. In contrast, also compounds decreasing expression or increasing clearance of αSyn 
might appear as hits in a primary screen. Moreover, we cannot exclude the possibility of false 
positive results since compounds might also act on fluorescence intensity or Venus fragment 
complementation. 
However, Venus shows a β-barrel structure which is typical for GFP-derived fluorescent 
proteins250,320, and the complementation of Venus fragments relies on the interaction of β-sheets 
in both fragments with interaction of hydrophobic amino acids appearing to be a driving 
force284,285. This is comparable to the situation observed in the aggregation process of αSyn, 
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where the NAC-region (comprising amino acids 61-95, see Figure 2-2) appears to be of critical 
importance95-100. The NAC-region comprises the amino acids 61-95 of which almost 50% are 
hydrophobic. Indeed, Giasson et al.100 found that the 12-amino-acid stretch comprising amino 
acids 71-82 (VTGVTAVAQKTV) in the NAC region is necessary and sufficient for the assembly of 
αSyn filaments. Notably, six of these amino acids (underlined) exhibit hydrophobic side chains. 
Therefore, both the complementation of Venus fragments and the aggregation of αSyn appear to 
be at least partly driven by the interaction of hydrophobic amino acids. For this reason, 
inhibitors of αSyn aggregation are not unlikely to also act on complementation of Venus 
fragments. Thus, excluding compounds that do not act specifically on αSyn aggregation but also 
on Venus fragment complementation might result in the exclusion of promising therapeutic 
candidates. That is why we decided not to do a control for specificity (in contrast to the leucine 
zipper (LZ)-hemi-Venus used by Moussaud et al.206). Still, we would expect that our strategy 
leads to more false positive results that will have to be extracted in secondary screenings which 
are independent of protein complementation. For this, cell lines inducibly overexpressing 
untagged αSyn in combination with western blot or sucrose gradient centrifugation analysis 
(Figure 4-14), immunohistochemical stainings for total or phosphorylated αSyn or αSyn 
oligomers using specific antibodies321,322, and cytotoxicity assays will likely prove beneficial.   
 
5.5 Inducible Transgene Expression in LUHMES Cells 
The first step towards the creation of stable LUHMES cell lines was to test the transduction 
protocol that was used for the creation of stable H4 cell lines. Interestingly, LUHMES cells did not 
tolerate this protocol and we had to reduce the amount of virus from 1:3.5 (volume per volume) 
to 1:100 in order to obtain stably transgene-expressing LUHMES cells (Figure 4-15). Using 
protocol C we finally obtained 75% of Venus-positive cells and further used this protocol to 
create stable LUHMES cell lines that inducibly overexpress αSyn variants.  
In order to test the inducible LUHMES cells, we first induced differentiation according to the 
two-step protocol by Scholz et al.237. Two days after induction of differentiation, cells were split 
and seeded into 384-well plates for Opera® analysis and T75 flasks for western blot analysis in 
differentiation medium, respectively. Cells were incubated with 10 µM tebufenozide for 4 days 
to induce transgene expression or DMSO as control, respectively.  
After 6 days of incubation in differentiation medium LUHMES cells showed a morphological 
change to a neuron-like phenotype with an extensive network of neurites (Figure 4-15 B; Figure 
4-16 B). Comprehensive characterization on the phenotype of differentiated LUHMES cells has 
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been performed before and revealed that they release dopamine and display neuronal electric 
properties237,238. For all inducible LUHMES cell lines we detected no obvious increase in 
background fluorescence upon incubation with DMSO compared to untreated LUHMES cells 
(Figure 4-16). In contrast, we observed an increase in western blot signal of the POI upon 
incubation with tebufenozide for all inducible LUHMES cell lines (Figure 4-16 D). Despite the 
clear increase in protein amount in LUHMES_GE-V1S+SV2 cells upon treatment with 
tebufenozide (Figure 4-16 D), we observed only a very faint increase in mean cellular 
fluorescence intensity (Figure 4-16 B, C). This is in line with our findings in H4_GE-V1S+SV2 cells 
and fits the observation by Moussaud et al.206 that significant amounts of V1S and SV2 are 
required for a detectable BiFC signal. However, since these data were obtained from one single 
experiment they should be carefully regarded as proof of concept, and further evaluation of the 
LUHMES_GE cells concerning expression characteristics will need to be performed. 
It has to be mentioned that, in our hands, the two-step differentiation protocol described by 
Scholz et al.237 was hampered by the fact that harsh conditions had to be used for trypsinization 
after two days of differentiation. Unfortunately, proliferation of LUHMES cells is not immediately 
stopped upon incubation with differentiation medium, but cells proliferate markedly for at least 
two additional days. Thus, skipping the splitting step after two days of differentiation is difficult 
in small formats (like 384-well plates). We are currently optimizing the differentiation protocol 
for different formats (T75 flasks, 6-well plates, 24-well plates, 96-well plates, 384-well plates).  
According to Schlachetzki et al., the perfect cell line to study possible disease processes in PD 
would comprise “a homogeneous cell culture system that is easy to handle (…). Cells should be 
easy to expand in order to generate large numbers of neuronal precursor cells. Next, these cells 
should be easily directed towards a postmitotic state in a synchronized manner with a mature 
neuronal (dopaminergic) phenotype”1. LUHMES cells fulfill these criteria and seem to become 
more and more popular in PD research. In order to overexpress αSyn in LUHMES cells, different 
strategies have been applied so far including the stable constitutive overexpression of αSyn and 
the induction of αSyn overexpression by lentiviral transduction242,243. To the best of our 
knowledge, we here present the first report on LUHMES cells where overexpression of αSyn can 
be triggered by incubation with a chemical agonist.  
Taken together, the model presented in this work shows several advantages compared to 
strategies where αSyn is constitutively overexpressed or where αSyn overexpression is induced 
by lentiviral transduction. Exemplarily, strength and kinetics of αSyn expression should be 
highly reproducible in our system since we have produced several homogeneous stocks of 
inducible H4_GE and LUHMES_GE cells that should not differ significantly between one another 
concerning fraction of transgene expressing cells and expression characteristics. The transgene 
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induction using the GE system was highly reproducible in H4_GE cells (Figure 4-10, Figure 4-11, 
Figure 4-12) and it is unlikely that reproducibility in LUHMES_GE cells is significantly worse. On 
the contrary, we would expect greater inter-experimental variation concerning the number of 
transduced cells and the strength of transgene expression when αSyn overexpression is induced 
by lentiviral transduction. Moreover, the success of lentiviral transduction critically relies on the 
quality of the produced lentiviruses, which itself is subject to variation between different virus 
productions and purifications. Furthermore, the production of lentiviruses is rather time- and 
money-consuming compared to purchasing the chemical agonist tebufenozide. 
Several factors may contribute to the affection of dopaminergic cells in the SN in PD. 
Correspondingly, dopaminergic neurons show high metabolic needs due to their high density of 
connections to other neurons and their high-frequency autonomous firing32,323,324. This is 
accompanied by increased oxidative stress and increased calcium entry via opened L-type 
calcium channels (driving the rhythmic pacemaking activity) into the cell which is not well 
tolerated by SN neurons32,325-327. The effect of calcium is even more pronounced since they lack 
the expression of calcium binding proteins (like calbindin) which can act as calcium buffers32. 
Additionally, their large number of synapses increases the risk of being exposed to seeding 
species, and synaptic connections are generally thought to be “hot spots” for pathology in 
various types of neurons32,104. Using differentiated and undifferentiated LUHMES cells might be a 
valuable tool to unravel the role of dopamine metabolism on the pathological effect of αSyn 
aggregation. 
Since PD represents a slowly progressing neurodegenerative disorder and a combination of 
genetic background and long-term exposition towards environmental risk factors at low-dose 
appears to be a driving force in disease progression, the use of acute cytotoxicity studies seems 
to be of limited use197,328. In this context, differentiated LUHMES cells represent a valuable tool 
since they allow prolonged exposure for up to 9-12 days in conventional cell culture compared 
to other immortalized cell lines where exposure time is usually limited by proliferation and a 
following increase in cell number. Recently, a protocol for 3D culturing of LUHMES cells has been 
published. Following this protocol, differentiated LUHMES cells showed a stable dopaminergic 
phenotype for up to 21 days, further strengthening the LUHMES cell model for the investigation 
of long-term exposure against low-dose toxicants197.  
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6 Conclusions and Suggestions for Further Work 
We here present the development of a system for the fast and easy creation of cell lines which 
inducibly overexpress the fluorescence protein Venus (V) or different variants of αSyn-140, 
namely human wildtype αSyn (S), αSyn coupled to Venus (SV), and αSyn coupled to the 
N-terminal (V1S) or C-terminal (SV2) part of Venus for a BiFC assay. The induction machinery 
was stably inserted into the host genome mediated by lentiviral transduction and relies on a 
modified GAL4-UAS system where GAL4 is coupled to an ecdysone receptor to allow inducible 
transgene expression (GE)255. Alternatively, induction was achieved by using a Cre_ERT2-loxP 
system (CET2). Both induction systems were applied successfully to H4 cells, where the GE 
system showed stronger inducibility compared to the CET2 system. Transgene expression 
properties of H4_GE cells were characterized in detail both with regard to kinetics and 
dependence on tebufenozide concentration. 
Iron has been discussed extensively as possible risk factor for the development of PD. Here, we 
observed a striking effect of FeCl3 on αSyn aggregation which was not observed for other tri-, di-, 
or monovalent ions. The incubation of H4_GE cells with DMSO and FeCl3 led to increased 
aggregation of αSyn demonstrated by increased fluorescence intensity in the BiFC model, 
increased αSyn protein load in αSyn overexpressing H4_GE cells, and by sucrose gradient 
centrifugation.  
Moreover, the GE system was successfully implemented in LUHMES cells, and inducibility was 
demonstrated in a proof of concept experiment. To the best of our knowledge, this is the first 
report on inducible overexpression of αSyn in LUHMES cells mediated by a chemical agonist. 
Further experiments to characterize transgene expression are currently in progress. 
It will be interesting to investigate effects of αSyn overexpression on its aggregation in 
combination with αSyn-mediated cytotoxicity and susceptibility to cytotoxic agents. Preparatory 
experiments to screen for modulators of αSyn aggregation and αSyn-mediated toxicity are 
currently in progress. 
Moreover, using the system described herein, we have developed H4_GE cell lines that inducibly 
overexpress variants of αSyn carrying disease-associated mutations. Patients with SNCA 
mutations show distinct clinical and neuropathological phenotypes, and different mutations in 
αSyn lead to distinct aggregation and lipid-binding properties in vitro329-334. This suggests 
different pathological molecular mechanisms acting in synucleinopathies. Thus, investigating 
disease-associated αSyn mutations might provide information on general processes occurring in 
familial and sporadic PD as well as in other synucleinopathies. 
Conclusions and Suggestions for Further Work 
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Aggregation of αSyn is not a specific pathological feature of PD but in contrast occurs in a variety 
of disorders summarized as synucleinopathies. Yet, the location of αSyn aggregation and 
neuronal degeneration differs between these disorders. Exemplarily, in multiple system atrophy 
(MSA), αSyn aggregates mainly in oligodendrocytes with glial cytoplasmic inclusions (GCIs) or 
Papp-Lantos bodies being the neuropathological hallmark, and cytoplasmic aggregation of αSyn 
may also occur in astroglial cells in PD, dementia with Lewy bodies (DLB) or MSA306. The 
strategy presented in this work appears to be applicable to a variety of cell models and thus 
holds the potential to create distinct αSyn overexpression models for several different 
synucleinopathies. 
We believe that the strategy presented in this work holds high potential for cutting edge 
questions in research on synucleinopathies in general and PD in particular since it is suitable for 
the application in a variety of established and primary cell lines for the investigation of 
aggregation, modulation, and toxicity of αSyn oligomers.  
This could lead to the development of valuable models for PD and other synucleinopathies that 
help to unravel the underlying molecular pathological mechanism(s) and to develop disease-
modifying therapies. In line with this, we are currently investigating a combination strategy of 
different treatment approaches modifying the homeostasis or aggregation of αSyn in an 
oligodendroglial cell model for the treatment of MSA in an E-Rare-funded project using the 
system presented in this work. For this, the induction machinery has been implemented in the 
oligodendroglial MO3.13 cell line. 
The combination of the Venus-based BiFC assay and inducible expression appears to be 
especially suitable for high-throughput screenings of possible anti-aggregative compounds when 
combined with proper secondary readouts like sucrose gradient centrifugation and cytotoxicity 
assays. However, the cell models created here are not limited to the investigation of formation, 
modulation, and toxicity of αSyn oligomers but also enable the examination of further important 
effects in neurodegeneration like mitochondrial dysfunction, neurotoxicity, oxidative stress, 
defects in the protein degradation machinery or seeding and spreading mechanisms1,32,335. Thus, 
we hope that the system presented in this work will prove beneficial for the discovery and 
detailed characterization of novel drug candidates which be can be translated to clinical 
application in the end.  
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8 Appendix 
8.1 Plasmid Maps  
 
Figure 8-1: Plasmid maps I 
A) Plasmid carrying the construct V1S (db #1) 
B) Plasmid carrying the construct SV2 (db #2) 
C) Plasmid carrying the construct αSyn-Venus (db #3) 
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Figure 8-2: Plasmid maps II 
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Figure 8-2: Plasmid maps II 
A) pCR8/GW/TOPO+pCS2-MCS 
B) F2P-Delta Zeo-LoxP-Ko.Puro-LoxP-STNST-GW(DEST) (db 636) 
C) F2-Delta Zeo-Kozak-Puro-5XUAS-E1b-(GW)Dest (db 597) 
D) F2-Delta Zeo-Kozak-Hygro-5XUAS-E1b-(GW)Dest (db #44) 
E) F2-Delta Zeo-Kozak-Zeo-5XUAS-E1b-(GW)Dest (db #45) 
F) Delta Zeo-Kozak-mCherry-NLS-5X UAS-E1b-(GW)Dest (db #92) 
Amp: ampicillin; att: attachment site for Gateway® cloning; bla: beta-lactamase; ccdB: control of cell 
death B; Chl: chloramphenicol; cPPT: central polypurine tract; hCMV: human cytomegalovirus; HIV: 
human immunodeficiency virus; hPGK: human phospho-glycero-kinase; Hygro: hygromycin; LTR: long 
terminal repeat; Prom: promoter; Psi: retroviral Psi packaging element; pUC Ori: pUC origin of 
replication; Puro: puromycin; R: resistance; RRE: rev response element; Spec: spectinomycin; UAS: 
upstream activation sequence; WPRE: woodchuck hepatitis virus posttranscriptional regulatory element; 
Zeo: zeocinTM  
  
Appendix 
 
 
133 
 
Figure 8-3: Plasmid maps III  
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Figure 8-3: Plasmid maps III 
A) FUVALENTIN Delta Zeo-Gal4-VP16 (db #99) 
B) FUVALENTIN Delta Zeo-Gal4-VP16-EcdR-F’ (db #100) 
C) F2U-Delta Zeo-iCre (db #101) 
D) F2U-Delta Zeo-iCre-ERT2 (db #102) 
E) psPAX2 (db #97) 
F) pcDNAT3.1(-)VSVG (db #98) 
Amp: ampicillin; bla: beta-lactamase; cPPT: central polypurine tract; Cre: Cre recombinase; EcR: ecdysone 
receptor; ER: estrogen receptor; hCMV: human cytomegalovirus; HIV: human immunodeficiency virus; LTR: 
long terminal repeat; Prom: promoter; Psi: retroviral Psi packaging element; pUC Ori: pUC origin of replication; 
R: resistance; RRE: rev response element; Ubi: ubiquitin; VSV-G: Vesicular stomatitis virus, glycoprotein G; 
WPRE: woodchuck hepatitis virus posttranscriptional regulatory element. 
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